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CHAPTER I 
 
SEPARATIONS IN MASS SPECTROMETRY-BASED CHEMICAL ANALYSIS 
 
1.1.  Introduction 
 Life sciences have benefited greatly from numerous advances in mass 
spectrometry (MS) techniques in the last decades due to its selectivity, sensitivity and 
broad dynamic range.
1,2
 Its robustness and capability to rapidly analyze samples makes it 
an ideal technique for large-scale studies that require high-throughput. While MS has 
been largely utilized to answer biological questions, synthetic scientist, and in particular, 
polymer chemists have taken advantage of the quantitative relationship between intensity 
and concentration to characterize a wide range of oligomers and polymers as well.  
 A challenge prevalent in the single dimension MS analysis of complex samples is 
that isobaric interferences produced by molecules with the same mass tend to occur, 
leading to difficulties in data interpretation. Considering the low diversity of elements 
found in biomolecules and synthetic polymers (H, C, N, O, P and S) as well as the long 
chains built by C-C bonds, the possibilities of multiple analytes possessing the same 
molecular formulas but different structures or atom arrangement are considerably high. 
This limitation necessitates a secondary analytical technique orthogonal to molecular 
mass, which combined create a multidimensional analysis. Traditionally, 
chromatographic separations are coupled on-line with mass spectrometers and mass 
spectra are acquired over the length of the chromatogram. This results in a two-
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dimensional analysis with chromatographic retention time and mass-to-charge ratio (m/z) 
represented on each axis.  
 The various types of separations coupled to MS can be divided into two groups 
depending on whether he separation occurs pre- or post-ionization. Ion-mobility (IM), as 
the name suggests, is a post-ionization separation technique. In IM, ions are separated 
based upon their gas-phase packing efficiency, which provides information about 
structure and conformation on the order of milliseconds (ms).
3, 4
 However, the need for 
analyte ionization prior to mobility separation is a major limitation. This plays an 
important role in the analysis of complex biological samples where ion suppression 
effects decrease the analyte coverage, reproducibility and accuracy of measurements. On 
the other hand, ion suppression effects can be addressed by combining pre-ionization 
separations with MS. This pairing is widely used with mobile phases in different physical 
states such as gas, liquid and supercritical fluid. The coupling of gas chromatography 
(GC) is mostly applied to the analysis of volatile compounds,
5, 6
 while liquid 
chromatography (LC) or more commonly known, high performance liquid 
chromatography (HPLC) can be applied for a wider range of molecules.
7-10
 The use of 
supercritical fluids for chromatographic purposes has not been widely adopted. Early in 
the development of this technology, technical limitations in pressure controllers and 
injection systems diminished the confidence in its potential. Nonetheless, supercritical 
fluid chromatography (SFC) provides access to faster separations and polarities not easily 
accessible to other mobile phases due to the special physical properties of supercritical 
fluids.
11
 For the characterization of synthetic polymers, size exclusion chromatography 
(SEC) is most commonly used, both on and off-line.
12
 In SEC, the separation is based on 
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molecular weight or chain length, allowing for shorter and longer chains to be ionized 
and detected with less interferences and biases.  
 The aim of this introductory chapter is to provide an overview of the different 
separation techniques coupled to IM-MS and review the advantages and benefits realized 
from three-dimensional separation, which include IM between pre-ionization and mass 
analysis for the profiling and identification of metabolomic studies, as well as the 
characterization of complex synthetic polymer mixtures.   
 
1.2. Ion Mobility-Mass Spectrometry 
 Mass spectrometry and ion mobility techniques could be broadly described as 
gas-phase separations of charged particles.
13
 MS operates under vacuum (10
-5
 – 10-9 
Torr) in order to avoid collision with neutral particles and provides molecular weight 
information. On the other hand, IM pressure regions are in the order of 1-10 Torr, where 
collisions with neutral gas are necessary for the basic principles of the separation, 
providing molecular size information. The coupling of IM-MS is possible due to the 
differences in their separations speed. Mass spectra in TOF instruments are collected on 
the order of µs, while IM separations is on the order of ms. This translates to several MS 
spectra being acquired for each IM spectrum.  As both techniques utilize charged 
particles for their analysis, ion sources considerations need to be recognized.    
 The most common soft ionization sources in the analysis of biomolecules and 
synthetic polymers are electrospray ionization (ESI) and matrix assisted laser 
desorption/ionization (MALDI) and they offer complementary capabilities.
14-16
 The three 
main differences between these ionization techniques are important when considering the 
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type of experiment to perform. First, charge state of the analytes varies between both 
ionization techniques. MALDI generally generates singly charged ions in the form of 
[M+H]
+
, [M+Na]
+
, etc., where M is the intact analyte. On the other hand, ESI generates 
both singly and multiply charged ions primarily as multiprotonated species, e.g. 
[M+Hn]
n+
. Typically in ESI, larger molecules such as proteins, peptides and polymers 
tend to be multiply charged, while small molecules such as metabolites and short chain 
oligomers tend to be singly charged. In addition to the inherent complexity of biological 
samples, partitioning the in signal of each analyte into several charge states further 
convolutes the interpretation of the sample composition. Secondly, the high tolerance of 
non-volatile salts present in the sample in MALDI reduces the number of steps in sample 
preparation. However, an empirical knowledge of appropriate matrices is necessary. 
Third, and probably most significant in the selection during experimental design is the 
pulsed and continuous ion generation modes of MALDI and ESI, respectively. This has 
pragmatic implications regarding the technical integration of these ionization techniques 
to other instrumental components.  
 As mentioned previously, isobaric molecules cannot be separated by MS alone. 
However, other separation techniques coupled to MS can resolve these interferences. In 
the next sections IM will be discussed in more detail.  
 
1.2.1. Ion Mobility Fundamentals 
 The concepts of gas-phase IM separations and the coupling to MS have existed 
for over a century and since the 1960s, respectively.
17-19
 But the adoption in the analysis 
of biomolecules was delayed until the implementation of he two primary soft ionization 
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techniques, ESI and MALDI.
20-26
 Despite its great potential and the expansion into the 
biological fields, IM-MS was initially only available to a few laboratories who could 
build the instruments in-house. However the introduction of a commercially available 
IM-MS instrument a decade ago transformed IM into a widely utilized technique, similar 
to the integration of liquid chromatography and mass spectrometry (LC-MS).
27-30
   
 Generally, IM can be defined as the velocity (kinetic energy) of ions in a neutral 
gas. Differences in ions velocities, travelling through a neutral gas is primarily dependent 
on their structure (size and shape) and not their mass (molecular formula). Smaller ions 
experience fewer collision with the neutral gas, and thus drift faster than larger ions. This 
takes place in a mobility separation drift tube (DT) or cell composed of stacked ring 
electrodes that apply an electric field across a defined region (DTIM). This DT is filled 
with an inert gas, usually helium or nitrogen at a constant pressure. Other names such as 
gas-phase electrophoresis and plasma chromatography have also been to describe the IM 
analytical technique.
31, 32
 
In the fields of bioanalysis, IM has the potential of separating complex samples 
based on the differences in gas-phase packing efficiencies among the different classes of 
biomolecules.
33-37
 For example, lipids are less efficient in their gas-phase packing than 
peptides with similar molecular weights due to their long fatty acid chains. The trend for 
the IM-MS separation of biomolecules is illustrated in Figure 1.1. 
IM experiments can be divided into temporally and spatially dispersive methods. 
While temporally dispersive methods separate ions in time but along the same path, 
spatially dispersive methods separate ions along different trajectories. Temporally 
dispersive methods can obtain a complete IM spectrum in one cycle. In contrast, spatially 
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Figure 1.1. 2D-separation plot of mass-to-charge ratio (MS) and ion mobility (IM). 
Different biomolecular classes are separated based upon their gas phase packing 
efficiency allowing for separation of isobaric molecules. Adapted from L.S. Fenn and 
J.A. McLean, Analytical and Bioanalytical Chemistry 2008, 391, 905-909, Figure. 2(a), 
with permission from Springer Science+Business Media. 
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dispersive methods are conventionally configured to transmit ions within a narrow range 
of mobilities at a time. This work focuses on temporal ion dispersion through the use of 
travelling wave ion mobility instrumentation. 
 
1.2.2. Travelling Wave Ion Mobility 
 Despite travelling wave ion mobility (TWIM) being a relatively new IM 
technique, it was the first commercially available IM instrument (Syanpt HDMS, Waters 
Corporation).
38
 The basic components of the travelling wave IM are similar to those in 
DTIM, where ions travel through the drift region under the influence of an electric field 
filled with a low static pressure (1-5 Torr) of nitrogen gas. In TWIM the ring electrodes 
confine ions to the center of the device to reduce ion loss by applying a radio-frequency 
potential.
39
 A key difference between TWIM and DTIM is the manner in which ions are 
propelled through the drift region. In TWIM, a pulsed voltage is applied on neighboring 
ring electrodes and is rapidly switched in the direction of the mass spectrometer (TOF). 
This generates a travelling wave with the capacity of separating ions by their mobility. 
Smaller ions are capable of traveling with or “surf” the wave and have higher velocities. 
On the other hand, larger ions due to the higher number of collisions have a slower 
velocity and cannot travel efficiently with the wave. These slower ions roll over the top 
of the wave and wait for the next wave cycle to carry them forward. The number of times 
an ion rolls over a wave is directly related to its mobility. In this manner, only ions that 
roll over a wave will be separated and ions with different sizes travelling in the same 
wave will arrive at the same time with no useful mobility separation. Therefore, tuning of 
factors such as traveling wave height and velocity and the neutral drift gas pressure is 
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necessary in order to obtain high quality mobility separation and avoid activation via 
high-energy ion-neutral collision-induced dissociation (CID).
39
 
 
1.3 Pre-ionization Separations 
 Pre-ionization separations techniques are commonly coupled to both MS and IM-
MS in order to circumvent analyte signal interferences. Despite the potential of IM to 
separate isobaric interferences, a third dimensional separation is commonly needed due to 
two limitations: i) IM has a limited resolving power of ca. 40 (author’s laboratory), 
resulting in limited mobility separation for analytes of interest contained within complex 
samples and ii) ion suppression effects have long been known to hinder the ionization 
process particularly in ESI sources. Thus, if an insufficient number of ions are generated 
in the ion source, low signal-to-noise ratios (S/N) will be observed in the mass spectrum. 
This ultimately limits the limit of detection and dynamic range of the analysis. The 
underlying reason for these suppression effects is due to the fundamentals of 
electrospray, including droplet formation and fission. Previous work suggests that 
reduced evaporation efficiency is the most likely suppression mechanism.
40-44
 The main 
reasons for this reduced evaporation are hypothesized to be several-fold.  
i) Non-volatile molecules increase the boiling point by altering the colligative 
properties of the solution. 
ii) Certain non-volatile compounds (e.g. detergents) can have a high surface activity 
and accumulate on the surface blocking analyte and solvent molecules from 
reaching the outer surface of the droplet. This results in a higher surface tension 
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and decreases the evaporation of the solvent from the droplet, which are key 
processes for both the charge residue model and the ion evaporation model.    
iii) Non-volatile salts can crystallize during ESI, causing co-crystallization with 
analyte molecules preventing the transition from liquid- to gas-phase. 
iv) Large sphere of hydration of strongly solvated ions (e.g. Na
+
, K
+
, etc.) restrict the 
mobility of analyte molecules to the surface of the droplet. 
v) Competition for the charge can occur between different analytes with different 
affinities to adopt a charge being present in the same droplet, causing ion 
suppression. This type of ion suppression effects are not easily avoided in the 
analysis of complex samples, whereas different offline techniques for the removal 
of detergents and salts are widely utilized to address the often causes of 
suppression. 
The use of pre-ionization separations reduces ion suppression effects by 
separating the different analytes of complex samples to a different droplet composition 
and reducing the number of co-eluting molecules at a particular time. Furthermore, the 
separation of non-volatile salts from analytes of interest increases the ionization 
efficiency of the ESI source. Several pre-ionization techniques have been utilized with 
both MS and IM-MS. Gas chromatography, high performance liquid chromatography and 
capillary electrophoresis (CE) have proved to be amenable for enhancing peak capacity 
and orthogonality in the analysis of complex samples.
45-48
 One shortcoming of coupling 
condensed-phase separations with IM-MS is the reduction of throughput and analysis 
speed. While IM-MS spectra can be acquired in ms, condensed-phase chromatography 
techniques range in the order of minutes to hours. As mentioned previously, the 
10 
 
application of LC separations can be applied to wider range of analytes and it is not 
restricted to only volatile compounds, as is the case for GC. However, the high viscosity 
and low diffusivity of water and organic solvents combined with the trend of smaller 
particle size (< 2µm) stationary phases (ultra or ultra-high performance liquid 
chromatography, UPLC or UHPLC) cause extremely high column backpressure, 
resulting in lower flow rates. Some of these limitations can be addressed by utilizing 
supercritical fluid chromatography (SFC). An interesting concept of utilizing the special 
physical properties of supercritical fluids for chromatography was first described by 
Klesper and co-workers in 1962 for the separation of organometallic compounds.
49
 The 
supercritical fluid is defined as any substance at a temperature and pressure above its 
critical point, where distinct liquid and gas phases do not exist. The critical point for CO2, 
the most common mobile phase used today, lies at 31.1 °C and 72.9 atm. In this region 
CO2 acts as both gas and liquid therefore, has the density and extraction properties of a 
liquid and diffusivities and viscosity characteristics of a gas (Figure 1.2). These 
properties allow for higher flow rates compared to LC techniques.  Increased flow rates 
decrease the analysis time, which can be of great benefit in large studies.
50-53 
A subset of LC is size exclusion chromatography (SEC), which applications range from 
the separation of large proteins in the life sciences to the characterization of synthetic 
oligomers and polymers in large-scale industry processes. The advantage of SEC is the 
separation of molecules based only on size and
 
length regardless of their chemical 
composition and atom arrangement, similarly to IM. Interestingly, both IM and SEC have 
been utilized in obtaining useful structural information about specialized polymers in 
their respective conformations in both solution and gas-phase.
54-59 
11 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. (A) Schematic of the relationship between solvating power and volatility 
of analytes in gas chromatography (GC), liquid chromatography (LC) and SFC. (B) 
Schematic of the wide polarity coverage of analytes in SFC compared to normal phase 
(HILIC) and reversed phase liquid chromatography (RPLC). 
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1.3.1. Liquid Chromatography 
 Separating very polar high molecular weight biopolymers was at one time thought 
to be impossible by GC due to concerns of thermal instability. This challenge attracted 
the interest of many scientists and led to the development of HPLC in the 1960s.
60, 61 
The 
basic principle of LC separations could be described as exploiting differential chemical 
and physical interactions (e.g. adsorption, partition, hydrogen-bonding, etc.) between 
analytes and both mobile and stationary phases. In current LC column technology, the 
most predominant stationary phase material used are porous silica particles with different 
surface chemistries tailored for different applications. For example, reversed phase liquid 
chromatography (RP-LC) stationary phase consists of silica particles with long aliphatic 
chains, usually C18, which are design to retain analytes based on their hydrophobic 
characteristics.
62
 On the other hand, HILIC (hydrophilic interaction liquid 
chromatography) stationary phase consist of a polar particle surface with free hydroxyl-
groups or other basic functional groups such as amino or amide moieties. These highly 
polar functionalized surfaces are designed to retain analytes based on much more 
complex interactions, such as polarity and electrostatics.
63
   
As with the stationary phase, the selection of the mobile phase requires certain 
considerations. In reversed-phase chromatography, highly aqueous mobile phases are 
used at the beginning of the chromatogram and gradients increasing the content of 
organic solvents are applied to systematically release retained molecules from the 
hydrophobic stationary phase.
64
 Conversely, HILIC utilizes high organic solvent 
composition during the early stages of the separation and gradually increasing the H2O 
content elutes more polar metabolites.       
13 
 
1.3.2. Supercritical Fluid Chromatography 
Historically, supercritical fluid chromatography (SFC) developed an unfavorable 
reputation of being irreproducible as a result of post-column pressure fluctuations and a 
low polarity mobile phase (CO2), which limited its use to a small number of applications, 
especially the analysis of nonpolar analytes. Significant technical advancements in the 
development of pressure regulation instrumentation, and more precise injection systems 
were subsequently developed to significantly improve analytical reproducibility.
65-68
 In 
order to broaden the applicability of SFC analysis, the community optimized the 
technique for the analysis of polar analytes by using organic solvents as modifiers (e.g. 
methanol, acetonitrile, etc.) with polar and/or ionic compounds as additives (e.g. 
ammonium acetate, ammonium formate).
69
 These improvements allowed both the mobile 
phase and surface chemistry of the stationary phase to be tailored based on experimental 
necessity.
70
 Recently, these developments have resulted in the application of 
contemporary SFC to a wide variety of analyte classes (e.g. lipids, small molecules and 
peptides).
71-73
 Since the mobile phase is predominately CO2, only small amounts of 
organic solvents are used in contrast to HPLC, which has allowed SFC to be categorized 
as a “green” analytical tool.71 Furthermore, numerous parameters can be used 
independently to optimize separation, such as pressure, temperature, and mobile phase 
composition, allowing for tunable separations. For example, pressure and temperature 
affect the density of the mobile phase, which is directly proportional to the solvating 
power. The mobile phase composition and polarity interacts with both the analytes and 
stationary phase, which results in polar stationary phases adsorbing modifier molecules 
(e.g. methanol), changing the stationary phase polarity and separation characteristics.
53,
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SFC has been coupled to numerous different types of detectors including: ultraviolet-
visible (UV-Vis), evaporative light scattering detector (ELSD), Fourier transform 
infrared (FT-IR) and mass spectrometry (MS) to name a few. 
74,
 
77
 
While these advancements have resulted in a highly versatile chromatography 
technique, one area of SFC separations which requires significant exploration is the 
selection of both stationary and mobile phases.
53
 Conventionally, columns and co-
solvents are selected by screening different combinations using representative analyte 
standards. This approach is costly and time-consuming, but necessary, since predictions 
of ideal parameters and conditions are not currently available. Screening stationary and 
mobile phases for retention and separation is straightforward when the analyte 
composition of the sample is known and standards are available, which is the case in the 
majority of the studies in the pharmaceutical industry. However, when analyzing 
unknown biological samples (e.g. bacterial extracts, cancer tissue, cell lysate, etc.) in 
untargeted metabolomic studies, the countless possibilities of different parameter settings 
is a daunting endeavor. The selection and screening of the optimum mobile phase, 
stationary phases and other physical parameters (temperature, pressure, etc.) during 
method development is a formidable challenge, especially when thousands of analytes 
with different chemistry are present. 
 
1.3.3. Size Exclusion Chromatography 
 Size exclusion chromatography, also known as gel permeation or gel filtration 
chromatography, separates particles on the basis of molecular size.
78
 Molecules with 
different length or size but similar chemical composition will be separated in SEC based 
15 
 
solely on their hydrodynamic volume.
79
 The principle lies in that longer chains, with 
larger hydrodynamic volumes cannot enter the pores of the stationary phase, flowing 
through the column faster than smaller molecules whose elution path or distance 
increases when entering the pores. This technique is largely applied to high molecular 
weight molecules or macromolecular complexes such as proteins and industrial polymers 
with the purpose of separating different sized particles for further analysis but also for the 
determination of the molecular weight distribution (MWD).
80, 81 
 
 The characterization of the MWD of synthetic polymers represents a major 
challenge for polymer chemists in spite of the large economic incentives in detailed 
formulations of specialized compounds. Some of those challenges are: i) synthetic 
processes are known to create complex mixtures of products with different physical and 
chemical properties such as linear, cyclic and dendrimers structures to name a few. This 
results in different ionization efficiencies for the different species, making quantitation 
extremely difficult by MS. ii) The separation of such complex mixtures based solely in 
their chemical composition is achieved only through liquid chromatography at critical 
conditions (LCCC), where parts of the analyte are made invisible to the stationary phase. 
However, LCCC requires extensive optimization and the conditions can only be 
determined empirically.
82, 83
 Figure 1.3 illustrates the different chromatographic 
behaviors of SEC, LCCC and traditional liquid adsorption chromatography (LAC), where 
only LCCC shows no selectivity for analytes exhibiting different molecular weights.  
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Figure 1.3.  Conceptual plot of the relation between molecular weight and elution 
time for size exclusion chromatography (SEC), liquid chromatography at critical 
conditions (LCCC) and liquid adsorption chromatography (LAC). 
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1.4. Integration of Pre-ionization Separations with Ion Mobility-Mass Spectrometry 
 The integration of pre-ionization separation to the two-dimensional separation 
space of ion mobility and mass spectrometry adds a third dimension of separation, which 
is orthogonal to IM-MS (Figure 1.4). It is worth discussing the fact that that IM and MS 
are not completely orthogonal to each other due to the correlation of molecular mass and 
size.
46 
This is perceptible when considering that heavier ions will inherently occupy a 
larger volume or space. This mobility-mass correlation is termed “conformational 
space”.84 
 
1.4.1. Analyte Coverage 
Comprehensive metabolite coverage, especially for untargeted studies, increases 
the possibilities of detecting relevant features for biological probing. In an effort to 
integrate metabolomics into a systems biology-based analysis, all-inclusive analyte 
coverage incorporating a variety of analytical techniques is desirable. With this in mind, a 
study was undertaken in which the metabolite coverage between four different separation 
techniques coupled to IM-MS was evaluated based on the number of features unique to 
each particular chromatography technique. These consisted of two stationary phases with 
SFC (silica and ethyl-pyridinium, Si and EP respectively) and two stationary phases with 
LC (RP and HILIC). The different interactions between stationary and mobile phase 
inherent amongst these different separation techniques (RP-LC, HILIC, SFC-Si and SFC-
EP) suggest very different analyte coverage. For this study, SFC columns were selected 
based on the “normal phase” characteristics of silica columns and orthogonality of the EP 
packing material to more common phases, as suggested in previous studies by West and 
18 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Three-dimensional separations space of pre-ionization separation 
(chromatography) coupled to the two-dimensional conformational space of IM-MS. 
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Lesellier.
85
 Previous experiments comparing RP-LC and SFC using a cyano column for 
separation of pharmaceutical compounds have been conducted,
86
 however, to our 
knowledge, no comprehensive analysis of complex biological samples using RP-LC, 
HILIC and SFC (Si and EP) have been reported. Siuzdak and coworkers studied 
differences between HILIC and RP-LC separations of bacterial cell pellets and human 
cancer cells and determined ≥30% overlap, while in our laboratory results demonstrate an 
overlap of 2%.
87
 These results could be explained by the differences in samples types 
(bacterial strains, extraction, etc.). 
In this work, features detected in positive and negative ion mode were combined 
and then compared for each separation techniques (Figure 1.5 (A)). The total number of 
features for each sample results was determined by subtracting the background and 
eliminating chemical noise using blank samples. The highest number of unique features 
was detected by RP-LC (1657), while HILIC, SFC-EP and SFC-Si had similar number of 
detected unique features (966, 979 and 959 respectively). Minimal overlap is observed 
across all 4 separations (only 8 features). The overlap between HILIC and SFC 
techniques is much higher (7.6%) than between RPLC and the SFC techniques (2.1%), 
which suggest that the SFC methods have more “normal-phase” characteristics. When 
comparing SFC-Si and SFC-EP, the number of overlapping features is only 17.5%. These 
results indicate very specific types of interactions and specialized chromatography 
interaction that exist between stationary phase, mobile phase and analytes in supercritical 
fluid separations, which agree with previous work described by West and Lesellier.
53
 
Further exploration of different columns with different functional groups (i.e. cyano, diol, 
amino and phenyl) could potentially increase metabolome coverage.  
20 
 
 
 
 
 
 
 
Figure 1.5.  A) Venn diagram illustrating the number of features observed in the 
bacterial extract mixture detected by RPLC, HILIC, SFC-Si and SFC-EP and the 
relations between. B) Venn diagram represents the relation of features detected between 
LC and SFC separation techniques.   The total number of detected species across all 
separation techniques is 5,304. 
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A Venn diagram depicting the number of features observed in LC and SFC 
techniques is contained in Figure 1.5 (B). The LC techniques (RPLC and HILIC) were 
capable of detecting more than half of the total number of observed features (~57%), 
however SFC (SI and EP) detected a considerable number of unique features (~43%). 
These data demonstrate that SFC analyses nearly doubled the number of detected features 
allowing for a more comprehensive global metabolic profile. In these studies, a total of 
5,304 features were observed by combining all techniques (RPLC, HILIC, SFC-Si and 
SFC-EP).  
The ion polarity is another factor to take into consideration due to different 
analyte affinities to preferentially adopt different ion forms. The different contribution of 
unique features observed in both positive and negative ion mode for each separation 
technique investigated is illustrated in Figure 1.6. The data illustrates that the highest 
number of features detected in RP-LC were in positive mode (~70%, 1265 features). 
Positive ion mode also contributed slightly more to the number of features in both SFC-Si 
and SFC-EP techniques (~60% and 56% respectively). On the other hand, ~56% of the 
features observed in HILIC were also observed in negative ion mode. These results 
concur with a previous study where, positive and negative ion mode contributed more to 
RPLC and HILIC respectively.
87
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Figure 1.6.  Metabolome coverage by RP-LC, HILIC, SFC-Si and SFC-EP in both 
ESI positive and negative ion mode expressed as the percentage of total number of 
features detected by each separation technique. 
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1.4.2. Peak Capacity and Peak Capacity Production Rate 
In the evaluation of analytical separation efficiency ad throughput, two relevant 
descriptors are peak capacity () and peak capacity production rate ( s-1). These values 
represent the number of peaks that theoretically can be observed within the observation 
range and resolution of a given analysis. Higher peak capacity and peak capacity 
production rate translate to an increase in the number of samples that can be analyzed 
during a defined period of time.  
Since IM is not completely orthogonal to MS due to the correlation between size 
and mass,
46 
full separations space in IM-MS is not utilized. As a result, the effective area 
in an IM-MS spectrum must be scaled appropriately by calculating and dividing the 
average FWHM of several selected peaks in both dimensions (mobility and m/z).
88
 In 
order to determine the areas in which analytes emerge, selected peaks with high, medium 
and low drift times across the entire m/z range (100 to 1,000) are plotted such that all 
peaks are enclosed, thereby establishing an empirically derived set of separation 
boundaries. Peaks detected by several different separation techniques possessing high, 
medium and low drift times were selected for these calculations. Using these parameters, 
the effective IM-MS analysis area is calculated. The chromatographic peak capacity () is 
determined by dividing the total time of the chromatographic run time by the average 
FWHM of the eluting analytes. Because polarity and hydrogen bonding capability are 
ostensibly orthogonal to IM-MS measurements, the peak capacity of each platform (SFC 
with a silica and ethyl-pyridine stationary phase, HILIC and RPLC) was calculated by 
multiplying by the chromatography dimension. Peak capacity production rates ( s-1) 
were determined by dividing the total peak capacity by the total analysis time (or 
24 
 
chromatogram length). These calculations are elaborated on later in this section for SFC-
EP. What follows is a brief review of experimentally reported peak capacities for these 
separations techniques, which can be used for theoretical estimations.  
Previously, peak capacities have been conservatively measured for SFC and ion 
mobility to be ~30-50,
89, 90
 and ~40,
 48 
respectively. The peak capacity for high resolution 
TOF is estimated here as and ~30,000 (routinely, a mass resolution of 15,000 is obtained 
with the Synapt G2-S in resolution mode with a mass range from 100 to 1000 m/z) 
respectively.  Theoretically, the combined peak capacity for the LC-IM-MS system 
described above using conventional LC would be ~3.6 x 10
7 
with a peak capacity 
production rate of 3.0 x 10
4
 s
-1
 for a 20 min chromatography run. However, using the 
above parameters and taking into consideration the speed of SFC, we calculate a peak 
capacity production rate of 1.0 x 10
5 
s
-1
 for a 3 min run, which is comparable to 
previously reported peak capacity production rates for small molecules (<1000 m/z) 
analysis by SFC-MS.
86
 In our calculations, we conservatively chose a mass resolution of 
15,000 and m/z between 100 -1000.  
Figure 1.7 illustrates the analytical area of IM-MS conformational space plot, 
with 84 features plotted across all four separation techniques (21 each) and includes 
selected high and low drift times across the 100-1000 m/z range. Lines were selected to 
enclose all features and therefore define the effective analysis area of IM-MS (2779.02 
ms x Da). Once the analytical area of IM-MS was determined, the peak capacity of the 2-
D separation was calculated by dividing by the average FWHM of the selected mobility 
peaks and m/z correlated values of peaks extracted from each of the different separation 
techniques (e.g. 5.49 x 10
-3
 ms x Da, IM-MS ϕ = 5.06 x 105 for SFC-EP). Subsequently,  
25 
 
 
 
 
 
 
 
 
 
Figure 1.7. Peak capacity diagram of IM-MS for the range of 100 – 1000 m/z. The 
area is calculated by means of integration (2779.02 ms x Da).  Lines capable of enclosing 
all of the selected features in all chromatography types are plotted and used to calculate 
the effective area of emerging analytes.  
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total peak capacity of the 3-D separation was calculated by multiplying the peak capacity 
of each chromatography method (e.g. SFC-EP ϕ = 52, 3-D ϕ = 2.29 x 107). The peak 
capacity production rate is then calculated by dividing by 720 seconds, which is the full 
length of the chromatogram (ϕ s-1 = 3.18 x104). Calculations were performed for each 
experiment type (SFC-Si, SFC-EP, RP-LC and HILIC) (Table 1.1), where similar values 
were obtained for peak capacities for all separations. However, SFC exhibits higher peak 
capacity production rates, which underscores the enhanced analytical throughput afforded 
by SFC. 
 
1.5.3. Tandem Ion Mobility Methods and Fragment Ion Correlation  
 Ion mobility-mass spectrometry instrumentation offer substantial flexibility for 
conduction tandem experiments. Given the necessary transition between pressurized IM 
and vacuum MS, ion guides, operated at relatively high pressures are used to transfer ions 
efficiently into and out of the IM region.  For TWIMs instruments, this in turn, provides 
the conditions necessary to perform collision induced dissociation experiments before 
and after ion mobility separation. In this work, all ion mobility experiments were 
performed in the Synapt G2 and G2-S platforms, which consist of two ion transfer 
regions capable of CID experiments in front and after the mobility region in addition to 
conventional in-source fragmentation. The practical benefit of pre-mobility fragmentation 
is the possibility to separate the fragmentation product ions in the mobility cell, allowing 
for mobility information to be obtained for the different products (Figure 1.8.). However, 
in this configuration, isobaric precursor species will not be separated prior to mobility. 
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Table 1.1. Comparison of peak capacity and peak capacity production rate among 
RPLC, HILIC, SFC-Si and SFC-EP stationary phases.    
Instrument 
setting 
Stationary 
phase 
Peak capacity [ɸ] Peak capacity production rate [ɸ s-1] 
HPLC-IM-MS 
C18 1.86 x 10
7
 1.73 x 10
4
 
HILIC 1.84 x 10
7
 2.04 x 10
4
 
SFC-IM-MS 
EP 2.29 x 10
7
 3.18 x 10
4
 
Si 1.97 x 10
7
 2.74 x 10
4
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Figure 1.8. ESI-TWIM-MS/MS ion fragmentation schematic illustrating the two 
modes of IM-MS/MS. Fragmentation in the Trap and Transfer region are referred as pre- 
and post-mobility fragmentation. In pre-mobility fragmentation, ions are fragmented 
before IM separation (TWIM), resulting in different drift times for the different 
fragments ions. Alternatively in post-mobility fragmentation, the fragments ions are 
aligned to their respective precursor ion due to the fact that the mobility measurement is 
performed on the precursors. 
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Thus, a convoluted tandem spectrum will be acquired and fragment ions originating from 
multiple isobaric species will not be resolved. 
 The alternative tandem mode is to first separate the isobaric interferences by their 
different mobilities and subsequently fragment the ions in the post-mobility transfer 
region (Transfer). The result is a correlation of the product ions with the precursor ion in 
the mobility dimension. In addition to resolving fragment ions originating from isobaric 
precursors, chemical noise is also attenuated through this fragmentation mode. In this 
work and other literature this type of tandem experiments is termed “post-mobility”, 
“parallel ion” or “all ions” fragmentation.91-93 
In the identification of metabolites, particularly from untargeted workflows, high 
mass resolution and high mass accuracy are necessary to obtain an accurate measurement 
of the primary analyte descriptor, molecular mass.
94
 High confidence mass information is 
then used to search databases
95-97
 and compare to literature for putative metabolite 
identifications. Without high mass accuracy, the confidence levels are not high enough 
for distilling the different possible molecular formulas of the metabolite of interest. 
 In order to increase the throughput, an approach has been applied to metabolite 
identification that relies primarily on high mass accuracy to interrogate the entire sample, 
post separation. This methodology is termed MS
E
, and achieves comprehensive ion 
fragmentation in to interlaced steps: i) data is acquired over the desired m/z range in full 
scan mode.
98
 Then ii) collision energy is applied to all ions present in the collision cell 
(no prior mass selection) in a ramp from low to high energy. This process is repeated 
over and over again for the duration of the chromatography resulting in two separately 
accessible data files at each LC time bin, which combines both full scan and 
30 
 
fragmentation data. With the high mass accuracy and post mobility separation of the 
instrument, product ions can be correlated back to their corresponding precursor ions 
during offline data analysis. Furthermore, the addition of pre-ionization separation allows 
for further product-precursor ion correlation by comparing retention times and peak 
shapes of extracted ion chromatograms. 
 The limitations inherent to conventional tandem mass spectrometry are also 
present in tandem experiments incorporating IM, namely the insensitivity to low intensity 
precursor ions and limited information for structurally similar compounds. For example, 
fragmentation spectra of compounds differing in one chiral center are indistinguishable 
form one another and this are insufficient for specific molecular identification. 
Additionally, constitutional isomers such as leucine and isoleucine yield very similar 
fragmentation patterns and consequently other techniques such as NMR can provide 
better information about structural arrangements.  
 
1.5. Summary and Perspectives of Dissertation Research 
 Ion mobility techniques rely on the separation of ions in the gas-phase based upon 
differential velocities under the influence of an electrical field in a neutral gas 
environment. These differences in the velocity of ions are a result of collisions between 
the ions and the neutral gas molecules, with larger ions experiencing more collisions than 
smaller ions due to their larger gas-phase packing efficiency.  
 The integration of ion mobility separation with mass spectrometry (IM-MS) has 
been developed for various arrangements all post-ionization as both IM and MS require 
that the analyte be in ion form. These integrations produce two-dimensional separations 
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based upon both mobility and mass-to-charge (milliseconds to microseconds, 
respectively). The differences in separation times allows for hundreds of mass spectra to 
be obtained for each mobility spectrum. Despite limited orthogonality between these two 
separations, more information is generated with combined IM-MS and, both peak 
capacity and signal-to-noise are increased. Furthermore, the correlation between mobility 
and mass shows dependence upon inherent molecular characteristics such as 
intramolecular forces, atomic composition and molecular architecture, which allows for 
preliminary biomolecular and metabolite class designation.  
 While IM is an important separation technique for differentiating isomers, 
isobaric molecules with identical molecular formulas can have similar mobilities, which 
cannot be resolved by IM and thus limits the capabilities of IM-MS for comprehensive 
analysis. AS a result, efforts to expand the coverage of different type of molecules in both 
complex biological and synthetic samples analysis have turned to coupling IM-MS to 
pre-ionization separation techniques based on orthogonal properties, mostly through 
electrospray ionization. The dispersion of analytes to different regions of the 
chromatogram can increase the analyte coverage by limiting analyte ionization 
competition in the ion source, while simultaneously reducing concomitant signals in the 
analysis. 
 The ability to perform fragmentation experiments between separations in an ion 
mobility-mass spectrometer increases analyte information, which results in an increased 
identification confidence. Fragmentation is commonly prefaced with mass-to-charge 
selection using scanning mass analyzers, commonly a quadrupole (Q), with the goal of 
isolating a single mass-to-charge band or window. The option of fragmentation both 
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before and after ion mobility separation results in product ions or isobaric precursor ions 
separated in the mobility dimension, respectively. Broadband fragmentation (MS
E
)
 
can be 
also be obtained by ramping the fragmentation energy applied in the CID process and 
with ion mobility in post-mobility fragmentation in MS
E
 mode product ions can be 
correlated to their respective precursors. 
 The large amount of data acquired with a high-resolution mass spectrometer of 
complex metabolite samples containing thousands of compounds, requires intricate 
processing and prioritizing steps. Additionally, as described in section 1.4.1. Analyte 
Coverage, the selection of pre-ionization technique for untargeted metabolomic studies 
requires careful consideration, especially in instances where limited sample volumes are 
available. The focus of the work described herein seeks to utilize different separation 
techniques with diverse capabilities for improved characterization of complex samples 
and improve interrogating tools in support of systems biology. Chapter II describes the 
initial efforts to develop new methodology towards lipidomic studies using the special 
properties of supercritical fluids. Subsequently, lipidome changes were observed in innate 
immune cells of distinct phenotypes following polarization. Chapter III focuses on 
strategies for the analysis of mock-human liver constructs over time following specific 
toxic and antidote stimuli and comparison of results to in vivo metabolism, which resulted 
in the observation of a number of well-known metabolites. Chapter IV demonstrates the 
capabilities of state-of-the-art stationary phases and offers an alternative to LCCC for the 
separation and characterization of telechelic synthetic oligomers. Finally, Chapter V 
contains perspectives on future directions for both the work described here and, more 
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broadly, for the development and improvement of analytical tools for temporal 
interrogation of systems biology. 
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CHAPTER II 
 
UTILIZATION OF SUPERCRITICAL FLUIDS FOR ENHANCED 
CHARACTERIZATION IN LIPIDOMICS 
 
2.1.   Introduction 
Macrophages are tissue resident innate immune cells that defend against infection 
and help maintain a homeostatic microenvironment.
1, 2
 Traditionally, the term 
“macrophage” described a simple phagocytic leukocyte that existed essentially in two 
states: a resting/basal state and an activated, proinflammatory state. The latter, 
classically-activated form of the macrophage was thought to be the major cellular 
phenotype responsible for antimicrobial activities and the elaboration of inflammatory 
mediators such as TNFα and interleukins.  
This paradigm has been upended by the growing appreciation of cellular plasticity 
of macrophages to move across many shades of both pro- and anti-inflammatory 
phenotypes, a process referred to as polarization. Akin to T lymphocyte activation, the 
emerging model illustrated that macrophages are not only activated towards a classical, 
proinflammatory (M1) state but can also exist in an alternatively-activated, anti-
inflammatory (M2) state.
3-5
 Most recently, macrophage polarization has gone far beyond 
the dichotomous M1/M2 model, to include subsets of alternatively activated cells referred 
to as M2a, M2c, Mhem, etc.
4-7
 Polarization alters the repertoire of secreted cytokines, 
phagocytic capacity, and surface proteins presented by macrophages, allowing the cell to 
carry out varying effector functions. A number of diseases and pathogenic conditions are 
associated with specific polarization states,
8-11
 making the understanding of macrophage 
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polarization in the context of health maintenance and disease pathogenesis critical to 
improving the capacity to prevent macrophage-mediated diseases.  
Peripheral blood monocytes, differentiated with macrophage colony stimulating 
factor (M-CSF) into macrophage-like cells, serve as a predominant human model cell 
type for characterizing macrophage polarization known as monocyte-derived 
macrophages (MDMs).
12-16
 Classical, M1polarization is typically generated by 
stimulating these cells with IFN-γ in combination with bacterial lipopolysaccharide 
(LPS).
12-15
 The M2a and M2c phenotypes are generally modeled by incubating 
monocyte-derived macrophages with either IL-4 or IL-10, respectively.
12-15
  
Conventional approaches to define polarized activation states have been confined 
to gene expression profiles, the display of certain cell surface proteins, or the expression 
of characteristic intracellular or secreted proteins. Furthermore, marker overlap between 
polarized subsets is sometimes observed when using these approaches.
14,
 
17
 This lack of 
marker specificity supports the notion of a spectrum of activation as opposed to distinct 
subsets and requires the use of several markers when defining similar phenotypic 
subtypes.
7,
 
18
 Additionally, post-transcriptional and post-translational modifications do 
not always allow for direct correlation of protein levels. Metabolomics, on the other hand, 
has the potential to overcome the limitations of genomics and proteomics given its 
position at the end of the “omics” cascade.19 While both unbiased proteomic20, 21 and 
transcriptomic
13, 15
 approaches have been used to more fully characterize macrophage 
polarization, there are limited studies that have applied an unbiased metabolomic 
approach to this evolving paradigm. It is well-recognized that metabolic differences 
between activated macrophages exist
22-24
 however, little research has been done to 
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develop the association between metabolic differences and macrophage polarization and 
what the relationship between the two entails.  
Metabolites are broadly defined as small molecules involved in cell metabolism. 
A metabolite profile that includes the total metabolites produced by cells is known as the 
metabolome. An emerging field of science, metabolomics is deeply advanced by the 
onset of new technologies allowing for the analysis of large data sets.
25, 26
 Regardless of 
their chemical diversity, the totality of lipid molecules in cells is referred to as the 
lipidome and forms a subset of the metabolome given the rapid metabolism into 
biologically active metabolites. Located on many cellular structures, particularly 
membranes, lipids play critical roles in energy storage, membrane structure, and 
signaling.
27, 28
 Many autocrine and paracrine signaling molecules are lipids, including, for 
example, the eicosanoids, which have substantial immunoregulatory capabilities.
29, 30
 
Furthermore, dysregulated lipid biosynthesis and metabolism have been implicated in a 
number of human diseases, such as atherosclerosis,
31
 non-alcoholic fatty liver,
32
 
diabetes,
33
 Alzheimer’s disease,34 and cancer.35, 36  
Advances in lipidomic techniques and strategies, led by the LIPID MAPS 
consortium, have greatly enhanced our understanding of the distribution and biological 
roles of lipids.
37-41
 Furthermore, modern mass spectrometry (MS) coupled with 
electrospray ionization (ESI) have played key roles in qualitative and quantitative 
lipidomic analysis. Typical MS-based lipidomic strategies are shotgun (i.e., direct 
infusion) lipidomics
37, 42
 and liquid chromatography LC-MS lipidomics.
39, 43, 44
 Shotgun 
lipidomics relies on partial intrasource separation of lipid classes through varying the pH 
of the lipid solution and identification of lipid species by their characteristic 
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fragmentation in tandem MS analysis.
37, 45
 This approach has the advantage of being 
high-throughput, but it also has several disadvantages: a) suppression of low-abundant 
species by major polar lipids such as phosphatidylcholines; b) difficulty in analysis of 
lipid species that are poorly ionized by ESI; and c) inability to provide structural 
information on isobaric and isomeric species. The LC-MS-based strategy utilizes targeted 
analysis of each lipid class under conditions that are optimized for that particular class.
39, 
43, 44, 46 
This strategy has the advantages of being specific, sensitive, and comprehensive, 
but it also has limitations such as low throughput and once again, no structural 
information can be obtained. To increase the throughput of the LC-MS lipidomics while 
maintaining the specificity and sensitivity, improved chromatographic techniques and 
additional dimensions of separation that is orthogonal to LC and MS would be desired. 
 Ion mobility spectrometry (IMS) provides such orthogonal separation.
47-52
 IMS 
separate ions based on the mobility of the ions traveling through a neutral background gas 
(most commonly helium and nitrogen), which is governed by collision frequency 
between the ions and the neutral gas, i.e., the ion-neutral collision cross section (CCS; Ω). 
The CCS is determined by the size and shape of the ions in the gas phase and the specific 
neutral gas, with larger molecules experiencing more collisions than smaller ones. When 
ion mobility is coupled with mass spectrometry, a two-dimensional separation is achieved 
on the basis of the charge-to-collision cross section (z/Ω) and the mass-to-charge (m/z), 
respectively. Several ion mobility (IM)-mass spectrometry (MS) techniques have been 
applied to lipidomic analysis, including drift time ion mobility (DTIM)-MS,
53-55
 traveling 
wave ion mobility (TWIM)-MS,
56, 57
 and differential ion mobility spectrometry (DMS).
 
58-60
 In DTIM-MS, the ions travel through the neutral gas-filled drift tube under a low and 
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static electric field, which leads to separation of ions on the scale of micro to 
milliseconds.
49
 DTIM offers high IM resolving power and allows direct measurement of 
CCS. Using DTIM-MS, the Woods
53
 and our laboratories
54, 55
 have independently 
reported some separation of different polar lipid classes based on their headgroups and 
the acyl chain composition. DMS, or asymmetric-field ion mobility spectrometry 
(FAIMS), separates ions based on their different mobilities at high and low electric fields 
as the ions are swept by a flowing gas through an asymmetric voltage waveform 
comprised of high and low fields. Recently, the groups of Ekroos and Dennis 
successfully applied DMS to both shotgun and LC-based lipidomics, achieving more 
specific and sensitive analysis.
59, 60
 While DMS offers the highest resolving power, the 
drawbacks include a) only selective ions with certain mobilities in the two fields can pass 
through the device and b) the separation in DMS does not correlate with the CCS of the 
ions, i.e., no structural information can be obtained directly and the behavior of certain 
ions cannot be predicted by CCS values. Traveling wave ion mobility (TWIM) also 
separates ions based on their CCSs, similar to DTIM, but it uses a migrating low-voltage 
wave to push the ions through the inert gas,
61
 instead of a steady electric field as in 
DTIM. TWIM offers higher sensitivity than traditional DTIM, but has lower IM 
resolution and does not allow direct measurement of CCS values. However, CCS of 
unknown ions can be indirectly calculated by calibrating against appropriate ions with 
known CCS values.
57
 TWIM has been used to characterize the effect of unsaturation on 
the mobility of phosphatidylcholines,
56
 i.e., double bonds on the acyl chain lead to 
reduction in drift time, and thus smaller CCS. The commercial TWIM platform, used in 
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this study, is well integrated with different chromatographic separation techniques and 
MS analysis. 
  To achieve fast and efficient lipid separation, we turned to supercritical fluid 
chromatography (SFC). Supercritical fluids (SF) have the density and extraction ability 
that is similar to liquids, but viscosity and diffusivity more similar to gases, which makes 
SF suitable for high-speed separation without causing excess backpressure.
62, 63
 SFC 
utilizes a supercritical fluid as mobile phase, with CO2 being the most common one used 
because of its wide availability and easily-reached critical state (73 atm and 304 K). 
Frequently, a small amount of a modifier solvent, such as methanol and acetonitrile, is 
used to make SFC applicable to the separation of polar compounds. Previous studies 
comparing the analyte coverage between traditional LC (such as reverse phase, normal 
phase, and HILIC) and SFC suggest similar coverage for a large and diverse library of 
compounds, but offering in certain cases some high degree of orthogonality.
64, 65
 A few 
years ago, Bamba and co-workers pioneered the application of SFC-MS in lipidomics, 
demonstrating separation of lipid classes using a cyano column and separation of lipid 
species within the same class by the length of the acyl chains using a C18 column.
66
 
In this study, we report a) the development of an SFC chromatographic method 
that rapidly separates over ten lipid classes with a wide variety of polarity; b) coupling of 
SFC with TWIM-MS to achieve a three-dimensional separation of lipids; c) application 
of SFC-IM-MS to profiling the lipidome of the brain from wild type mice; and d) 
interrogate distinct lipidome alterations in macrophages corresponding to major 
polarization phenotypes (M1, M2a, M2c). We found that ion mobility selection of lipid 
signals was particularly powerful in increasing the signal-to-noise ratio of the 
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chromatographic peaks, deconvoluting overlapping lipid species, and fully characterizing 
fatty acid composition of the different lipid classes in negative ion mode. These findings 
introduce new technologies that can be used to deepen our current understanding of the 
molecular biology of macrophage polarization. 
 
2.2.   Experimental 
Materials 
All solvents were CHROMOSOLV-grade (Sigma-Aldrich, St. Louis, MO). Lipid 
standards were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Lipid 
standards include phosphatidylcholines (PC, chicken egg), phosphatidylethanolamines 
(PE, porcine brain), phosphatidylserines (PS, porcine brain), phosphatidylglycerols (PG, 
chicken egg), phosphatidylinositols (PI, bovine liver), phosphatidic acids (PA, chicken 
egg), sphingomyelins (SM, porcine brain), ceramides (CE, porcine brain), 
monogalactosyldiacylglycerol (MGDG, plant) and sulftides (porcine brain).  
Triglycerides (TG) were purchased from Nu-Chek Prep, Inc. (Elysian, MN). The 
standards were prepared as 10 μM solutions in a 1:1 mixture of chloroform and 0.1% 
(w/v) ammonium formate in methanol. Recombinant Human M-CSF and IFNγ 
(PeproTech, Rocky Hill, NJ). Recombinant Human IL-4 and IL-4 (R&D Systems, 
Minneapolis, MN).  HyClone Charcoal/Dextran Treated FBS (GE Healthcare Life 
Sciences HyClone Laboratories, Logan, Utah).  RPMI 1640 Medium 1X without HEPES 
supplemented with L-Glutamine and Phenol Red (Gibco by Life Technologies, Carlsbad, 
CA).  Ultra-pure LPS from Escherichia coli K12 in endotoxin-free water (Invivogen, San 
Diego, CA). 
50 
 
Mice model 
Wild type C57BL/6J mice were purchased from Jackson Laboratories. The mice 
were kept and bred in Division of Animal Care facilities at Vanderbilt University to give 
the desired number of 3-week old mice (N = 3). At the appropriate time, the mice were 
euthanized, brain tissue dissected, and instantly frozen in pre-cooled 2-methylbutane (on 
dry ice) and stored at -80ºC until lipid extraction. All procedures were performed in 
accordance with the Guide for the Humane Use and Care of Laboratory Animals. The use 
of mice in this study was approved by the IACUC of Vanderbilt University. 
 
Human subjects 
 This study was reviewed and approved by the Vanderbilt University Institutional 
Review Board (protocol #140699). Subjects included healthy, non-pregnant adults (age 
18-60). Exclusion criteria included: fever >101
 o
F in preceding 48 h, antibiotic therapy 
currently, or within the prior 2 weeks, current immunosuppressive therapy or short-term 
steroid therapy within the prior 2 weeks, chronic viral infection, including, but not limited 
to, HIV infection (per self-report), and/or currently diagnosed with or undergoing 
treatment for cancer 
 
Isolation and cultivation of monocyte-derived macrophages 
Peripheral blood mononuclear cells (PBMCs) were isolated from human 
peripheral blood by density gradient centrifugation using Ficoll-Paque
TM
 as outlined by 
the manufacturer Miltenyi (Auburn, CA). Following centrifugation, monocytes were 
isolated from PBMCs via negative selection using the Miltenyi Monocyte Isolation Kit 
51 
 
II
®
 as instructed by the manufacturer. Monocytes were cultured in 6 well plates at a 
concentration of 1.35x10
6
 monocytes per well for seven days in 100ng/mL M-CSF in 
RPMI+/- with 20% FBS to differentiate into MDM as previously described.
15
 Following 
differentiation, cells were allowed to rest for 24 hours by replacing M-CSF+ RPMI+/- 
with M-CSF- RPMI+/- prior to carrying out downstream experiments.  
 
Macrophage polarization  
After monocyte differentiation (7 days), cells were treated for 24 hours in 
RPMI+/- with 5% FBS with 20 ng/mL of polarizing stimuli, IFNγ, IL-4 and IL-10 for 
M1, M2a and M2c respectively. Additionally, 100 ng/mL LPS were added to M1 cells. 
Cultures destined for both PCR and Lipidome analysis were treated equally.  
 
Lipid extraction 
Lipid extraction of mouse brains (vertical cut half brain; ~ 200 mg) was 
performed following previously reported procedures and the dried extracts were re-
constituted in 1 mL of methylene chloride.
67
 Macrophage lipids were extracted with 500 
µL of 5% HCl and 750µL of Folch solution (2:1, CHCl3:MeOH with 17mg/L butylated 
hydroxytoluene) were added to cell pellets for lipid extraction. Samples were vortexed 
and centrifuged briefly at 15,000 rpm. The organic layer was removed and dried under 
vacuum. Samples were stored at -80°C until analysis.  
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Supercritical Fluid Chromatography-Ion Mobility-Mass Spectrometry (SFC-IM-MS) 
All MS analyses were conducted on a Synapt G2-S (Waters Corp., Milford, MA) 
time-of-flight mass spectrometer (TOF-MS) with an electrospray ionization (ESI) source. 
An UPC
2
 SFC (Waters Corp., Milford, MA) system with Ethylene Bridged Hybrid 
(BEH) Silica column (1.7m, 3.0 x 100 mm, Waters Corp., Milford, MA) was used. The 
temperatures of autosampler and column were maintained at 8 and 60 °C, respectively. 
Unless otherwise specified, chromatographic conditions for SFC separation were 
as follows:  injection volume 2 μL, mobile-phase flow rate 1 mL/min (measured in the 
liquid state) and column outlet pressure 2000 psi. The mobile-phase composition gradient 
was as follows: Initial 10% modifier in CO2 and after injection, modifier concentration 
increased to 40% in 7 minutes. Then the concentration was increased to 80% in one 
minute and held at 80% for 4 minutes. The modifier consisted of 10 mM ammonium 
formate in methanol. 
The positive-mode (+) ESI conditions were as follows: capillary, +2.28 kV; 
sampling cone, 40 V; source temperature, 100 °C; desolvation temperature, 150 °C; 
desolvation gas flow, 500 L/h; and cone gas flow, 20 L/ h, respectively. The traveling 
wave velocity and height for IM separation were 652 m/s and 40 V, respectively. 
Leucine–enkephalin (m/z 556.2771) was used for lock mass correction. The negative-
mode (-) ESI conditions were the same as that of the positive-mode except for the 
capillary voltage, source temperature and desolvation temperature (-2.52 kV, 125 °C, 150 
°C). The data acquisition was carried out in MS
E
 mode with transfer collision energy 
ramping from 40 to 50V in both positive- and negative-mode. 
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Data Analysis 
Lockspray mass correction was applied after acquisition using the vendor 
supplied software, followed by batch conversion to mzXML format. After peak filtering, 
detecting and aligning with XCMS
68
 the features (discrete retention time and m/z values) 
were assigned to a phospholipid class by their retention time and accurate mass. For 
further analysis, features only found in standards or databases such as METLIN
69
 and 
LIPIDMAPS
38,
 
70
 with mass tolerance below 10 ppm were taken into account.  
 
2.3.  Results and Discussion 
2.3.1. Optimization of SFC separation using lipid standards.  
We first attempted to develop a SFC chromatographic condition using glycerol 
lipid and sphingolipid standards with a wide range of polarity, including triglyceride 
(TG), phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylglycerol (PG), and 
phosphatidic acid (PA). We found that using a similar condition to the one reported by 
Bamba and co-workers, a gradient of 10% to 40% of the modifier solvent (methanol) at a 
flow rate of 2 mL/min, most lipid classes were eluted from the Waters UPC
2
 ethylene-
bridged hybrid (BEH) column except for PS and PA. We reasoned that the retention of 
PS and PA was due to their large polarity. Thus, we applied a rapid increase (within 1 
min) in the percentage of methanol from 40% to 80% (at a slower flow rate of 1 mL/min 
due to large backpressure) after the initial slow gradient from 10% to 40% (over 7 min), 
which allowed the elution of PA and PS as one peak. Although there is partial 
overlapping between a few lipid classes, such as PE and PI, PA and PS, etc., the 
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additional ion mobility separation allowed deconvolution of individual classes as 
discussed in the following sections. Under the optimized chromatographic condition, all 
lipid classes were eluted within 11 min as shown in Figure 2.1. 
 
2.3.2. Analysis of lipid extracts from mouse brain 
Brain is the organ that is most rich in lipids. For example, human gray matter 
contains 36-40% of lipids (out of dry weight), white matter contains 49-66% of lipids, 
and myelin has the highest lipid content at 78-81%.
71
 In addition to the absolute amount, 
the lipid species found in the brain are quite diverse.
37
 Abnormal brain lipid metabolism 
has been suggested to be associated with a number of human diseases with defective 
central nervous system, such as Alzheimer’s disease,34 cholesterol biosynthesis 
disorders,
72
 and Niemann–Pick C disease.73 Thus, a comprehensive lipidomic analysis of 
the brain is of high significance. 
Here we examined the lipid extracts from brain tissues of three-week old wild-
type mice using the newly developed SFC-IM-MS method (Figure 2.2). The 
chromatogram obtained from total ion current (TIC) is somewhat noisy and only a few 
peaks were recognizable (Figure 2.2 (B)). However, upon extraction of the lipid signals 
from the two-dimensional IM-MS spectrum (as drift time and mass-to-charge ratio, 
respectively) (Figure 2.2 (A)), a chromatogram with more peaks and significantly larger 
S/N was obtained, highlighting the benefit of this three-pronged approach (Figure 1.2 
(C)). Not surprisingly, unknown lipid species not tested during our method development 
were detected. However, after analyzing the accurate mass of the unknown peaks and 
subsequently additional lipid standards, all peaks in the chromatogram were identified. 
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Figure 2.1. Chromatogram of lipid standards in A) positive-ion and B) negative-ion 
mode as described in Experimental. Higher ionization efficiencies are observed for 
different classes in both positive and negative mode. TG, triglyceride; PG, 
phosphatidylglycerol; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PC, 
phosphatidylcholine; SM, sphingomyelin; PA, phosphatidic acid; PS, phosphatidylserine.  
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Figure 2.2. Chromatogram of lipid extracts from mouse brain with and without IM in 
negative mode as described in Experimental. A) 2-D lipid region of drift time and mass-
to-charge ratio separation space. B) SFC chromatogram without IM extraction. C) SFC 
chromatogram after IM extraction increases signal-to-noise ratio. 1, ceramide; 2, MGDG; 
3-5, cerebroside; 6, sulfatide + P- or O-phosphatidylglycerol (PG); 7, sulfatide + diacyl 
PG; 8, phosphatidylethanolamine (PE); 9, phosphatidylinositol (PI); 10, 
phosphatidylcholine (PC); 11, sphingomyelin (SM); 12, phosphatidic acid 
(PA)+phosphatidylserine (PS). 
 
 
  
57 
 
The ability of IM separation to remove chemical noises can be reasonably 
understood based on previous reports.
52, 74
 We have shown that at the same m/z value, 
lipids occupy the largest gas phase conformation (i.e., CCS), followed by peptides, 
carbohydrates, and nucleotides, in that order.
52
 In other words, lipid ions are the least gas-
phase packing efficient among all biological molecules. On the other hand, ions that give 
rise to chemical noise, such as those formed from other classes of biological molecules 
(metabolites, peptides, etc.), plasticizer and salt aggregates, generally have high gas-
phase packing efficiencies, resulting in smaller CCS. Thus, extraction of the lipid specific 
two-dimensional IM-MS separation space led to a much cleaner chromatogram as shown 
in Figure 2.2 (C). 
 The IM-MS analysis was also carried out with post-mobility collision-induced 
dissociation (CID) to obtain additional structural information. In MS
E
 mode both low- 
and high-energy spectra for all ions present are collected. Additionally, one unique 
feature of the post-mobility fragmentation is that all the fragments would align with their 
corresponding precursors at the same drift time in the IM-MS 2D spectrum, which allows 
extraction of all MS/MS spectrum for each individual precursor even if the species were 
eluted at the same time (as long as they are separated in IM). Thus, in the positive ion 
mode, identification of some lipid classes can be confirmed by their characteristic 
fragmentation of the headgroups, such as PC, SM, and PE. In the negative ion mode, fatty 
acid composition (as fatty acid anions) of majority of lipid classes can be obtained. Post-
mobility fragmentation of PE in both modes was illustrated in Figure 2.3 as an example, 
which shows loss of the headgroup and fatty acid anions as the predominant fragments in  
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Figure 2.3. Illustration of post-mobility fragmentation (MS
E
) of individual peaks in 
both positive and negative modes. A) and B) show the SFC chromatogram for both 
positive and negative mode. Panels C) and D) illustrate the 2-D separation space of drift 
time and mass-to-charge ratio for PE with post mobility fragmentation, where fragments 
ions (e.g. loss of ethanolamine phosphate and arachidonic acid (AA) in E) and F) 
respectively) have the same drift time as the molecular ion. This advantage of IM 
facilitates fragment ion to molecular ion assignment in untargeted MS/MS analyses.  
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positive- and negative-ion mode respectively. Thus, data obtained from the two modes 
provide complementary information for lipid identification. 
 
2.3.3. Deconvolution of co-eluting lipid classes by IM separation 
Although most lipid classes were separated by SFC, a number of them co-elute or 
overlap, such as sulfatide and PG, PI and PE, PA and PS, etc. In the event of co-elution, 
the advantage of the IM separation is evident in deconvolution of individual lipid classes. 
Because the gas-phase packing efficiencies of different lipid classes are intrinsically 
different, co-eluting lipid species tend to occupy different space in the IM-MS 2D 
spectrum further demonstrating the advantages of coupling techniques with separations 
based on orthogonal physical properties such as IM and SFC (size and polarity, 
respectively). A few examples are illustrated below (Figures. 2.4-2.7; all in negative ion 
mode).  
As seen in Figure 2.2, sulfatides co-elute with PGs as two peaks at 3.6 and 3.9-min, 
respectively. By searching through the LIPID MAPS database, we found that PGs eluting 
at 3.6-min contain mainly ether-linked PGs (plasmalogen or alkyl ether; P- or O-PGs) at 
sn-1 position (observed as [M-H2O-H]
−
) while PGs eluting at 3.9-min are made up of 
normal diacyl PGs (observed as [M-H]
−
). This is not surprising considering that brain is 
rich in plasmalogen lipids, mostly in the form of PE.
75, 76
 For each peak, sulfatide and the 
co-eluting species occupy unique space in the IM-MS 2D spectrum, which allows 
differentiation of not only the parent ions but also their fragments (Figures. 2.4 and 2.5). 
Specifically, both types of PGs adopt smaller gas-phase conformations than sulfatides 
and undergo almost complete fragmentation to give fatty acid anions as the major  
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Figure 2.4.  IM-MS deconvolution of sulfatides (observed as [M-H]
-
) and 
plasmalogen or alkyl-ether-linked phosphatidylglycerols (PGs) (observed as [M-H2O-H]
-
) on top and bottom panels respectively, co-eluting at 3.6-min. MS
E
 in negative mode 
(right panels) illustrate fragment ions for each particular lipid class. Sulfatides have 
longer drift times compared to co-eluting PGs but much lower fragmentation yields 
(panels B and F).  
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Figure 2.5. IM deconvolution of sulfatides (observed as [M-H]
-
) and diacyl 
phosphatidylglycerols (PGs) (observed as [M-H]
-
)
 
on top and bottom panels respectively, 
co-eluting at 3.9-min using MS
E
 in negative mode. 
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fragments in the negative mode. On the other hand, sulfatides adopt larger conformation 
and undergo less fragmentation at the same CID conditions. The complete MS and 
MS/MS spectra of sulfatides can be obtained by the sum of the 3.6 and 3.9-min peaks, 
followed by extraction of the sulfatide IM-MS 2D spectrum region. A similar approach 
can be applied to deconvolute the partially overlapping PIs and PEs as well as PAs and 
PSs as shown in Figures. 2.6 and 2.7. 
 
2.3.4. Fatty acid composition of individual lipid classes obtained by post-mobility 
fragmentation in negative mode. 
As discussed above, in the negative ion mode, lipid anions tend to fragment to 
give fatty acid anions that would reflect the fatty acid composition of each lipid class. In 
addition, the position of substitution (sn1and sn2) can in some cases be identified by not 
fully fragmented ions (loss of one chain) shown in Figure 2.3. By examining the 
negative-mode MS/MS data of all lipids found in Figure 2.2, three categories of lipid 
classes can be defined: i) lipid classes that fragment almost completely to fatty acids 
anions, such as PE, PA, PC, ceramide, MGDG, and PG; ii) lipid classes that give 
significant, but not predominant, amount of fatty acid anions, such as PI and PS; and ii) 
those that give minimum amount of fatty acids fragmentation, including sulfatide, 
cerebroside, and SM. Thus, using the fragmentation information, the fatty acid 
composition of lipid classes belonging to categories i) and ii) can be qualitatively 
obtained (Table 2.1). We emphasize that CID fragmentation yields are indirectly 
proportional to ion mass.
77
 Thus, the relative fatty acid composition does not provide  
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Figure 2.6. IM deconvolution of phosphatidylinositols (PIs) and 
phosphatidylethanolamines (PEs) on top and bottom panels respectively, co-eluting at 
5.7-min using MS
E
 in negative mode. 
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Figure 2.7.  IM deconvolution of phosphatidylserines (PSs) and phosphatidic acids 
(PAs) on top and bottom panels respectively, co-eluting at 8.8-min using MS
E
 in negative 
mode. 
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absolute quantitation data. However, these fatty acid profiles allow for estimations of the 
composition of the different lipid classes. 
Additionally, same lipid class comparisons between different samples can be 
made. As seen from the table, PE and PI have the highest content (percentage) of 
polyunsaturated fatty acids (PUFAs). Specifically, PE contains the highest level of 
docosahexaenoic acid (DHA) while PI is the richest in arachidonic acid (AA). This is 
consistent with a previous report, which further supports the ability of this lipid profiling 
technique.
78
 Overall, the PUFA content decreases in the order of PI ≈ PE > PA > PG > 
PS > P- or O-PG > PC > MGDG while ceramides do not contain any PUFA. Note that for 
ceramides, fatty acyl amide anions were observed instead. Although PCs and SMs 
strongly co-elute, the fatty acid fragments would mostly origin from PCs due to the 
smaller fragmentation yields of SMs in comparison to PCs under the CID conditions used 
in our study (no significant amount of fatty acyl amide anions from SMs were detected).  
 
2.3.5. Gene expression confirms in vitro polarization of MDMs 
Previous studies have identified markers that can be used to characterize polarized 
macrophages.
14, 15, 79, 80 
To confirm that MDMs were successfully polarized into distinct 
subsets, four representative genes were selected to conduct gene expression profiles of in 
vitro polarized cells in comparison to that of untreated cells (Figure 2.8). CD80 and 
CCR7 were used as markers of M1 polarization while CD209 and CD163 were used as 
markers of M2a and M2c polarization, respectively.
14, 15, 79
 In response to M1 polarization 
generated by treating cells with IFNγ in combination with LPS, CD80 and CCR7 
expression was upregulated compared to untreated controls (Figure 2.8 (A, B) while  
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Figure 2.8. In vitro polarization of MDMs confirmed using gene expression. 
Following polarization, cells were lysed and evaluated for expression of M1 markers 
CCR7 (A) CD80 (B), M2a marker CD209 (C) and M2c marker CD163 (D). Values 
expressed as fold change using ΔΔCt method compared to untreated controls. Resting 
untreated controls were set to 1 and all treatments normalized to GAPDH. (Experiments 
repeated > n=4; * indicates p ≤ 0.05, ** indicates p ≤ 0.01, and **** indicates p ≤ 
0.0001) 
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CD209 and CD163 expression were down regulated (Figure 2.8 (C, D). M2a polarization 
generated by IL-4 treatment was evidenced by an increase in CD209 expression with no 
changes seen in M1 or M2c marker expression. In response to IL-10 generated M2c 
polarization, expression of the M2c marker CD163 was significantly upregulated. IL-10 
treatment also induced the expression of CD80 and CD209. Together these data confirm 
that we can successfully polarize MDMs into M1, M2a, and M2c subsets using well-
established in vitro stimuli.  
 
2.3.6. Membrane phospholipid composition of MDMs 
For the analysis of membrane phospholipid composition, the combination of SFC 
with IM-MS provides the necessary information for the identification of the lipid classes 
and their respective fatty acid composition. The separation of phospholipids classes is 
achieved efficiently based on the polarity of their respective head group, with less polar 
classes (e.g., phosphatidylglycerols) eluting before more polar classes (e.g. 
phosphatidylcholines).
66
 Subsequently, low- and high-energy spectra collected in MS
E
 
mode provides accurate mass and fragments for lipid class identification and fatty acid 
composition in positive and negative ion-mode respectively. Despite the fact that lower 
intensities are observed for longer chain lengths and higher degrees of unsaturation,
81
 the 
separation of lipid classes prior to ionization minimizes ionization suppression effects 
and permits direct comparison of the distribution of individual phospholipids species 
within its class across samples. 
Six major membrane phospholipid (PL) classes were identified, 
phosphatidylcholines (PCs), phosphatidylethanolamines (PE), phosphatidylserines (PS),  
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phosphatidylglycerols  (PG), phosphatidylinositols (PI) and sphingomyelins (SM). Their 
total mass spectrometry signal (intensity) was calculated and individual species 
abundancies are reported as the percent (percent contribution or distribution, Tables in 
Appendix B) of the total signal for each class. This relative quantitation lipidome analysis 
was able to detect changes in species distribution within each phospholipid class in all 4 
activation states. It is evident from the 3D principal component analysis plot in Figure 2.9 
that controls and M1 MDMs are the furthest apart in principal component 1 Furthermore, 
both M2 groups are separated from controls and M1 but group closely in principal 
components 1 and 2. However, in principal component 3, substantial differences were 
recognized between M2a and M2c MDM, identifying them as unique “phenotypes” in the 
three-dimensional macrophage polarization space.  
We analyzed the membrane lipid composition of each class independently and compared 
them across resting, M1, M2a and M2c MDMs. Given the different lipid composition 
within different organelles and plasma membranes as well as asymmetric lipid 
distribution, the localization of lipid changes is not surveyed in this lipid profiling 
study.
28
 PL classes mainly located in the cytosolic leaflet or luminal side of plasma 
membranes are shown in Figures 2.10 and 2.11 respectively. During the polarization of 
macrophages, distinct phospholipase A2 enzymes are involved in the arachidonic acid 
(AA) mobilization for consequent eicosanoid production.
82
 Figure 2.10 (A-C) shows the 
percent composition of selected species (higher composition and higher changes) for PE, 
PI and PS respectively. Phospholipid species are abbreviated (lipid class, number carbon 
atoms and double bonds of both acyl chains combined) due to the fact that fragmentation 
of individual m/z species result in fragments corresponding to various acyl groups, 
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making the assignment of individual structures not possible. Drops in the composition of 
species with an unsaturation degree of 4 or higher (possibility of containing AA) were 
expected for polarized MDMs.
83
 However, small overall changes were observed for 
statistically significant (p–value <0.05) lipids. The highest changes were detected for 
PE(38:4) and PI(38:4), where the composition decreased after activation by 1.6-2.5 and 
2.3-3.8% respectively. Interestingly, the opposite profile was observed for PI(38:5). 
Given the nature of the percent distribution of all species within a lipid class, the decrease 
of one species is commensurately compensated by the increase of other species. Thus, 
lipids with lower degrees of unsaturation show an increase in polarized MDMs such as, 
PI(36:2), PS(36:2) and PE(34:1). Similarly, on the non-cytosolic (luminal side), changes 
in the fatty acid distribution of PCs and SMs were observed (Figure 2.11). The increase 
of PC(30:1), PC(32:0) and PC(34:0) and the decrease of PC(36:4), PC(38:4) and 
PC(40:5) indicate AA mobilization. However, it is not clear if this mobilization is 
entirely for lipid mediator synthesis or the release of AA surpasses the eicosanoid 
production. Another possibility is that the released AA is simply being exchanged with 
serum proteins as it has been previously reported for RAW 264.7 cells.
84
 Figure 2.11 (C) 
illustrates the changes observed in in PG. These are consistent with the other classes, 
particularly PE and PC. Higher distribution is determined for species not containing AA 
(PG(34:1), PG(34:2), PG(36:1) and PG(36:2)) for polarized MDMs compared to resting. 
Statistically different lipid species, not only between polarized and resting macrophages 
but also between similar phenotypes such as M2a and M2c are of great interest for the 
determination of polarization. Six species, PC(32:1), PC(O-32:1), PC(34:3), PI(38:3), 
PI(38:5) and PS(36:2) are statistically different in the different polarization states. It is  
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Figure 2.9. Three-dimensional PCA plot of lipid profiles for control, M1, M2a and 
M2c MDM. PC1 separates controls, M1 and both M2 groups (M2a and M2c have similar 
grouping in PC1). In both PC2 and PC3 M2a and M2c are grouped separately.  
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Figure 2.10. Comparison of relative distribution of individual lipid classes in in the 
cytosolic leaflet in controls, M1, M2a and M2c MDM. A), B) and C) illustrate the 
changes for PE, PI and PS respectively. Lipids with highest contribution and changes 
were plotted. (* indicates p-value<0.05 for control-M1 comparison, **indicates p-
value<0.05 for control-M2a comparison, *** indicates p-value<0.05 for control-M2c 
comparison and **** indicates p-value<0.05 for M2a-M2c comparison). 
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Figure 2.11. Comparison of relative distribution of individual lipid classes in in the 
luminal side are illustrated in A) and B) (PC and SM respectively) for controls, M1, M2a 
and M2c. Panel C) represents the lipid distribution for PG Lipids with highest 
contribution and changes were plotted. (* indicates p-value<0.05 for control-M1 
comparison, **indicates p-value<0.05 for control-M2a comparison, *** indicates p-
value<0.05 for control-M2c comparison and **** indicates p-value<0.05 for M2a-M2c 
comparison). 
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worth noting that only PI(38:5) potentially contains AA. The largest change for species 
containing AA was observed in PG(40:7). The mechanisms of this particular changes is 
still unclear however, the fact that macrophages were derived from 3 different donors 
suggests a higher degree of orchestration in the polarization process.   
It should be noted that in spite of little difference in relative distributions, many 
species showed significantly different profiles across all groups, and the low variabilities 
(error bars) between biological replicates have an average standard deviation of 3.1% for 
lipids in all treatments plotted in Figures 2.10 and 2.11. The standard deviations for all 
species detected and for species with odd-numbered chain fatty acids are 4.2 and 6.7% 
respectively. The slightly higher deviation for odd-numbered chain fatty acids 
distribution could be caused by differences in the donor’s diet since they are not 
endogenous.
85
 
 
2.3.7. Fatty acid composition of different lipid classes in polarized monocyte-derived 
macrophages 
In previous studies, the macrophage fatty acid composition in murine cells has 
been investigated and absolute quantitative amounts have been reported.
86, 87
 In our study, 
we focused on differences between relative fatty acid compositions for different lipid 
classes among different groups. It is worth emphasizing that with collision-induced 
dissociation, fragmentation yields are indirectly proportional to the mass of the ion, so 
these relative estimations of fatty acid distribution within the same lipid class. Figure 
2.12 shows the changes in AA composition of 6 different phospholipid classes for all 4 
groups. (These values were selected using Tables B.1-B.4 in Appendix B). AA 
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Figure 2.12. Changes in arachidonic acid composition for different lipid classes for 
controls, M1, M2a and M2c macrophages (* indicates p-value<0.05, ** indicates p-
value<0.01, *** indicates p-value<0.005). 
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composition values decreased after M1 polarization as it would be expected in all lipid 
classes. The largest changes compared to resting macrophages (P <0.005) are observed in 
SM, PE and PI with 2.2 and 2.6 and 3.5% decrease respectively. Furthermore, the low 
AA levels observed in PC and SM could be explained by the low AA and linoleic acid 
(LA) concentrations in FBS (~7% and 5.5%of fatty acid composition respectively), 
especially considering the long culture time during derivatization and polarization.
88-92
 A 
previous fatty acid comparison determined that the AA content of total lipids was three 
times lower in macrophages derived from bone marrow to lipids of peritoneal 
macrophages.
93
 The smallest changes for all 4 groups are observed in PG, which is 
consistent with a previous study of classically activated murine resident peritoneal 
macrophages (RPM) cells.
84
 Additionally, the AA levels for each lipid class are lower in 
M1 than in both M2 activation states, supporting the predominant role of cytoplasmic 
phospholipase A2 (cPLA2) in AA mobilization during M1 polarization.
82
 Interestingly, 
AA composition is significantly different (p-value<0.01) between M2a and M2c MDMs 
for good substrate lipid classes highly abundant in AA such as PE and PI, with M2c 
having higher AA levels. Some lipid mediators detected in human MDMs such as 
resolvins, maresins and protectins are synthesized from docosahexaenoic acid (DHA).
94
 
Small DHA changes in the fatty acid composition of PG’s are observed between resting 
macrophages, M1 and both M2 subtypes. A decrease from 3.9% composition in resting 
macrophages to 2.1 and 2.5% was measured after M2a and M2c polarization respectively 
(Tables B.1-B.4 in Appendix B). However, the biggest change was observed in classical 
activation with a decrease to 1.6%.  
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These studies demonstrate that macrophage polarization is associated with 
changes in the lipidome of MDMs as evidenced by alterations in various classes of 
membrane phospholipids.  Moreover, we have established an innovatively applied 
methodology for rapid lipid profiling of polarized macrophages.  Our untargeted lipid 
profiling integrated to traditional gene expression analysis allowed for the identification 
of a wide range of lipid classes for specific macrophage polarization phenotypes. 
Furthermore, the monitoring of several lipid species has the potential of determining 
polarization subsets with overlapping phenotypes at the end of the “omics” cascade 
(Figure 2.9). The methods used in this study advance the field of macrophage 
polarization research by demonstrating that state-of-the-art lipidomic techniques can be 
used to further interrogate polarized human macrophages, a class of cells that are still not 
well characterized. 
As previously discussed, our gene expression analysis revealed common caveats 
that are presented when classifying cells using solely this technique such as marker 
overlap. This is observed when M2c polarization generated by IL-10 treatment 
upregulated both CD163 (M2c) and CD209 (M2a) to a similar extent while M2a 
polarization generated by IL-4 treatment only upregulated CD209 expression. These 
findings demonstrate the importance of including i) multiple markers for polarization and 
ii) differently activated macrophages to distinguish between subsets.  While we do not 
provide an exhaustive set of polarization markers, we instead chose 4 markers that 
display relative specificity between subsets.  
After confirming our in vitro polarization using gene expression, we sought to 
explore the extensive lipidome of polarized macrophages and find possible specific 
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markers.  By simultaneously collecting low- and high-energy spectra, both PL and acyl 
chain composition of the different lipid groups was determined. This methodology was 
able to depict the global membrane lipidomic picture of macrophage polarization and 
reveal characteristic lipid species for resting, classic, alternative and deactivated human 
monocyte derived macrophages.  
 During the polarization process, different lipid mediators’ biosynthetic pathways 
involving several enzymes are expressed and activated to different extents. Studies have 
shown that different expression profiles of the major participants in fatty acid 
mobilization (hydrolysis), cPLA2 and sPLA2, have been observed in human monocyte-
derived macrophages treated with LPS + IFNγ , IL-4 and IL-10.95 These phospholipases 
differ in specificity for fatty acid species and position in the glycerol backbone, affinity to 
different PL classes and localization within the cell upon activation.
82
 Thus, different PL 
pools are substrates in this highly orchestrated and not fully understood enzymatic 
process at different times.  Furthermore, some crosstalk between both phospholipases has 
been observed in mouse macrophages (P388D1) and other studies in human neutrophils 
showed the ability of sPLA2 to induce leukotriene biosynthesis by activating cPLA2.
96, 97
 
Furthermore, the formation of lysophosphatidylcholine by sPLA2 in the outer membrane 
causes an increase of Ca
2+
 concentration, which subsequently causes cPLA2 to be 
activated and translocated through activating protein kinases needed for the 
phosphorylation of Ser
505
.
82, 98, 99
 On the other hand, in human eosinophils, sPLA2 
induced eicosanoid production at plasma membranes and perinuclear membranes, 
independently of cPLA2 activation.
100
 These examples show the complexity of 
interconnectivity in fatty acid release in innate immunity. However, the combination of 
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the localization and characteristics (specificity and activity) of these phospholipases and 
the different PL composition of organelle membranes suggest a specific course in which 
these changes occur in membrane PL composition (Figures 2.10 and 2.11). Generally, 
lipid species capable of containing AA in either sn-1 or sn-2 positions were of lower 
abundance in M1 compared to resting macrophages. Alternatively, lipid species with no 
AA were more abundant in M1 compared to resting macrophages. On the contrary, 
PI(38:5) is considerably lower in resting macrophages compared to M1 and both M2 
phenotypes. Brown and co-workers observed a similar but less drastic trend in murine 
resident peritoneal macrophages.
84
  Anti-inflammatory M2 activation states showed 
similarities to both resting and classically activated groups. Interestingly, the largest 
changes between M2a and M2c were detected in lipid classes with high affinity to cPLA2 
(PE, PC and PI) but in AA-free species. The characteristic upregulation of sPLA2 in M2 
macrophages and its lack of sn-2AA specificity suggest that sPLA2 is most likely the 
enzyme responsible for the hydrolysis of these species. It should be noted that due to the 
large size of human macrophages (diameter > 30µm) the amount of PL is significantly 
high.
95
 Therefore, the changes detected in our study between the different treatments are 
relatively small. 
 Analysis of fatty acid composition of distinct PL classes allowed us to track 
global acyl changes and assign them to a region in the polarization spectrum. As 
mentioned above, the sn-2AA specificity of cPLA2 is responsible for the majority of the 
AA release. Across the 6 major PL classes the AA composition was lowest in M1 
compared to resting, M2a and M2c macrophages indicating higher AA release in 
proinflammatory macrophages. This is consistent with previous studies comparing lipid 
80 
 
mediators for M1 and M2a polarized human macrophages after IFNγ + LPS and IL-4 
treatment respectively, where the biosynthesis of inflammation associated prostaglandins 
was higher for M1 macrophages compared to M2a. On the contrary, relevant to 
resolution-associated lipids (resolvins and maresins), we observed a higher release of 
docosahexaenoic acid (DHA) in M1 compared to M2a (Tables B1-4). However, we 
measured DHA bound to different PL classes and not the lipid mediators directly. The 
lipid composition of the cytoplasmic face of Golgi and ER is poorly defined (known 
cPLA2 locations);
101
 hence, it is not possible to determine the origin and the amount of 
the AA released for lipid mediator production. Furthermore, the differences in activation 
and translocation of phospholipases can alter AA mobilization not only by regulating the 
hydrolysis efficiency but also by inducing translocation to other lipid membranes with 
different composition. PI and SM had the highest percentage of AA mobilization, with PI 
showing the largest changes between resting, M1, M2a and M2c macrophages (Figure 
1.12). Two interesting observations in the AA metabolism of M2 MDMs are apparent. i) 
M2c had the lowest AA release in all PL classes and ii) in PE, a substrate to cPLA2, no 
statistical difference was detected between both M2 and resting macrophages, though 
M2a and M2c are statistically different (P <0.01). Furthermore, PG showed no change in 
AA composition between resting and both M2 groups. The small composition of AA in 
SM distributed among different species limited the probabilities of being detected as a  
SM species during the low-energy spectra collection. Thus, the SM species plotted in 
Figure 2.11 lack AA. 
These experiments were carried out at a single 24 hour time point after treatment. 
Thus, we are unable to examine the plasticity of polarized profiles at earlier time points 
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over time and identify lipids that initially contained AA and served as substrate for 
prostaglandins biosynthesis and were later replenished. Full time course studies with 
sufficient temporal resolution will be necessary to understand the flux of AA and other 
fatty acids. Additionally, a global picture of the localization of the AA pools perturbed 
during macrophage polarization can be determined by fractionation of major organelles 
/compartments prior to the methodology described herein. Furthermore, it should be 
noted that various in vitro methods are used to differentiate human peripheral blood 
monocytes into macrophages. Alternative methods of differentiating monocytes into 
macrophages have been shown to alter downstream activation states.
102-104
 Translating in 
vitro polarization studies can also be difficult when factors such as cytokines, cell 
maturation, cell origin, chemokines, and adhesion that are omitted in the in vitro systems 
play major roles in vivo.
105, 106
 The nomenclature and methodologies used for modeling 
macrophage polarization in vitro vary greatly within the field and have recently come 
under fire.
107
 We instead chose the most common method of differentiating monocytes, 
using M-CSF, in an effort to maintain a reproducible experimental standard for the 
discovery/exploration of phenotypic small molecules changes. 
 
2.4.  Conclusions 
Conventionally, to obtain fatty acids composition of glycerol lipids, the individual 
lipid classes need to be fractionated by chromatographic techniques, followed by base 
hydrolysis, re-acidification, and re-extraction of each fraction, which is time consuming 
and labor intensive. The strategy employed in this study provides an efficient way to 
profile fatty acids composition for the majority of the lipid classes, in addition to 
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molecular ions, in a single run (MS
E
). With appropriate standards for each lipids class as 
described by LIPID MAPS, both the molecular ions and the fatty acids within each class 
can be quantified. 
In summary, a rapid and three-dimensional separation of over ten classes of lipids 
from mouse brain was achieved by SFC-IM-MS. Combination of full scan and post-
mobility fragmentation (MS
E
) gave a large amount of information from two parallel 
analyses (positive and negative modes), including individual lipid classes, headgroup 
information from positive-ion mode, and lipid class fatty acid relative composition from 
negative-ion mode.  
This methodology in combination with the lipid profiling data of both PL and fatty 
acid composition might be of utility to better understand and quantify the lipidome 
dynamic changes in the human monocyte derived macrophage polarization spectrum. 
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CHAPTER III 
 
METHODS FOR METABOLOME COVERAGE EXPANSION FOR UNTARGETED 
BIOMOLECULAR INTERROGATION 
 
3.1. Introduction 
With a declining trend in new drug approvals and a marked increase in the cost of 
drug development in recent years,
1
 a paradigm shift in the current drug discovery pipeline 
is imminent. The estimated cost to bring a drug to market exceeds US $1 billion dollars 
per drug (~$0.8-1.8 billion), which is concurrent with a swell of alternative innovation for 
drug development testing using miniaturized 3D cell culture environments to mimic 
organ physiology.
2
 When interconnected, these 3D cell-culture models provide a means 
to perform on-chip drug testing through monitoring mock-human organ functionality. 
The forthcoming integration of a system of organs into a human “circuit” will provide a 
potential realization of emulated human drug response.  
However, a significant consideration for the determination of organ stability and 
homeostasis is how to best monitor organ health and the analytical implications that arise 
from determining organ response to stimuli. With certain organs, such as the heart, 
metrics such as contractility, morphology, or a small set of metabolic indicators are used 
to establish organ viability and status. However, many organs, such as the brain, gut, and 
liver, would benefit from the analytical means of monitoring organ fitness as a spectrum 
of descriptors, instead of a Boolean state. Additionally, mechanism-specific indicators 
would allow enhanced insight into off-target interactions and affected pathways, as 
opposed to monitoring generic indicators of organ failure, such as alanine transaminase 
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(ALT) or aspartate transaminase (AST) production. Certain bioreactor constructs 
preclude monitoring through optical microscopy, requiring alternative, non-invasive 
methods of interrogation. Congruently, morphology is often an all-or-none phenomenon, 
and organ stress and the dynamic nature of metabolic response are often not reflected.  
Metabolic information can be obtained through monitoring of the fluctuations in 
small molecule production and consumption reflected in the medium of these mock-
organ constructs through mass spectrometry-based methodologies.
3
 This method, known 
as exometabolomic profiling, affords phenotypic insight of a system in a non-destructive 
manner.
4
 As a result of the considerable interconnected nature of the metabolome, a small 
perturbation in the omic cascade can lead to propagated changes in the concentrations of 
many metabolites.
5
  
Herein we present the analysis of temporal metabolic response of a perfused 3D 
four-compartment hollow-fiber membrane bioreactor grown with primary human liver 
cells to acetaminophen (para-acetylamino-phenol or APAP) and N-acetyl cysteine (NAC) 
exposure at different concentrations using ultraperformance liquid chromatography-ion 
mobility-mass spectrometry (UPLC-IM-MS) and self-organizing map (SOM) approaches 
to dynamic data analysis.
6
 Using a metabolomics-based approach to liver bioreactor 
(LBR) interrogation, we demonstrate a method of interrogating organoid health, 
investigation of response to stimulus, and subsequent correlation to metabolic pathways. 
Liver response to, and metabolism of, APAP has been well-documented not only due to 
its wide use but also due to the high frequency of poisoning cases.
7
 On the other hand, 
NAC is commonly used as antidote in APAP poisoning and prevents hepatic injury by 
restoring glutathione levels in the liver.
8, 9
 Thus, the combination of these two compounds 
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represents an appropriate system for study. Observed are small molecules, which are 
indicative of xenobiotic biotransformation, stimulus-specific and temporally-differential 
metabolic responses and dysregulation resulting from liver stress/damage. Significantly, 
many of these metabolic responses are observed in both dose-influenced and donor-
dependent manner. 
 
3.2. Experimental 
Bioreactor Fabrication and Seeding 
The 3D bioreactors used in this study (Stem Cell Systems, Germany) are made of 
four layers of hollow-fiber capillaries integrated into a polyurethane housing. Each 
hollow-fiber layer is composed of alternately arranged capillaries for gas perfusion 
(Mitsubishi, Japan) and medium perfusion (Micro PES®, Membrana, Germany). Cells 
are inoculated into the extra-capillary space serving as cell compartment (Figure 3.1). 
The capillary layers are arranged at an angle of 45° allowing for counter-current medium 
perfusion and decentralized gas exchange. The bioreactors are integrated into a tubing 
circuit with a total volume of 7 ml that allows for medium recirculation through the 
bioreactor, as well as fresh medium substitution and removal of used medium. Bioreactor 
cultures are maintained in a perfusion system (Stem Cell Systems, Germany) equipped 
with pumps for medium recirculation and medium feed, an electronically controlled 
heating unit and electronically operated gas valves (Vögtlin Instruments, Aesch, 
Switzerland) for regulation of the gas mixture (air, CO2) and gas supply rates..   
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Figure 3.1. Configuration of artificial capillaries inside the bioreactor. The capillary 
bed consists of four capillary layers arranged on top of each other. Each layer is 
composed of medium perfusion capillaries belonging to two independent capillary 
systems (red and blue), which are counter-currently perfused to enhance mass exchange. 
Medium perfusion fibers alternate with capillaries for gas perfusion (yellow). Transparent 
lids at the bottom and the top of the cell compartment allow for observation of the cells 
seeded in the extra-capillary space (gray region). Media is recirculated through a pump 
module, and aliquots are extracted from the reservoir for UPLC-IM-MS analysis.  
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Each bioreactor was filled each with 10 million primary human hepatocytes from 
a unique donor. A total of 9 bioreactors with cells from 3 different donors were used for 
this study. Cells were isolated from tissue remaining from partial liver resection with 
agreement of the donors and with approval of the local ethical committee. Cell isolation 
was performed by collagenase digestion according to Damm et al.
10
 The gained cell 
suspension was not further purified to avoid a loss of non-parenchymal cell fractions. The 
cell viability after isolation was 76-85% as determined by their capacity to exclude trypan 
blue. 
 
Bioreactor culture operation  
Bioreactors were perfused with Heparmed culture medium (Vito 143, Biochrom, 
Germany), a modification of Williams´ Medium E specifically developed for serum-free 
perfusion culture of high-density 3D liver cell cultures.  The medium was supplemented 
prior to use with 20 IU/L insulin, 5 mg/L transferrin, 3 mg/L glucagon, 100,000 U/L 
penicillin and 100 mg/L streptomycin (all purchased from Biochrom). Culture medium 
was recirculated at a rate of 1 ml /min, fresh medium was continuously fed into the 
perfusion circuit at a rate of 0.6 ml/h for the first 24 hours followed by 0.2 ml/h until the 
end of culture. Used medium was removed accordingly. The pH value in the recirculating 
medium was kept between 7.35 and 7.45 by adjusting the CO2 concentration in the 
supplied gas mixture. 
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Chemical stimulus comparisons 
Cells from three different donors (Table 3.1) were loaded into 9 bioreactors (3 
bioreactors for each donor) and treated with different drug cocktails (composition and 
concentration). Three different time courses were performed for each donor set of liver 
bioreactors. A control (no stimuli) and two different chemical stimuli were performed, 
ensuring biological replicates for the different conditions. The different conditions are 
summarized in Table 3.1. The exact time course can be seen in Figure C.1. 
Drug application was started on culture day 3. APAP (Sigma-Aldrich, USA) and 
NAC (Sigma-Aldrich, USA) were dissolved in methanol. Subsequently the methanol was 
evaporated and the substance was resolved in culture medium. Drug incubation was 
initiated by adding 1 ml of a 7x concentrated solution (bolus application) to reach the 
desired final solution of each drug. Subsequently drug cocktails added to the fresh 
medium were continuously infused into the perfusion circuit. 
 
Sample Collection and Processing 
In order to monitor the cell viability and functionality in the bioreactors, the 
release of intracellular enzymes alanine transaminase (ALT), aspartate transaminase 
(AST) and lactate dehydrogenase (LDH) were measured daily throughout the entire 
culture period in samples from the culture perfusate using an automated clinical 
chemistry analyzer (Cobas® 800, Roche Diagnostics, Germany).  
For UPLC-IM-MS analysis additional samples from recirculating culture media 
were collected at set intervals during drug exposure. 100 μL aliquots were collected 
immediately prior to exposure for all experiments and then at 15 and 30 minutes, 1, 2, 6,  
100 
 
 
 
 
 
 
 
Table 3.1.       Drug exposures to different liver bioreactors 
LBR # Patient gender (age) APAP [mM] NAC [mM] 
1 male (64) 10 - 
2 male (64) 5 - 
3 male (64) - - 
4 male (77) 10 - 
5 male (77) 10 10 
6 male (77) - - 
7 female (47) - - 
8 female (47) 5 10 
9 female (47) 5 - 
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24 and 72 hours after drug exposure. 50 μL from each aliquot were treated with 3:1 
volume of cold (-20 °C) MeOH, vortexed for 15 seconds, and spun for 10 minutes at 
14,500 rpm at 4 °C. 100 μL aliquots were then extracted, avoiding the precipitated pellet, 
and samples were dried down in a SpeedVac. Samples were stored at - 80°C and 
reconstituted in 80:20 ACN:H2O shortly prior to analysis. The single exposure samples 
were reconstituted in 10 μL aliquots were taken from each sample and pooled into a 
quality control sample, which is used as platform stability diagnostic. 
 
Data Acquisition and Processing 
UPLC-IM-MS
E
 data acquisition was performed with a nanoAcquity LC-system 
coupled to a Synapt G2 HDMS mass spectrometer both from Waters Co. (Milford, MA). 
Samples were analyzed with hydrophilic interaction liquid chromatography (HILIC) and 
a 1x100 mm 1.7 μm particle BEH Amide column (Waters Co.) was used. The mobile 
phase was composed of A = 10mM ammonium acetate + 0.1% formic acid in 90% ACN 
and B = 10mM ammonium acetate + 0.1% formic acid in 10% ACN. The initial solvent 
composition at 100 μL/min was 87.5% A, which was held for 1 min and decreased to 
62.5% over the next 3 minutes and held for 6 minutes. Then the composition of A was 
decreased to 50% and held for 2 minutes and returned to 87.5% and held for 10 minutes 
for equilibration. An autosampler was used for sample injection and held at 4 °C, with a 
loop size of 5 μL. 
IM-MS
E
 spectra were acquired at a rate of 2Hz from 50-1400 Da in positive mode 
for the duration of the injection. The instrument was calibrated to greater than 1 ppm 
mass accuracy using sodium formate clusters prior to analysis. A two-point internal 
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standard of leucine enkephalin was infused in parallel at a flow rate of 7μL/min and 
acquired every 10 seconds. IM-MS conditions were as follows: source temperature, 80 
°C; capillary, +3.5 kV; desolvation gas flow, 400 L/hr; and desolvation gas temperature, 
150 °C, respectively. The sampling cone was held at a setting of 35.0, with the extraction 
cone at a setting of 4.0. In the MS
E
 configuration, low and high energy spectra are 
acquired for each scan. High energy data performed a collision energy profile from 10-30 
eV in the transfer region, providing post-mobility fragmentation. Ion mobility separations 
were performed with a wave velocity of 550 m/s, a wave height of 40.0 V, and a nitrogen 
gas flow of 90 mL/min, with the helium cell flow rate at 180mL/min. Internal calibrant 
correction was performed post acquisition.  
Data were converted to mzXML format using the msconvert tool from the 
ProteoWizard package.
11
 Peak picking and alignment were performed using XCMS in 
R.
12
 The resulting data matrix contained 2691 detected features. Prior to SOM, analytical 
triplicates were averaged. Subsequently, the data was formatted for analysis using SOM 
with a grid of 30x31, 100 first phase training iterations and 180 in the second phase. An 
initial training radius of 8.0 was defined with a learning factor of 0.5, a neighborhood 
block size of 4, and a conscience of 3.0. For the second phase, a neighborhood radius of 
2.0, learning factor of 0.05, neighborhood block size of 2, and conscience of 3.0 was 
defined. A random seed of 1 with a Pearson’s correlation distance metric and random 
selection initialization was used.  
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Peak Identification 
Peak identifications were performed using accurate masses to search MELTIN,
13
 
LIPID MAPS,
14
 and HMDB databases.
 15, 16
  Additionally, other literature sources were 
used for fragmentation spectra.
17, 18
 When appropriate, adduct identities were inferred 
from spectral data. Fragmentation spectra were extracted using ion mobility separation to 
extract product ions specific to the analyte of interest, and these spectra were used to aid 
and confirm identifications, both through manual interpretation and comparison with 
database and literature fragmentation spectra, when available. For spectral interpretations 
of putative identified metabolites and fold changes, further information can be found in 
Appendix C. 
 
3.3. Results and Discussion 
Bioreactor Description 
The described 3D four-compartment hollow-fiber membrane bioreactor 
technology supports the high-density culture of primary human hepatocytes in a perfused 
environment. The creation of an artificial capillary bed made of four layers of capillaries, 
which each dispose of alternating medium and gas perfusion fibers allows for 
decentralized nutrient supply and metabolite removal, mimicking a highly-vascularized 
construct. Previously the sustained functionality of primary liver cells grown within the 
bioreactor has been reported, in addition to the formation of physiologically relevant liver 
constructs, including bile ducts, vascular structures and Kupffer cell distribution similar 
to native liver tissue in vivo.
19
  Primary human hepatocytes cultivated in the bioreactor 
showed a better preservation of metabolic activities as compared to conventional 2D 
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cultures.
20
 Moreover, the technology permits serum-free culture of primary liver cells 
without functional impairment,
21
 which is advantageous for complex medium analyses. 
Due to the possibility of varying the perfusion flow and mode, different ways of drug 
application can be realized, including continuous infusion, closed-circuit incubation and 
single-pass application. 
In this study, the effect on bioreactor cultures of primary human liver cells of 
APAP and NAC exposure were investigated on the basis of metabolites measured in the 
recirculating media. APAP was applied in two different concentrations, 5 and 10 mM, in 
order to detect possible effects of varying the drug concentrations. On the other hand 
NAC was applied at a constant concentration (10 mM) with both APAP concentrations. 
A commensurate concentration of the drugs applied was spiked into the media reservoir 
to achieve immediately either 5 or 10 mM APAP and 10 mM NAC. In addition the fresh 
medium used for supplementation was changed to drug containing medium, whereas the 
control bioreactor medium was changed, but no drug administered.  
 To investigate a possible influence of APAP on the cell integrity as well as the 
preventive function of NAC in APAP induced hepatic injury the liver enzymes AST, 
ALT and LDH were measured on a daily basis. Enzyme kinetics showed no significant 
changes upon drug application indicating no disturbance of membrane integrity.  
 
3.3.1. Metabolic Perturbations 
The exometabolomic effects of APAP exposure upon the liver bioreactor 
metabolome were investigated through analysis of media perfusate. We selected APAP 
and NAC based upon the comprehensive toxicological understanding already in place. 
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This provides a foundation to evaluate both i) bioreactor efficacy in emulating in vivo 
liver functionality and stability, and ii) the utility of the application of the proposed 
analytical methodologies to interrogate temporal perturbations in apparent metabolic 
phenotype. However, the data analysis for this system was approached in an untargeted 
manner, similar to the method for studying an unknown chemical.  
 
3.3.2. Self-organized Maps 
This SOM-based methodology is a data-driven organization of metabolic features 
based upon underlying patterns in the data, which uses unsupervised learning to create a 
low-dimensional projection of the data. This is a type of artificial neural network, which 
does not sacrifice the conditional and temporal connectivity of metabolic features in data 
depiction. For a comprehensive understanding of SOM analytics, we direct the reader to 
references  6 and 22. Conceptually, metabolites are grouped based upon similarities in 
production/consumption in response to both sampling time and chemical exposure. 
Metabolite locations in the grid are then used to depict samples based upon the intensities 
of these metabolites. As a result, heat maps of correlated metabolic features are generated 
for each sample condition. These heat maps can then be averaged across technical 
replicates and differential analyses are performed with time-matched controls, yielding 
regions of interest (ROI) with metabolites, which are dysregulated. These prioritized 
metabolites are then putatively identified through database searching, using accurate 
mass information and fragmentation data when standard reference material is not readily 
available. A primary advantage of utilizing a SOM-based approach for data analysis is 
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the ability to represent and cluster features, which have similar conditional and temporal 
intensities. 
Figure 3.2 demonstrates the temporal metabolomic differences of biological 
replicates resulting from different APAP concentration exposure (Figure 3.2 (A, B) and 
Figure 3.2 (C, D) correspond to 10 and 5 mM APAP treatment respectively). The upper 
heat map time course represents metabolites that are found in increased abundances (red 
regions) when compared to the average control profile (days 3-5). The lower heat map 
time course displays the opposite, with red regions corresponding to metabolites that are 
found in decreased abundance as a result of APAP exposure. The corresponding intensity 
scale is shown on the right, and the number of peaks corresponding to each grid location 
is described in the metabolite density plot. These time courses demonstrate the temporal 
extracellular metabolic changes. Prior to APAP administration, the metabolic profiles of 
the experimental and control bioreactors loaded with cells from the same donor show 
strong similarities, but also, some small differences across time points can be apparent. 
This illustrates the metabolic signatures of cell adaptation to the new environment (Figure 
C.2).  Immediately after APAP exposure, large differences appear, and persist throughout 
the time course, with the emergence and accumulation of other metabolite clusters 
prioritized through differential analysis. Furthermore, the effects of NAC as antidote 
during APAP can be observed in Figure 3.3. Similarly to the heat maps in Figure 3.2, the 
upper and lower heat maps represent increased and decreased metabolites also when 
compared to the average control profiles. In this treatment other regions are highlighted 
in addition to the regions highlighted during APAP treatment (Figure. 3.2). 
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Figure 3.2. A) and B) SOM of 10 mM APAP exposure to cells from 2 different 
donors (64 and 77 years respectively). C) and D) SOM of 5 mM APAP exposure to cells 
from 2 different donors (47 and 64 years respectively). Features whose intensity 
increased and decreased relative to the corresponding control following APAP exposure 
are depicted in top and bottom rows respectively. The metabolite density plot depicts the 
number of peaks associated with a grid location. 
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A representation of the 10 mM APAP and 5 mM APAP + 10 mM NAC treated 
metabolic temporal profiles are depicted in Figure 3.3 (A) and (B) respectively. These 
result in other regions of metabolites with increased abundances (red and yellow). The 
relative number of metabolites per grid location is depicted in the metabolite density map 
in Figure 3.4 (C). These heat maps are the 72 hour and 30 minutes exposure time-points, 
baseline subtracted with the average control profiles of their respective bioreactors 
(control LBR with inoculated with cells from same donor). The immediately apparent 
region of interest 1 (ROI 1) of high intensity corresponds directly to APAP and 3,3’-
Biacetaminophen (Bi-APAP) (Figure 3.4 (A)). The formation of Bi-APAP occurs 
rapidly, giving rise to a time profile similar to the parent drug. Additionally, other regions 
(ROI 2 and 3) can be observed on the edges of the map corresponding to phenylalanine 
and arginine respectively. The gradual appearance of region 4 corresponds to other APAP 
metabolites such as APAP-sulfate and APAP-glucuronide, which are metabolized for 
APAP secretion.
17
 The different location on the heat map is due to the different time 
profile of these metabolites during the time courses. As previously mentioned, the effect 
of NAC in the metabolome is highlighted in other ROI’s (Figure. 3.4 (B)). Regions 7 and 
8 are only present when the cells are exposed to NAC and the metabolites identified in 
these regions are closely related to NAC metabolism. In region 7, the oxidized form of 
NAC (Ox-NAC) is found, while the product of both drugs (APAP and NAC) is 
highlighted in region 8. Interestingly other compounds in the media are highlighted in 
regions 5-8. These compounds correspond to different antibiotics such as penicillin G and 
streptomycin, which are used to prevent bacterial infection in the LBR during 
experiments. Region 5 corresponds to penicillin G and streptomycin-cysteine can be 
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Figure 3.3.  A) SOM of 5 mM APAP + 10 mM NAC exposure to cells (47 years). B) 
SOM of 10 mM APAP + 10 mM NAC exposure to cells (77 years). Features whose 
intensity increased and decreased relative to the corresponding control following APAP 
exposure are depicted in top and bottom rows respectively. The metabolite density plot 
depicts the number of peaks associated with a grid location. 
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Figure 3.4. A) and B) Differential metabolic profiles depicting metabolites with 
elevated abundances in different ROI  for 10 mM APAP exposed bioreactor, and 
metabolites with increased abundances for 5 mM APAP + 10 mM NAC exposed 
bioreactor respectively. The metabolite density plot indicates the numbers of peaks 
residing in the corresponding grid location (C). 
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observed in region 6. Interactions of antibiotics with thiol containing compounds have 
been previously reported.
23-27
 We observe different dynamics of these reactions in regions 
6, 7 and 8, where cysteine and NAC reacted with streptomycin and penicillin G. The 
different metabolites and their corresponding ROI are summarized in Table 3.2. 
 
3.3.3 Temporal metabolic signatures in APAP toxicity 
The extremely complex and highly dynamic changes of the hepatic metabolome 
during chemical stimuli represent a difficult challenge in the data analysis process. 
However, a general sense of the metabolomic profile during time course experiments can 
be visualized by SOM (Figures. 3.2 and 3.3). The increase and decrease of metabolites 
seeded in a particular ROI can be easily visualized by monitoring the color changes 
throughout the different time points. In Figure 3.5, these changes can be observed for a 
selected group of metabolites with different time profiles. Their time dependent 
differences are not only associated with both APAP and NAC exposure but also with the 
origin of the inoculated cells (donor). Variation in the production and consumption of 
some molecular species were observed in experiments conducted at equivalent conditions 
other than donor cells (biological replicates). In order to compensate for the differences in 
metabolism between the three donors, the highest relative intensity of a particular 
metabolite for all bioreactors from the same donor was set to 100% and all other 
intensities with their corresponding standard deviations (error bars) were normalized 
accordingly. It should be noted that this calculation was performed only for these plots 
(Figure. 3.5 and Figures. C.3-C.5) for visualization purposes and direct abundancy 
comparisons between different donors would be inaccurate. However, it allows us to 
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Table 3.2.     Metabolites from ROIs in single chemical stimulus indicated in Figure 3.4. 
 
 
 
 
 
 
Metabolite ROI
 
APAP 1 
3,3’-Biacetaminophen 1 
Phenylalanine 2 
Arginine 3 
APAP-sulfate 4 
APAP-glucuronide 4 
Penicillin G 5 
Streptomycin -cysteine 6 
Ox-NAC 7 
Penicillin G- cysteine 7 
APAP-NAC 8 
Penicillin G-NAC 8 
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examine time profiles of different donors at both equal and distinct conditions. Time 
points from different donors are represented by different marks (male 77-circles, male 
64-triangles and female 47-squares), APAP exposure was color coded (10mM, 5 mM and 
controls are blue, red and black respectively) and the administration of NAC (10 mM) 
was differentiated with dashed lines. The rapid appearance of APAP and Bi-APAP 
(Figure 3.5 (A) and (B)) is similar for all biological replicates (same conditions but 
different donor). Additionally, a dose dependent decrease is observed for APAP, with 
5mM being consumed at a faster rate than 10mM (red and blue triangles). Interesting but 
not surprising is the effect of NAC administration in the formation of Bi-APAP, which is 
formed through reactive oxygen species (ROS).
28
 As mentioned above, the function of 
NAC in APAP toxicity is to replenish the glutathione levels, which one of its many 
functions is the protection of cells from toxic reactive oxygen compounds.
29
 The levels of 
Bi-APAP are significantly lower when NAC is administered conjointly with APAP at 
two different compositions (blue circles and red squares). Changes in the concentration of 
NAC can be observed by monitoring the oxidized form of NAC (Ox-NAC), which occurs 
with the formation of a disulfide bond between two NAC molecules (Figure 3.5 (C)). 
This oxidation took place in standard reference material as well (data not shown). Here, 
distinctive profiles are observed for the liver bioreactors treated with same NAC but 
different APAP concentration, where more irregular changes in the lower APAP 
concentration (red squares). The conversion of APAP into the reactive electrophile, N-
acetyl-p-benzoquinone imine (NAPQI), by P450-mediated reactions causes the depletion 
of glutathione and covalent binding (arylation) to macromolecules.
30
 This leads to 
damage to mitochondria, cell membranes and nuclei, perturbation of vital cell signaling 
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and finally necrosis and apoptosis.
31
 The formation of APAP-NAC (Figure 3.5 (D)) is a 
process of multiple reactions including P450-mediated bioactivation and has been 
previously detected in untreated human urine samples.
17, 32 
Small profile differences 
between the NAC treated LBRs (blue circles and red squares with dashed lines) are 
observed at 30 and 60 minutes after drug exposure, which could be attributed to both 
varying concentrations and metabolic activity. On the other hand, the levels drop 
similarly over time after 2 hours. Other major urinary metabolites such as APAP-sulfate 
(Figure 3.5 (E)) and APAP-glucuronide (Figure C.3) were detected in all APAP exposed 
LBRs. It is believed that the purpose of these compounds is to facilitate the elimination of 
APAP due to their increased water solubility.
8
 The slightly delayed formation of APAP-
sulfate (6 hours) compared to other APAP metabolites lead to the grouping in ROI 4. 
Interestingly, several trends are observed during the time course measurements. i) higher 
concentrations are detected at lower APAP concentration (blue and red triangles), ii) the 
levels of APAP-sulfate at 10 mM APAP exposure drop between the last two time points 
(last 48 hours) with 2 different donors (blue circles and triangles) and with the exposure 
of NAC (blue circles with dashed line) and iii) the addition of NAC has a direct 
proportional effect on the production of APAP-sulfate (blue circles and red squares). 
These trends can be explained by the toxic effects of APAP at higher concentrations over 
time and the protective properties of NAC in the liver. Similar trends were observed for 
APAP-glucuronide except for earlier detection (2 hours) at 10 mM APAP and NAC (blue 
circles dashed line) and lower abundancy at 5 mM APAP + 10 mM NAC when compared 
to 5 mM APAP (red squares). These differences suggest different activities and 
susceptibilities of sulfotransferase and uridine diphosphoglucuronosyltransferase.
33
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Additional metabolic perturbations during stimuli were caused by thiol containing 
compounds, antibiotics in particular. Streptomycin-cysteine (Strep.-Cys.) was detected 
only in NAC treated bioreactors and different dynamics can be observed in Figure 3.5 (F) 
between different concentrations. These interactions, which can result in antibacterial 
inactivation, have been observed both in vitro and in vivo.
23, 24
 Further, penicillin G 
compounds also formed oxidized thiol compounds with cysteine and NAC causing the 
level of penicillin G to drop considerably, especially when NAC was used (Figure C.4). 
A comprehensive interpretation of these highly dynamic exometabolic interrogations is 
not possible at the moment and attributing all the trends and effects to a mechanism or 
pathway would be premature. 
Both gradual and drastic changes in the exometabolome after drug exposure 
represent a challenge in the monitoring of bioreactor status. Molecular signatures with 
relative consistent signal or narrow fluctuations have the potential to be early indicators 
of liver bioreactor health in dynamic experiments, provided a high signal-to-noise ratio is 
present. Initially, the depletion of antibiotics would suggest microorganism invasion of 
the bioreactor or some type of biotransformation. However, non-biological processes can 
be the source of these changes as well. During our experiments we observed 
phenylalanine (ROI 2) to fluctuate within a narrow range and no apparent correlation to 
stimuli at all conditions (Figure C5). Similarly, arginine (ROI 3) showed no correlation to 
stimuli but wider fluctuations proved phenylalanine a better indicator of liver bioreactor 
health. On the other hand, this could potentially change in future experiments, especially 
if different chemical compounds are studied. 
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Figure 3.5. Selected metabolites time profiles after drug exposure with relative 
intensity calculated to maximum value measured in liver bioreactors inoculated with cells 
form the same donor. Donor age 77 (circles), 64 (triangles) and 47 (squares). Control 
(black), 10 mM APAP (blue), 5mM APAP (red). 10 mM NAC (dashed line). A) APAP 
and B) Bi-APAP  were seeded in region 1and show similar profiles. C) Ox-NAC and D) 
APAP-NAC are only present in LBRs treated with NAC (region 7 and 8 respectively). E) 
APAP-sulfate (ROI 4) is detected only after 6 hours of drug exposure. F) Streptomycin-
Cysteine (Strep.-Cys.) detected in NAC treated LBRs was seeded in ROI 6. 
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3.4. Conclusions 
In this work we describe the implementation and analysis of the effects of APAP 
and NAC exposure on a surrogate liver bioreactor construct. This study provides a basis 
for the interrogation of bioreactor health and status by exometabolomic profiling.  
Through UPLC-IM-MS analysis of bioreactor effluent, we perform temporally resolved 
diagnostics of bioreactor health in a non-destructive manner. These preliminary data 
serve as a training set for the eventual extension as a diagnostic with high temporal 
resolution and extending beyond alive/dead assays. A set of metabolic signatures 
indicative of organ status for all organoids will be developed, allowing for on-line 
monitoring through targeted analyses. We apply a self-organizing map-based approach to 
clustering temporally covarying metabolites into regions of interest for further 
identification. This approach is used to distinguish the metabolomic response of liver 
organs mimic to varied doses of APAP and NAC inoculated with cells from different 
donors. Furthermore, similarities and differences between biological replicates not only 
further evidence the complexity of exometabolic responses but also support the organ-
mimic capabilities of our 3D hepatocyte bioreactor.  This method will next be applied to 
other liver toxins, and then extended to the heart, lungs, gut, and kidneys, leading to the 
eventual integration of all organs into a mock-human for pre-clinical drug testing. 
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CHAPTER IV 
 
ANALYSIS ADVANCES FOR CHARACTERIZATION OF WIDE MASS RANGE 
MOLECULAR COMPOSITION 
 
4.1.   Introduction 
In previous chapters, we explored different pre-ionization separation techniques 
coupled to IM-MS for the expansion of metabolite coverage in bioanalytical applications 
as possible strategies to circumvent ionization suppression effects for small and 
chemically diverse molecules. However, the analysis of molecules spreading over a wide 
mass range has represented a challenge particularly to synthetic polymer chemists 
characterizing different types of materials. Polymers exhibit a wide array of structures 
such as, linear, cyclic, branched chains, copolymers, dendrimers and star shapes.
1
 
Variations in their molecular mass, chemical composition, end group functionality and 
topology determine their physical properties and their use as materials for applications 
ranging from industrial construction products to drug delivery systems in the life 
sciences. Although significant advances have occurred in polymer synthesis, the focal 
point of characterization has been mostly on molecular weight distribution (MWD).
2, 3
 
Typically, the MWD of synthetic polymers is determined by size exclusion 
chromatography (SEC) and/or matrix assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF-MS).
3
 The two techniques are essentially 
complementary. MALDI-TOF-MS can detect differences in chemical composition and 
end-group functionality and SEC separations are based on polymer size (hydrodynamic 
volume). MALDI-TOF suffers from mass dependent response for polymers having 
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relatively wide polydispersities (Mw/Mn >1.2), because of diminished signal contribution 
by chains with higher degrees of polymerization.
4
 Additionally, the effectiveness of gel 
permeation chromatography (GPC) depends on the use of proper standards for 
calibration,
5
 which oftentimes are not available. Differences in hydrodynamic volumes 
make a standard calibration for some polymers unfeasible. Even though these limitations 
were addressed by coupling GPC with MALDI two decades ago,
6
 complete 
characterization of complex polymer mixtures still represents a challenging task for 
polymers with small chemical differences (e.g. cyclic and linear chains).
7
  
Traditional spectroscopic methods such as infrared (IR) and nuclear magnetic 
resonance (NMR) have been used to characterize telechelic (functionalized) polymers.
8, 9
 
However, low sensitivity and the inability to deal with functional complexity represent 
limitations. In contrast, liquid chromatography under critical conditions (LCCC) allows 
for the separation of complex mixtures solely on the chemical unit or moiety of interest. 
Entelis pioneered LCCC several decades ago and formulated a theory for operation under 
critical conditions, where both entropy and enthalpy values (which govern SEC and 
adsorption separations, respectively) are equal, eliminating interactions with the 
stationary phase (Gibbs free energy = 0).
10, 11
 Under critical conditions, polymers with the 
same chemical composition will elute at the same time independent of their molecular 
weight, whereas polymer chains with the same degree of polymerization but with 
different chemical compositions (e.g. end-group chemistry) will be separated, making 
one part of the analyte “chromatographically invisible”.2 The downside is that this 
technique is not as straightforward as other chromatographic techniques. The empirical 
process of identifying the critical conditions for a specific polymer and maintaining these 
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conditions for chromatography is challenging. For example, composition changes as little 
as 0.1% in the mobile phase can alter the LCCC delicate balance and compromise the 
analysis.
10, 11
 
In an ongoing study, investigating SEC coupled directly to MS for an improved 
comprehensive characterization of polyesters and polyurethanes, we observed two novel 
and interesting chromatographic effects. To the best of our knowledge, these effects have 
not been reported previously. We observed complete separation of cyclic and linear 
polyesters and polyurethanes with a pure solvent (acetonitrile - ACN) as the mobile phase 
(unlike LCCC, which requires at least two). Additionally, we observed an inverse elution 
order for cyclic chains under the same conditions, where shorter chains elute before 
longer ones, counter to normal SEC behavior. Currently, we are investigating these 
effects and a complete study for a wider range of polymers is under way to determine if 
the effect is general. These findings should be of great interest for the polymer 
community to develop alternative methods for the characterization of complex polymer 
samples. 
 
4.2. Experimental 
Materials 
All solvents were CHROMOSOLV-grade (Sigma-Aldrich, St. Louis, MO). The 
polyester (PE 225) was synthesized by melt polymerization using adipic acid 
(hexanedioic acid) and 1,4-butanediol (Bayer, Leverkusen, Germany) with Mn=2250 
(end-group analysis). A polyurethane (PUR 262) was synthesized using equimolar 
amounts of polybutylene adipate (Mn=1000) and 4,4’-methylene diphenyl diisocyanate 
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(MDI), (Bayer, New Martinsville, WV). The crown-ethers (12-crown-4, 15-crown-5 and 
18-crown-6) were purchased from Sigma-Aldrich, the methyl- and dimethyl-polyethylene 
glycol were purchased from Polymersource (Montreal, Canada) and the PEG was 
purchased from Polymersciences, Inc. (Warrington, PA). The structures of the oligomers 
observed are shown in Table 4.1 Mass spectra and ion mobility-mass spectra for the 
different polymers can be found in Appendix D (D.1-D.6) 
 
Size Exclusion Chromatography-Mass Spectrometry (SEC-MS) 
The SEC-MS experiments were carried out using a Waters (Milford, MA) 515 
HPLC pump coupled directly to a Synapt G2-S (Waters, Milford, MA) mass 
spectrometer via an electrospray ionization (ESI) source. The positive-mode (+) ESI 
conditions were as follows: capillary, +3.0 kV; sampling cone, 40 V; source temperature, 
100 °C; desolvation temperature, 120 °C; desolvation gas flow, 600 L/h; and cone gas 
flow, 18 L/ h, respectively. The instrument was calibrated with sodium-formate in the 
mass range of 200-2500 amu. Separations were performed at a flow rate of 0.3 mL/min 
and a temperature of 35 °C unless specified otherwise. The temperature was monitored 
with an independent digital thermometer (Radnor, PA). Two types of SEC stationary 
phases were used: traditional polymer particle substrate (GPC) and ethylene bridged 
hybrid silica particles (APC) both from Waters (Milford, MA). In both cases two 
columns with different molecular weight ranges were coupled in series. For GPC 
experiments, 2 columns in the order of Styragel® HR 3 THF (4.6 x 300mm) and 
Styragel® HR 0.5 (4.6 x 300mm) were connected. In parallel, the columns ACQUITY 
APC XT 125 (2.5 m, 4.6 x 150mm) and ACQUITY APC XT 45 (1.7 m 4.6 x 150mm) 
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Table 4.1.  Structural assignments for PE 225, PUR 262 oligomers and PEG 
compounds.  
Species Structure Mass Na adduct 
Linear  
PE 225 
 
313.3 (n=1) 
513.4 (n=2) 
713.5 (n=3) 
Cyclic  
PE 225 
 
423.2 (n=2) 
623.3 (n=3) 
823.4 (n=4) 
Linear 
PUR 262 
 
453.2 (n=0) 
653.3 (n=1) 
853.4 (n=2) 
Cyclic 
PUR 262 
 
563.2 (n=1) 
763.3 (n=2) 
963.4 (n=3) 
PEG 
 
217.1 (n=4) 
261.1 (n=5) 
305.2 (n=6) 
PEG-
methyl 
ether 
 
231.1 (n=4) 
275.1 (n=5) 
319.2 (n=6) 
PEG-
dimethyl 
ether 
 
245.1 (n=4) 
289.2 (n=5) 
333.2 (n=6) 
Cyclic 
PEG 
(crown-
ether) 
 
199.1 (n=4) 
243.1 (n=5) 
287.2 (n=6) 
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were used for APC. Tetrahydrofuran (THF) and ACN were the mobile phases for APC 
separations, while only THF was used for GPC. In order to obtain a stable electrospray 
with THF, ACN was infused at 0.3 mL/min via a T shortly before the ESI source. PE 225 
and PUR 262 were dissolved and diluted in their respective solvents, 100 ng were 
injected. PEG compounds were injected at different concentrations and equimolar 
solutions were created to investigate the ionization efficiencies of the individual species. 
 
4.3. Results and Discussion 
4.3.1. Exploration of SEC stationary phases with polyesters and polyurethanes 
The hydrodynamic volume of polymers, and therefore their separation efficiency, 
strongly depends on the solvent used for the separation. GPC columns typically are 
certified for a particular MW range for a particular solvent and the use of a different 
solvent can compromise not only the separation but also the column integrity. Therefore, 
a stationary phase with a broad solvent compatibility would be of great benefit for 
polymer characterization. As part of a larger project we evaluated a silica based 
stationary phase (APC) for the separation of polyesters and polyurethanes and 
subsequently compared APC to traditional GPC columns. Figure 4.1 (A) illustrates the 
elution plots for polyester PE 225 using GPC in THF compared to APC in both THF and 
ACN. The GPC separation in THF shows a normal profile with both linear (green 
squares) and cyclic (green circles) chains co-eluting. The elution times of the larger 
cyclic chains overlap with linear chains of the same size, whereas the shorter cyclic 
chains tend to elute somewhat after their linear counterparts. On the other hand, the 
elution profiles for cyclic and linear chains using APC as the stationary phase and THF as  
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Figure 4.1.  Elution plots of the molecular weights of cyclic (circles) and linear 
(squares) chains versus their elution times in SEC. A) Elution profiles for PE 225 and B) 
elution profiles for PE 225 and PUR 262 are color coded by polymer and separation 
conditions. PE 225 (green- GPC in THF, red- APC in THF and blue- APC in ACN), PUR 
262 (black- APC in THF and orange- APC in ACN). From Montenegro-Burke, J.R.; 
Bennet, J.M.; McLean, J.A.; Hercules, D.M., Analytical and Bioanalytical Chemistry 
2016, 408, 677-681. Figure 1, with permission from Springer and RightsLink. 
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the solvent show a small, constant time interval (~45 sec.) between cyclic (red circles) 
and linear (red squares)chains having the same degree of polymerization.  
A significant difference is quite evident when ACN is used as the mobile phase, 
significant separation of linear (blue squares) and cyclic (blue circles) oligomers is noted. 
There is a 2-3 minute longer elution time for linear chains and 3-4 minute for cyclic 
chains compared to THF for both stationary phases. More importantly, linear and cyclic 
chains were completely separated regardless of their close MW and chemical 
composition.  It should be noted that the elution profiles with ACN are steeper compared 
to THF, which might suggest a smaller number of theoretical plates in the former. Also, 
the separation of linear and cyclic chains seems to widen as the degree of polymerization 
increases. The reproducibility of these separations was determined by calculating the 
difference of elution times of equal polymerization degree for linear and cyclic chains. 
This was analyzed for 3 separate runs in all conditions and it was determined that even 
though small elution time changes, commonly observed in chromatography experiments, 
were detected, the times between the elution of same length linear and cyclic chains 
showed low variability under all conditions (1-6 seconds in 0.3 to 2.1 minute separation 
of linear and cyclic oligomers). Furthermore, different temperatures were investigated, 
showing effects on the retention time of all chains in the same direction (earlier elution 
times for higher temperatures). However, the separation of linear and cyclic chains as 
well as the order of elution did not change (Figure 4.2).   
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Figure 4.2. Temperature dependence of elution profiles for PE 225. Linear and cyclic 
chains are represented by diamonds and circles respectively. The temperature gradient is 
analog to the temperature gradient. 
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Given that different polymers will have different hydrodynamic volumes, and that 
these will be affected by the solvent (polarity), we selected a simple polyurethane (PUR 
262) for study, to see if increased chain rigidity caused by the addition of MDI to the 
chains would have an effect for solvents with different polarities (THF and ACN relative 
polarities are 0.207 and 0.460 respectively).
12
 Changes in flexibility can have an effect on 
the folding capability of the polymers, altering their hydrodynamic volumes. Figure 4.1 
(B) illustrates comparisons between the separations of PE 225 and PUR 262 on an APC 
column in both THF and ACN. The difference between both polymer elution profiles 
with THF is minimal; the plots for PE 225 (red) and PUR 262 (black) overlap 
completely. Of greater interest is the behavior observed for both the polyester and 
polyurethane in ACN, where the linear and cyclic chains are separated and the PE 225 
(blue) and PUR 262 (orange) data points completely overlap, showing the same 
separation of linear and cyclic oligomers. These results suggest that an increase in mobile 
phase polarity reduces the hydrodynamic volumes of these polymers, with the effect 
being greater for cyclic chains even in more rigid structures. Changes in elution times by 
altering the mobile phase composition are not unusual. Moreover, it is one of the main 
factors to be considered in any chromatographic experiment. However, the increase in 
separation between linear and cyclic chains under APC conditions with ACN as mobile 
phase provides an effective means to separate these architectures. 
These separations were performed rapidly (less than 15 minutes) and minimal 
optimization was needed due to the use of a single solvent system, which increases the 
reproducibility and ease of analysis. In critical chromatography (LCCC), the selection of 
the solvents is determined by their interactions with the polymer and stationary phase. 
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Typically, a good polymer solvent with a column showing good SEC behavior is 
selected. Subsequently, a non-solvent for the polymer is added to the mobile phase to 
induce enthalpic interactions until a delicate solvent balance is reached.
10, 11
 Previously, 
critical conditions for a single solvent system have been reported for polyisoprene (PI).
13
  
In that study PI chains eluted at the same time regardless of their MW with 1,4-Dioxane 
at exactly 47.7°C and small temperature changes (0.1°C) altered the balance. However, 
these conditions were not appropriate for the separation of block-copolymers 
(polystyrene-polyisoprene). This demonstrated that polymers with different chemical 
compositions need a two solvent system in in order to successfully separate complex 
polymer samples using LCCC for the separation. 
The coupling of LCCC’s unique sorting capability with MALDI offers great 
potential for the characterization of complex polymer samples. The first separation allows 
for fractionation based on chemical composition followed by measurement of the MW 
distribution. For example, for the characterization of PE 225 and PU 262, linear and 
cyclic chains would first be separated in LCCC, and fractions would be collected for MW 
distribution measurements with MALDI. Interestingly, in the present work we observe 
not only the separation of linear and cyclic chains but also an SEC behavior for linear 
chains, where chain length is inversely proportional to elution time. To the contrary, an 
inverse SEC behavior for cyclic chains was observed. Figure 4.3 (A) displays a 
magnified region of the PE 225 (blue) and PUR 262 (orange) elution profiles of cyclic 
chains shown in Figure 4.1 (B). With APC and ACN as the stationary-mobile phase 
system, cyclic chains with lower degrees of polymerization elute before chains with 
higher degrees of polymerization. In the case of the polyester (blue), a linear elution 
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profile (R
2
= 0.98) is observed for the first 3 species (n=2 to n=4). Nonetheless, this 
profile changes for longer chains (n=5 to n=8), where elution times are observed in a 
narrower time range, reminiscent of LCCC separations. This is not the case for 
polyurethane chains (orange), which show a more nearly linear elution profile (R
2
= 0.88) 
for all observed species. 
The two novel effects reported in this work can be visualized in the extracted ion 
chromatograms (EICs) shown in Figure 4.3 (B). The first eluting peaks correspond to 
linear polyester species, with longer chains eluting before shorter chains (n=6 to n=1). 
The later peaks correspond to the cyclic species with the opposite elution order (n=2 to 
n=6). The separation between both species is evident and given the well resolved 
characteristics of the separation, the possibilities of co-elution are minimal.  
The reason(s) for these interesting differences under APC and ACN conditions 
are not entirely clear. It is understood from LCCC theory that entropy governs SEC 
separations while enthalpy governs adsorption separations. In SEC, as described above, 
longer chains have shorter elution times than shorter chains. On the other hand, in 
adsorption separations longer chains have longer elution times, due to the higher 
interactions between long chains and the stationary phase. One possible explanation for 
the effects we observe is that, at the specific conditions for ACN on APC columns, 
entropy governs the separation of linear chains while enthalpy governs the separation of 
cyclic chains. This would suggest that ACN is what would be considered a good solvent 
in LCCC theory only for linear chains but a non-solvent for cyclic chains under the same 
conditions. These differences between linear and cyclic chains are supported by the fact 
that smaller hydrodynamic volumes, lower viscosities, higher thermostabilities, higher 
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Figure 4.3. A) Expanded SEC elution plot of the molecular weights of cyclic chains of 
PE 225 (blue) and PUR 262 (orange) versus time. B) Extracted ion chromatograms (EIC) 
of linear and cyclic PE-225 B chains. Chains are color coded by their degree of 
polymerization (e.g. n=2 is red…n=6 is yellow). From Montenegro-Burke, J.R.; Bennet, 
J.M.; McLean, J.A.; Hercules, D.M., Analytical and Bioanalytical Chemistry 2016, 408, 
677-681. Figure 2, with permission from Springer and RightsLink. 
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self-diffusion coefficients, enhanced fluorescence as well as both lower and higher glass 
transition temperatures have been reported for cyclic chains compared to their linear 
counterparts.
14, 15, 16
 
 
4.3.2. Application of novel chromatographic behavior for the separation and 
characterization of polyethylene glycol compounds 
 This effect of ACN with APC columns was further explored for a type of polymer 
where linear and cyclic chains are currently used in different applications. Polyethylene 
glycol (PEG) is broadly used, especially in medicine and biotechnology applications for 
its water solubility and low toxicity.
17, 18
 On the other hand, the cyclic counterparts, 
crown-ethers, are used as complexing agents due to their ability to bind alkali metal 
cations.
19
 Figure 4.3 shows the EICs of different PEG compounds collected with ACN in 
APC column at a flow rate of 450µL/min. It is evident that the predominant 
chromatographic effect observed for the crown-ether species (cyclic PEG chains) is 
adsorption. The larger chain (18-crown-6, black) elutes after the shorter oligomers (12-
crown-4 and 15-crown-5, green and purple, respectively) (Figure 4.4 (A)). Interestingly 
the shortest and longest crowns are separated from the linear PEG chain (red). This is not 
the case for 15-crown-5, which co-elutes with the linear PEG chains. Furthermore, the 
chromatographic separation of the crown-ethers is successful with baseline resolved 
peaks. It it’s worth mentioning that the 2 larger crown-ethers show similarities in their 
chromatographic behavior. Both species EICs seem to be composed of at least 2 peaks 
co-eluting. A possible explanation is that given their longer structures, different Na
+
 
bound conformations with different hydrodynamic volumes are possible. 
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Figure 4.4. A) EIC of crown ethers and linear PEG. 12-crown-4 (green), 15-crown-5 
(purple), 18-crown-6 (black) and linear PEG (n=6) (red). B) EIC of linear PEG chains (all 
n=6) with different end-groups. PEG-dimethyl ether (orange), PEG-methyl ether (blue) 
and PEG (red). 
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 We further investigated the polarity effects of different end-groups in the linear 
species and plotted the EICs for n=6 and Na
+
 adduct for chains containing two OH end-
groups, one free OH and one methyl ether end-group and two methyl ether end-groups   
(Figure 4.4 (B)). As expected, given the polar properties of the Silica APC stationary 
phase, PEG chains with free hydroxyl groups have stronger interactions, resulting in 
longer elution times and peak broadening. These interactions are reduced in chains with 
only one methylated end-group, due to the lower number of free OH groups available for 
interaction. Lastly, species with both methylated end-groups eluted first and had the 
narrowest peak, confirming that adsorption is playing a dominant role in the separation of 
PEG compounds under ACN and APC conditions. 
 Interestingly, in spite of the large adsorption effects inherent for the polar 
stationary phase with polar solutes, a slight size exclusion behavior is observed for the 
three classes of linear PEG (Figure 4.5). PEG-dimethyl ether species have a steeper slope 
compared to the species with free OH end-groups suggesting very small changes in their 
hydrodynamic volume compared to the species with free OH end-groups. Taking into 
consideration the low mass of the repeating unit (44 Da), more gradual slopes, like the 
case of PE and PUR, are less likely. Furthermore the linearity of their elution profiles 
decreases with number of free OH end-groups (R
2 
= 0.99, 0.91 and 0.84, respectively). 
This could be explained by the peak broadening effects observed for the different species 
in Figure 4.4 (B), where determining the apex can me more complicated. 
 The readily separation of the cyclic PEG species and in the commercial 
availability as pure compounds allowed us to calculate their respective ionization 
efficiencies and compare them to their linear PEF-dimethyl ether counterparts. For that, 
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Figure 4.5. Elution plots of the molecular weights of linear PEG species versus their 
elution times in SEC. 
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equimolar solutions of the three crown-ethers (n=4, 5 and 6) were analyzed and the 
molecular weight distribution for the linear species was calculated, including n=4, 5 and 
6. We appreciate that this calculation allows only for an estimate of ionization 
efficiencies, given the different peak width for the cyclic chains and the co-elution of all 
the linear chains. However, after integrating the detector response for the different 
species (e.g. cyclic, n = 4, area = 45195.2) and dividing by the moles injected of the same 
species (e.g. cyclic, n = 4, moles injected = 2.7 x 10-13), ionization efficiencies are 
calculated for each linear and cyclic species. For the cyclic species with a polymerization 
degree of 2, the ionization efficiency (area/ moles injected) was calculated to 1.7 x 1017. 
By comparing ionization efficiencies between cyclic and linear chains, a factor of ~103 
higher efficiencies was determined for the cyclic chains compared to their respective 
linear chains (n = 4, 5 and 6) (Table 4.1). This is not entirely surprising given their high 
affinity to alkali metal cations (e.g. Na
+
).   
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Table 4.2. Calculation of ionization efficiencies for cyclic (crown-ethers) and 
dimethylated PEG oligomers. 
 
n Structure Moles injected Area Area/moles injected 
4 Cyclic 2.7 x 10-13 45195.2 1.7 x 1017 
5 Cyclic 2.2 x 10-13 162669.5 7.3 x 1017 
6 Cyclic 2.2 x 10-13 131260.8 5.9 x 1017 
4 Linear 6.9 x 10-12 3998.5 5.8 x 1014 
5 Linear 2.2 x 10-11 12228.7 5.4 x 1014 
6 Linear 5.3 x 10-11 26918.7 5.1 x 1014 
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4.4. Conclusions 
 In this chapter, we have reported novel behavior observed for complex polymer 
samples using APC columns with ACN as a solvent, resulting in the separation of linear 
and cyclic oligomers for certain types of polymers. The methodology developed does not 
involve extensive optimization, utilizes an electrospray friendly solvent and has the 
potential for significantly improving polymer characterization. We identified that these 
conditions cannot be used for the general separation of all linear and cyclic polymers and 
a more comprehensive study using a broad library of polymer classes is necessary. 
Furthermore, the chromatographic behavior of polyesters and polyethers (PEGs), both 
with free hydroxyl and protected groups, show similarities and differences. The 
separation of linear and cyclic chains for PE and PUR was successful; on the other hand, 
this was not the case for cyclic PEGs and the methylated linear chains (both elute at 9 
minutes). Additionally, in spite of the elution profiles of cyclic PE, PUR and PEG being 
governed solely by adsorption, the complete separation of the individual PE and PUR 
species (different length) seems unlikely with the current methodology, the complete 
separation of the individual crown-ethers is readily accessible. These observations 
suggest that end-group polarity and chemistry are not the only factor in the adsorption-
size exclusion intricate balance. The opposite effects played by enthalpy and entropy 
seem to affect different chemistries to different extents under the investigated conditions, 
making a chromatographic prediction extremely challenging at the current state of 
understanding and data available. 
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CHAPTER V 
 
PERSPECTIVES AND PROPOSED IMPROVEMENTS ON THE APPLICATION OF 
SEPARATIONS WORKFLOWS FOR HIGH TEMPORAL RESOLUTION 
MEASUREMENTS 
 
 Systems biology is a comprehensive quantitative analysis, which focuses on 
studying the biochemical time-resolved networks interactions. In order to understand 
biology at a system level, the structure and dynamics of the cellular and organismal 
function must be analyzed as opposed to isolated parts of a cell or organism. While 
proteomics and genomics information continues to be important, systems-wide 
information encompasses more than genes and proteins alone. Diagrams depicting 
interactions cannot understand the system’s properties. A good analogy would be to try to 
gain information about traffic patterns from a static roadmap. The roadmap cannot 
explain why these patterns occur or how they can be controlled for example.  
 A comprehensive understanding of the properties of whole systems would have 
an enormous influence in the future of medicine. The ability to predict the behavior of a 
system after any type of stimulus would make drug discovery more efficient and 
economical. Such information would also enable personalized medicine a routine 
treatment in healthcare. Redesigning gene regulatory networks with a specific stimulus 
could create new systems properties and would transform the field of preventive 
medicine. However, in order to acquire such data, sensitive tools for identifying the 
concentration, flux and interactions of various types of molecules at high resolution both 
in space and time need to be developed. Miniaturized and automated mock-organ 
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constructs and detection platforms capable of parallel multiparameter analysis are key 
elements for the reproducibility and multiplexing of this technology. 
 Mass spectrometry, as discussed in previous chapters, is a widely used high-
throughput method for chemical analysis and can simultaneously detect multiple analytes 
even at low sample volumes. However, obtaining quantitative information across a broad 
dynamic range of concentrations is hindered by the need to remove the abundant low-
volatile salts, which are present in all biological fluids and media used for cell cultures. 
Furthermore, other nonvolatile analytes, which exist in the sample, have long been 
known to have significant suppression effects on the electrospray process and ionization 
efficiencies. These effects limit quantitation and reproducibility for MS, and by proxy, 
any interfacing technologies such as IM.   
To address these limitations, desalting techniques such as solid phase extraction, 
liquid chromatography and capillary electrophoresis have been implemented prior to MS 
analysis. To date, these approaches have necessitated offline sample preparation and, in 
some cases, low throughput fraction collection. Clearly this hinders the temporal 
resolution of the analysis since the biologically dynamic molecular signals, are averaged 
along the collection time. A problem with systems biology is that each level of biological 
interactions – gene expression, protein expression and metabolism – operates on a 
different timescale from one another, making it challenging to find casual linkages.  
Using the previous analogy of a static roadmap, the signal averaging would be similar to 
predicting the time of high vehicle traffic flows when the available data represents the 
average of vehicle traffic flows in a 48-hour window. This measurement would fail to 
recognize high vehicle traffic flows in the morning as well as the type of vehicles 
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involved for example. The Nyquist sampling theorem, which states that a function 
containing frequencies lower than x Hz can only be completely identified by collecting 
measurements at a series of points spaced 1/(2x) seconds apart or less thus necessitates 
near real-time analysis. Therefore, developing a technique whereby the cell culture 
medium effluent is sampled and desalted online via microdialysis (MD), would increase 
the time resolution, while facilitating sample compatibility with MS instrumentation. 
Such a technology could potentially allow for real-time experiments, where cell cultures, 
mock-organ constructs or even animal models could be monitored directly to a mass 
spectrometer. For example, in Figure 5.1, a cell culture can be monitored with a 
microscope for morphological changes after any stimuli. The cellular secretome would 
then be processed by the microdialysis apparatus, displacing the nonvolatile salts (e.g. 
Na
+
) with volatile salts such as NH4
+
, and facilitating an efficient electrospray process. 
Finally, the biochemical signatures secreted by the cells following a specific stimulus can 
be measured with state-of-the-art mass spectrometers. 
Preliminary experiments in our laboratory have been performed utilizing this 
technique by monitoring signal-to-noise ratio (S/N) of certain compounds dissolved in 
commonly used media, with ~130 mM salt concentration. In Figure 5.2 (A), Ubiquitin 
(8.5 kDa) was injected at 10 µg/mL in RPMI media with and without dialysis prior to the 
ionization source. It is evident that the microdialysis system has a significant 
improvement on the S/N of the measurement (Figure 5.2 (B)). We have previously 
applied this technology to metabolic studies by monitoring the activity of invertase in 
Saccharomyces cerevisiae. Invertase hydrolyzes sucrose into glucose and fructose on the 
cell surface and the monitoring of the increase of isobaric glucose and fructose signals  
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Figure 5.1. Cell culture-microdialysis-MS platform with (Left) Harvard Apparatus 
syringe pumps, Nikon Eclipse Ti-e inverted fluorescence microscope with stage 
incubator, (Center) microdialysis desalting device, (Right) nanoelectrospray ionization 
source for continuous flow sample analysis in the Waters Synapt G2 mass spectrometer. 
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(m/z = 203.05, [M + Na
+
]
+
) and the simultaneous decrease of sucrose (m/z = 365.11, [M + 
Na
+
]
+
), demonstrating in real time metabolomics data. It is worth mentioning that not 
only size but also polarity will have an effect on the recovery of the different analytes 
during the dialysis process. Larger molecules are less likely to travel across the 
membrane into the counter buffer flow. On the other hand, small metabolites such as 
monosaccharides diffuse faster through the pores of the hollow fiber membranes. 
Additionally, hydrophobic and hydrophilic characteristics of the different analytes will 
play an important role in the adsorption to the surface of the membrane or tubing. These 
issues can be mitigated to some degree by infusing mixtures of organic solvents and 
water between the cell culture and the microdialysis device, creating an environment 
capable of maintaining a wider range of molecules in the solvent, with the effect of a 
more comprehensive metabolite coverage of real time measurements. 
With the improvement of temporal resolution towards the biomolecular 
characterization of the secretome, the characterization of the cellular composition could 
be approached in parallel by online sample preparation systems. Commonly, sample 
preparation of biological tissue and cell cultures involves cell lysis followed by protein 
precipitation for metabolomics studies. This is achieved by mixing the biological 
materials with organic solvents at low temperatures, which precipitates the proteins, and 
retains the metabolites in solution. Alternatively, hot water introduced for short periods of 
time can also be used to lyse cells and extract metabolites.  The stationary phase used in 
the chromatographic separation of synthetic polymers discussed in Chapter IV represents 
the advantage of versatility in solvent selection over wide temperature ranges. This 
advantage could also potentially be utilized in the sample preparation steps by 
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Figure 5.2. Comparison of 10 μg/mL ubiquitin mass spectra in 1640 RPMI media 
(~130 mM NaCl) before microdialysis (A) and after microdialysis (B). Spectrum (B) is 
completely resolved (insert [M+12H]
12+
), while ubiquitin cannot be observed in the 
spectrum (A). 
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simultaneously lysing cells and separating molecules by their molecular weight using 
bioanalytical-friendly solvents. The size exclusion characteristics and the wide solvent 
and temperature range compatibility of the APC columns could potentially be utilized in 
the separation of macromolecules from smaller biomolecules in online systems. Large 
molecules elute much earlier than smaller molecules in SEC, allowing the separation of 
the high molecular fraction such as proteins to be separated from the small molecular 
fraction such as metabolites. The high molecular weight fraction could be further 
processed for proteomics studies, where denaturing protocols are commonly utilized. The 
lysing of the cells and the separation of the different molecular weight fractions in the 
distinct solvents could easily be coupled with downstream HPLC separations for further 
MS analysis. For example, the metabolite fraction collected by hot water sample 
preparation could be injected into a C18 column prior to MS analysis, without further 
manipulation. Furthermore, in the case of organic solvents being utilized for sample 
preparation, the small molecular fraction could be analyzed with HILIC stationary 
phases, where high organic solvent compositions are used in the early stages of the 
chromatogram. These techniques could easily be applied to SFC, where the inherent high 
flow rates make the polarity of the sample solvent negligible, allowing for a wide variety 
of stationary phases to be used for more comprehensive metabolomic studies such as 
previously discussed in the earlier chapters of this dissertation. 
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APPENDIX B 
 
SUPPORTING INFORMATION FOR CHAPTER II 
 
B.1. Data processing  
Data can be mass corrected with Lockspray during and after acquisition. The 
function “Automatic Peak Detection” from MassLynx software package (Waters, 
Milford, MA) is used to reduce the file sizes. The files are then converted to. mzXML 
format with ProteoWizard (http://proteo wizard.sourceforge.net/) using the MSConvert 
and “sortByScanTime” function. 
R studio is a user friendly version of the R package and it is compatible with 
XCMS. It can be downloaded from http://www.r-project.org/. For peak peaking, 
alignment and quantitation the XCMS package is used. It is downloaded directly from R 
studio by running the code below: 
source("http://bioconductor.org/biocLite.R") 
biocLite("xcms", dep=T) 
 
 
B.1.1. XCMS Method 
NAME <-xcmsSet() 
NAME <-group(NAME) 
NAME2 <-retcor (NAME, method=”obiwarp”) 
 NAME2 <-group(NAME2, bw=10) 
 NAME3 <-fillPeaks(NAME2)  
reporttab <-diffreport(NAME, “Group_1”, “Group_2”, “File_Name”, Number of 
EICs, Number of boxplots) 
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Table B.1. Fatty acid percentage composition of individual lipid classes for control 
MDMs obtained from MS
E
 in negative ion mode. 
 
Lipid classes 
Fatty Acid PG PE PI PC SM PS 
14:0 0.4 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 2.2 ± 0.1 2.3 ± 0.3 1.4 ± 0.5 
16:0 8.8 ± 0.1 6.2 ± 0.1 5.2 ± 0.05 32.6 ± 0.3 30.7 ± 0.9 17.7 ± 1 
16:1 4.8 ± 0.2 8.6 ± 0.1 5.7 ± 0.1 15.5 ± 0.2 12.8 ± 0.2 6.2 ± 0.8 
16:2 0.1 ± 0.1 0 0.1 ± 0.1 0.1 ± 0.1 0 0 
18:0 8.0 ± 0.4 11.3 ± 0.2 4.5 ± 0.1 4.8 ± 0.1 9.9 ± 0.9 38.9 ± 1.5 
18:1 54.2 ± 0.6 40.6 ± 0.6 24.2 ± 0.9 31.4 ± 0.5 27.0 ± 0.3 26.9 ± 1.2 
18:2 5.6 ± 0.2 4.6 ± 0.1 4.1 ± 0.4 4.9 ± 0.5 5.1 ± 0.7 2.5 ± 0.3 
18:3 0 0.3 ± 0.1 0.5 ± 0.1 0.2 ± 0.1 0 0 
20:0 0.2 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 
20:1 1.1 ± 0.1 0.7 ± 0.1 2.9 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.2 
20:2 3.4 ± 0.1 0.8 ± 0.1 3.0 ± 0.9 0.6 ± 0.1 0.7 ± 0.2 0 
20:3 4.1 ± 0.2 4.6 ± 0.1 9.4 ± 0.8 2.2 ± 0.1 2.8 ± 0.4 1.8 ± 0.5 
20:4 2.3 ± 0.1 15.3 ± 0.2 22.2 ± 0.7 3.6 ± 0.3 6.0 ± 0.3 2.8 ± 0.4 
20:5 0 0.8 ± 0.1 1.1 ± 0.1 0.3 ± 0.1 0 0 
22:0 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0 0 0 
22:1 0 0.1 ± 0.1 1.6 ± 0.1 0.1 ± 0.1 0 0 
22:3 0 0.4 ± 0.1 2.9 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0 
22:4 0.7 ± 0.1 1.5 ± 0.1 5.9 ± 0.5 0.3 ± 0.1 0.4 ± 0.1 0 
22:5 2.2 ± 0.2 2.1 ± 0.2 5.0 ± 0.4 0 0 0 
22:6 3.9 ± 0.3 1.7 ± 0.1 1.7 ± 0.1 0.4 ± 0.1 0.7 ± 0.4 0.8 ± 0.3 
24:6 0 0 0.1 ± 0.1 0 0 0 
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Table B.2. Fatty acid percentage composition of individual lipid classes for M1 
MDMs obtained from MS
E
 in negative ion mode. 
 
Lipid classes 
Fatty Acid PG PE PI PC SM PS 
14:0 0.7 ± 0.1 0.4 ± 0.1 0.1 ± 0.1 3.4 ± 0.2 3.1 ± 0.1 1.4 ± 0.4 
16:0 10.6 ± 0.5 7.8 ± 0.3 7.1 ± 0.2 32.8 ± 0.6 31.9 ± 0.5 17.9 ± 2.4 
16:1 5.0 ± 0.3 8.9 ± 0.1 5.7 ± 0.3 16.1 ± 0.1 13.8 ± 1 6.2 ± 0.6 
16:2 0.2 ± 0.1 0 0 0.1 ± 0.1 0 0 
18:0 7.4 ± 0.1 10.3 ± 0.3 4.8 ± 0.4 4.3 ± 0.1 9.2 ± 1.1 39.5 ± 3.4 
18:1 56.6 ± 1.2 41.1 ± 0.3 24.8 ± 1.4 32.0 ± 0.6 27.6 ± 0.1 26.6 ± 0.5 
18:2 5.0 ± 0.2 4.8 ± 0.1 4.0 ± 0.1 4.8 ± 0.1 5.0 ± 0.6 2.2 ± 0.3 
18:3 0 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0 0 
20:0 0.2 ± 0.1 0.1 ± 0.1 0.3 ± 0.1 0 0.2 ± 0.1 0.3 ± 0.1 
20:1 1.4 ± 0.2 1.0 ± 0.1 3.4 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 1.0 ± 0.2 
20:2 3.6 ± 0.1 1.0 ± 0.1 2.4 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0 
20:3 4.1 ± 0.2 4.1 ± 0.1 7.6 ± 0.1 1.5 ± 0 1.8 ± 0.2 1.6 ± 0.2 
20:4 1.8 ± 0.2 12.7 ± 0.4 18.7 ± 0.1 2.4 ± 0.1 3.8 ± 0.4 2.1 ± 0.1 
20:5 0 0.6 ± 0.1 0.9 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0 
22:0 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0 0 0 
22:1 0 0.2 ± 0.1 1.9 ± 0.1 0 0 0 
22:3 0 0.6 ± 0.1 3.6 ± 0.2 0.1 ± 0.1 0 0 
22:4 0.6 ± 0.1 1.8 ± 0.1 6.9 ± 0.5 0.3 ± 0.1 0.5 ± 0.1 0 
22:5 1.0 ± 0.1 2.5 ± 0.1 5.4 ± 0.4 0 0 0 
22:6 1.6 ± 0.1 1.6 ± 0.1 1.8 ± 0.1 0.4 ± 0.1 0.7 ± 0.2 0.6 ± 0.1 
24:6 0 0 0.1 ± 0.1 0 0 0 
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Table B.3. Fatty acid percentage composition of individual lipid classes for M2a 
MDMs obtained from MS
E
 in negative ion mode. 
 
Lipid classes 
Fatty Acid PG PE PI PC SM PS 
14:0 0.5 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 2.8 ± 0.1 2.6 ± 0.1 1.2 ± 0.1 
16:0 9.2 ± 0.3 6.7 ± 0.3 5.5 ± 0.2 31.5 ± 0.4 30.1 ± 0.7 16.1 ± 1.1 
16:1 6.3 ± 0.2 9.6 ± 0.1 6.1 ± 0.4 18.5 ± 0.6 16.6 ± 0.4 6.8 ± 0.7 
16:2 0.1 ± 0.1 0 0 0.1 ± 0.1 0 0 
18:0 6.7 ± 0.2 10.3 ± 0.1 4.9 ± 0.1 3.7 ± 0.1 7.2 ± 0.2 38.9 ± 2.7 
18:1 56.8 ± 0.5 42.6 ± 0.2 25 ± 0.6 31.7 ± 0.9 28.3 ± 0.3 28.8 ± 0.6 
18:2 5.7 ± 0.1 0.9 ± 0.1 4.2 ± 0.2 4.6 ± 0.1 4.9 ± 0.3 2.3 ± 0.4 
18:3 0 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0 0 
20:0 0.2 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0 0.2 ± 0.1 0.4 ± 0.1 
20:1 1.2 ± 0.1 0.9 ± 0.1 3.0 ± 0.2 0.6 ± 0.1 0.6 ± 0.2 0.6 ± 0.1 
20:2 3.2 ± 0.2 1.0 ± 0.1 2.6 ± 0.1 0.5 ± 0.1 0.7 ± 0.1 0 
20:3 3.7 ± 0.1 4.7 ± 0.1 8.7 ± 0.2 1.6 ± 0.1 2.5 ± 0.2 1.7 ± 0.3 
20:4 2.1 ± 0.2 14.9 ± 0.3 19.1 ± 0.6 3.1 ± 0.2 4.3 ± 0.6 2.3 ± 0.3 
20:5 0 0.8 ± 0.1 1.0 ± 0.1 0.2 ± 0.1 0.4 ± 0.1 0 
22:0 0.1 ± 0.1 0 0.1 ± 0.1 0 0 0 
22:1 0 0.1 ± 0.1 1.6 ± 0.1 0 0 0 
22:3 0 0.5 ± 0.1 3.2 ± 0.1 0 0.1 ± 0.1 0 
22:4 0.5 ± 0.1 1.6 ± 0.1 6.2 ± 0.3 0.2 ± 0.1 0.5 ± 0.1 0 
22:5 1.2 ± 0.1 2.5 ± 0.1 5.4 ± 0.2 0 0 0 
22:6 2.1 ± 0.2 1.9 ± 0.1 1.8 ± 0.1 0.3 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 
24:6 0 0 0.1 ± 0.1 0 0 0 
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Table B.4. Fatty acid percentage composition of individual lipid classes for M2c 
MDMs obtained from MS
E
 in negative ion mode. 
 
Lipid classes 
Fatty Acid PG PE PI PC SM PS 
14:0 0.6 ± 0.1 0.6 ± 0.1 0.2 ± 0.1 2.6 ± 0.2 2.4 ± 0.2 1.1 ± 0.2 
16:0 8.7 ± 0.1 6.6 ± 0.1 5.7 ± 0.1 31.5 ± 0.2 30.2 ± 1.5 17.5 ± 1.2 
16:1 5.8 ± 0.5 8.7 ± 0.1 5.6 ± 0.1 16.9 ± 0.5 15.2 ± 0.1 5.4 ± 0.7 
16:2 0.2 ± 0.1 0 0 0.1 ± 0.1 0 0 
18:0 7.4 ± 0.4 9.6 ± 0.2 4.7 ± 0.1 4.2 ± 0.2 8.6 ± 0.3 39.0 ± 1.1 
18:1 54.6 ± 1.9 39.7 ± 0.1 24.7 ± 0.8 32.2 ± 0.2 27.7 ± 0.3 28.1 ± 0.4 
18:2 6.0 ± 0.1 4.6 ± 0.1 3.7 ± 0.2 5.0 ± 0.1 5.2 ± 0.2 2.4 ± 0.2 
18:3 0 0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0 0 
20:0 0.2 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0 0.1 ± 0.1 0.3 ± 0.1 
20:1 1.1 ± 0.1 0.8 ± 0.1 3.0 ± 0.1 0.5 ± 0.1 0.6 ± 0.2 0.7 ± 0.1 
20:2 3.3 ± 0.1 0.9 ± 0.1 2.3 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0 
20:3 4.1 ± 0.1 4.6 ± 0.1 8.7 ± 0.2 1.7 ± 0.1 2.5 ± 0.2 1.9 ± 0.3 
20:4 2.7 ± 0.6 15.6 ± 0.1 20.6 ± 0.2 3.3 ± 0.2 4.7 ± 0.2 2.5 ± 0.1 
20:5 0 0.8 ± 0.1 1..0 ± 0.1 0.3 ± 0.1 0.6 ± 0.2 0 
22:0 0.1 ± 0.1 0 0.1 ± 0.1 0 0 0 
22:1 0 0.1 ± 0.1 1.6 ± 0.1 0 0 0 
22:3 0 0.5 ± 0.1 3.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0 
22:4 0.7 ± 0.1 1.7 ± 0.1 6.1 ± 0.1 0.2 ± 0.1 0.4 ± 0.1 0 
22:5 1.6 ± 0.1 2.5 ± 0.1 5.6 ± 0.2 0 0 0 
22:6 2.5 ± 0.2 1.8 ± 0.1 1.8 ± 0.1 0.4 ± 0.1 0.8 ± 0.1 0.8 ± 0.2 
24:6 0 0 0.1 ± 0.1 0 0 0 
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Table B.5. Monocyte-derived macrophages phosphatidylglycerols percent 
composition distribution. 
Species Control M1 M2a M2c 
PG(34:1) 9.0 ± 0.1 11.7 ± 0.3 11.9 ± 0.1 8.9 ± 0.1 
PG(34:2) 7.1 ± 0.1 7.9 ± 0.1 9.2 ± 0.3 8.9 ± 0.2 
PG(36:1) 8.7 ± 0.1 9.5 ± 0.2 8.3 ± 0.2 8.5 ± 0.3 
PG(36:2) 43.9 ± 0.1 45.5 ± 0.3 44.4 ± 0.6 45.4 ± 0.5 
PG(36:3) 8.0 ± 0.1 7.9 ± 0.3 9.0 ± 0.1 9.3 ± 0.2 
PG(38:3) 6.4 ± 0.3 6.2 ± 0.3 5.8 ± 0.2 6.1 ± 0.1 
PG(38:4) 6.8 ± 0.1 6.6 ± 0.1 5.8 ± 0.1 6.6 ± 0.1 
PG(40:7) 9.8 ± 0.5 4.2 ± 0.4 5.2 ± 0.3 6.0 ± 0.4 
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Table B.6. Monocyte-derived macrophages phosphatidylethanolamines percent 
composition distribution. 
Species Control M1 M2a M2c 
PE(32:0) 0.4 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
PE(32:1) 1.9 ± 0.1 2.2 ± 0.1 2.1 ± 0.1 1.9 ± 0.1 
PE(33:0) 0.2 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
PE(33:1) 0.7 ± 0.1 1.1 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 
PE(33:2) 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.1 
PE(34:0) 1.2 ± 0.1 1.3 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 
PE(34:1) 9.6 ± 0.2 10.6 ± 0.3 9.7 ± 0.2 9.1 ± 0.1 
PE(34:2) 4.3 ± 0.2 4.3 ± 0.2 4.7 ± 0.1 4.4 ± 0.1 
PE(34:3) 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
PE(35:0) 0.7 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 1.1 ± 0.1 
PE(35:1) 1.4 ± 0.1 1.7 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 
PE(35:2) 0.8 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 
PE(35:4) 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
PE(35:5) 0.3 ± 0.1 0.3 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 
PE(36:0) 1.4 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 
PE(36:1) 13.3 ± 0.4 13.4 ± 0.2 12.8 ± 0.1 12.1 ± 0.2 
PE(36:2) 15.2 ± 0.2 15.3 ± 0.1 16 ± 0.3 15.6 ± 0.1 
PE(36:3) 2.6 ± 0.1 2.6 ± 0.1 2.8 ± 0.1 2.7 ± 0.1 
PE(36:4) 2.6 ± 0.1 2.3 ± 0.1 2.6 ± 0.1 2.4 ± 0.1 
PE(36:5) 1.1 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 
PE(36:6) 1.4 ± 0.2 1.5 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 
PE(37:1) 0.5 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 
PE(37:4) 0.9 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 
PE(37:5) 1.7 ± 0.3 1.9 ± 0.1 1.9 ± 0.1 2.3 ± 0.2 
PE(37:6) 1.1 ± 0.1 0.9 ± 01 0.9 ± 0.1 1.1 ± 0.1 
PE(38:2) 1.4 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 
PE(O-38:6 or 
P-38-5) 
5.2 ± 0.1 4.6 ± 01 4.9 ± 0.1 5.2 ± 0.1 
PE(38:4) 13.1 ± 0.2 10.6 ± 0.1 11.4 ± 0.3 11.5 ± 0.4 
PE(38:5) 5.1 ± 0.1 4.3 ± 0.1 4.9 ± 0.1 5.0 ± 0.2 
PE(38:6) 1.1 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 
PE(38:7) 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.4 ± 0.1 
PE(39:5) 0.7 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 
PE(40:4) 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 
PE(40:5) 1.6 ± 0.1 1.7 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 
PE(40:6) 2.1 ± 0.1 2.0 ± 0.1 1.9 ± 0.1 1.9 ± 0.1 
PE(40:7) 1.6 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 
PE(40:8) 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
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Table B.7. Monocyte-derived macrophages phosphatidylinositols percent 
composition distribution. 
Species Control M1 M2a M2c 
PI(34:1) 5.0 ± 0.6 6.2 ± 0.7 4.6 ± 0.4 5.4 ± 0.7 
PI(34:2) 5.8 ± 0.4 5.8 ± 0.1 6.7 ± 0.4 7.7 ± 0.5 
PI(36:2) 13.6 ± 0.4 17.6 ± 0.4 14.5 ± 0.3 15.7 ± 0.4 
PI(36:3) 4.9 ± 0.2 4.8 ± 0.2 5.9 ± 0.3 5.5 ± 0.3 
PI(36:4) 3.7 ± 0.1 3.5 ± 0.1 4.2 ± 0.1 3.3 ± 0.1 
PI(38:2) 4.6 ± 0.1 4.1 ± 0.1 4.4 ± 0.2 4.3 ± 0.1 
PI(38:3) 21.5 ± 0.7 16.9 ± 0.3 19.5 ± 0.1 19.1 ± 0.1 
PI(38:4) 32.3 ± 0.4 29.9 ± 0.2 29.1 ± 0.7 28.5 ± 1.2 
PI(38:5) 8.2 ± 0.3 10.8 ± 0.1 10.6 ± 0.1 10.0 ± 0.3 
 
 
 
 
 
 
 
 
 
 
161 
 
 
Table B.8. Monocyte-derived macrophages phosphatidylcholines percent 
composition distribution. 
Species Control M1 M2a M2c 
PC(30:0) 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
PC(30:1) 2.1 ± 0.1 2.3 ± 0.1 1.6 ± 0.1 1.7 ± 0.1 
PC(32:0) 23.0 ± 0.2 23.9 ± 0.2 23.1 ± 0.1 21.9 ± 0.1 
PC(32:1) 3.7 ± 0.1 3.4 ± 0.1 2.7 ± 0.1 3.1 ± 0.1 
PC(O-32:1 or 
P-32:0) 
9.4 ± 0.1 8.9 ± 0.1 7.2 ± 0.1 8.1 ± 0.1 
PC(32:2) 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
PC(32:4) 1.3 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 1.3 ± 0.1 
PC(33:0) 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 
PC(33:1) 14.8 ± 0.2 14.8 ± 0.2 14.6 ± 0.2 15.6 ± 0.1 
PC(34:0) 1.5 ± 0.1 2.5 ± 0.1 1.8 ± 0.1 1.6 ± 0.1 
PC(34:1) 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 
PC(34:2) 0.7 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
PC(34:3) 10.7 ± 0.1 11.8 ± 0.1 12.9 ± 0.3 11.5 ± 0.1 
PC(34:4) 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
PC(35:0) 2.1 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 2.1 ± 0.1 
PC(35:1) 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
PC(36:0) 11.6 ± 0.1 11.1 ± 0.1 12.8 ± 0.1 12.6 ± 0.1 
PC(36:1) 5.2 ± 0.1 4.9 ± 0.1 5.6 ± 0.1 5.5 ± 0.1 
PC(36:2) 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
PC(36:3) 4.6 ± 0.1 4.1 ± 0.1 4.2 ± 0.1 4.7 ± 0.1 
PC(36:4) 0.6 ± 0.1 0.5 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 
PC(38:2) 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.1 
PC(38:3) 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
PC(38:4) 1.5 ± 0.1 1.2 ± 0.1 2.1 ± 0.1 1.8 ± 0.1 
PC(38:5) 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 
PC(40:5) 1.1 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 
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Table B.9. Monocyte-derived macrophages sphingomyelins percent composition 
distribution. 
Species Control M1 M2a M2c 
SM(d32:0) 12.4 ± 0.5 13.1 ± 0.1 12.2 ± 0.4 12.1 ± 0.1 
SM(d32:1) 40.6 ± 0.1 40.9 ± 0.2 40.2 ± 0.1 40.6 ± 0.7 
SM(d33:1) 19.6 ± 0.7 20.2 ± 0.3 19.9 ± 0.4 19.5 ± 0.7 
SM(d41:1) 3.7 ± 0.1 3.4 ± 0.1 3.8 ± 0.1 3.8 ± 0.1 
SM(d41:2) 5.6 ± 0.4 5.1 ± 0.1 5.9 ± 0.3 5.8 ± 0.3 
SM(d42:1) 4.5 ± 0.1 4.1 ± 0.1 4.5 ± 0.1 4.4 ± 0.2 
SM(d42:2) 7.5 ± 0.3 6.8 ± 0.3 7.6 ± 0.7 7.7 ± 0.3 
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Table B.10. Monocyte-derived macrophages phosphatidylserines percent composition 
distribution. 
Species Control M1 M2a M2c 
PS(34:1) 10.9 ± 0.4 12.2 ± 0.3 12.2 ± 0.9 11.8 ± 0.4 
PS(36:1) 55.9 ± 0.8 53.4 ± 0.1 53.5 ± 0.4 52.9 ± 0.5 
PS(36:2) 10.6 ± 0.1 11.7 ± 0.1 11.6 ± 0.2 12.3 ± 0.2 
PS(38:3) 6.1 ± 0.1 6.1 ± 0.2 6.3 ± 0.1 6.4 ± 0.4 
PS(38:4) 13.0 ± 0.3 12.5 ± 0.2 12.5 ± 0.1 12.7 ± 0.5 
PS(40:5) 3.2 ± 0.1 3.9 ± 0.1 3.6 ± 0.1 3.6 ± 0.2 
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APPENDIX C 
 
SUPPORTING INFORMATION FOR CHAPTER III 
 
 
 
 
 
 
Figure C.1. A) Time course of A) APAP and NAC stimulus and B) control bioreactor 
experiments in primary human hepatocyte cultures maintained in 3D bioreactors. 
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Figure C.2. SOM of first three days after LBR cell inoculation without baseline 
subtraction. At this point no LBR has been treated. Different LBR with cells from same 
donor show similar evolution through the 3 time points (horizontal comparison). Some 
similarities are also observed for all 9 LBRs at the same time point (vertical comparison). 
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Figure C.3. APAP-glucuronide (ROI 4) time profiles after drug exposure with relative 
intensity calculated to maximum value measured in liver bioreactors inoculated with cells 
form the same donor. Donor age 77 (circles), 64 (triangles) and 47 (squares). Control 
(black), 10 mM APAP (blue), 5mM APAP (red). 10 mM NAC (dashed line).  
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Figure C.4. Penicillin G compounds time profiles after drug exposure with relative 
intensity calculated to maximum value measured in liver bioreactors inoculated with cells 
form the same donor. Donor age 77 (circles) and 47 (squares). Control (black), 10 mM 
APAP (blue), 5 mM APAP (red). 10 mM NAC (dashed line). A) Penicillin G seeded in 
region 6. LBRs treated with NAC profile drops after 24 and 72 hours. B) Penicillin G-
cysteine (Pen. G-Cys.) was grouped in region 7 with Ox-NAC. C) Penicillin G-NAC 
(Pen. G-NAC) has a profile closer related to APAP-NAC (grouped in ROI 8). 
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Figure C.5. Phenylalanine time profiles after drug exposure with relative intensity 
calculated to maximum value measured in liver bioreactors inoculated with cells form the 
same donor (ROI 2). Donor age 77 (circles), 64 (triangles) and 47 (squares). Control 
(black), 10 mM APAP (blue), 5mM APAP (red). 10 mM NAC (dashed line). 
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Table C.1.    Metabolites from ROIs in single chemical stimulus indicated in Figure 
3.4. 
Metabolite ROI
 Mass Accuracy 
(ppm) 
Database/Reference 
APAP 1 3.9 
METLIN and Standard 
material 
3,3’-Biacetaminophen 1 3.3 Ref.17 
Phenylalanine 2 5.8 
METLIN and Standard 
material 
Arginine 3 1.1 
METLIN and Standard 
material 
APAP-sulfate 4 3.8 Ref. 
17
 
APAP-glucuronide 4 6.6 Ref. 
17
 
Penicillin G 5 0.6 Ref.
18
 
Streptomycin -cysteine 6 1.6 METLN (separated) 
Ox-NAC 7 4.3 Standard material 
Penicillin G- cysteine 7 2.2 Ref.
18
 and METLIN 
APAP-NAC 8 8.7 
METLIN and Standard 
Material 
Penicillin G-NAC 8 1.4 Ref.
18
 and Standard Material 
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Table C.2.  Intensities, standard deviation and fold-changes for APAP from Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 14217 3843 -  
15 min 16497 881 -  
30 min 15003 1000 -  
1 h 16247 1696 -  
2 h 14627 714 -  
6 h 14467 400 -  
24 h 15037 2183 -  
72 h 14359 233 -  
77 10 mM APAP 
0 12394 455 1 
15 min 471208 76511 29 
30 min 559935 10699 37 
1 h 558597 34342 34 
2 h 510845 39708 35 
6 h 603762 9507 42 
24 h 484631 864 32 
72 h 448827 22588 31 
77 
10 mM APAP 
+ NAC 
0 15564 783 1 
15 min 457098 5419 28 
30 min 423933 32793 28 
1 h 650636 20788 40 
2 h 537507 40371 37 
6 h 555148 15015 38 
24 h 487569 15854 32 
72 h 485677 3775 34 
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Table C.3. Intensities, standard deviation and fold-changes for APAP from Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 10933 588 -  
15 min 13422 85 -  
30 min 9013 128 -  
1 h 9892 619 -  
2 h 11320 9 -  
6 h 7724 913 -  
24 h 9987 1375 -  
72 h 9922 948 -  
64 5 mM APAP 
0 11158 2523 1 
15 min 818114 73863 61 
30 min 726587 34451 81 
1 h 506924 78395 51 
2 h 464200 15789 41 
6 h 314662 16084 41 
24 h 370727 7130 37 
72 h 469217 12978 47 
64 10 mM APAP 
0 9816 1913 1 
15 min 835869 36553 62 
30 min 874999 39830 97 
1 h 606717 48615 61 
2 h 744140 46649 66 
6 h 772915 65134 100 
24 h 716844 14373 72 
72 h 629029 22004 63 
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Table C.4. Intensities, standard deviation and fold-changes for APAP from Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 11444 743 -  
15 min 11765 726 -  
30 min 8708 1200 -  
1 h 12606 2543 -  
2 h 8621 191 -  
6 h 10281 3743 -  
24 h 9933 1978 -  
72 h 10114 1451 -  
47 5 mM APAP 
0 10834 617 1 
15 min 935562 10984 80 
30 min 556676 61198 64 
1 h 560266 2537 44 
2 h 360168 41657 42 
6 h 384825 36705 37 
24 h 303907 13658 31 
72 h 315689 16211 31 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 9090 829 1 
15 min 753416 27997 64 
30 min 401047 73919 46 
1 h 368480 12224 29 
2 h 292710 12557 34 
6 h 753567 53519 73 
24 h 333144 29714 34 
72 h 266967 23552 26 
 
 
 
 
173 
 
 
 
 
Table C.5. Intensities, standard deviation and fold-changes for 3,3’-Biacetaminophen 
from Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 1698 437 -  
15 min 3658 1779 -  
30 min 4965 1310 -  
1 h 2377 826 -  
2 h 1904 124 -  
6 h 1912 124 -  
24 h 1557 358 -  
72 h 1438 181 -  
77 10 mM APAP 
0 2288 375 1 
15 min 132312 12123 36 
30 min 160086 2507 32 
1 h 202462 19474 85 
2 h 137358 6489 72 
6 h 184326 7551 96 
24 h 118693 15038 76 
72 h 115202 7045 80 
77 
10 mM APAP 
+ NAC 
0 2018 279 1 
15 min 40310 4245 11 
30 min 62049 7753 12 
1 h 123915 6312 52 
2 h 56087 10941 29 
6 h 83209 10180 44 
24 h 54329 9639 35 
72 h 79832 3335 56 
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Table C.6. Intensities, standard deviation and fold-changes for 3,3’-Biacetaminophen 
from Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 1837 141 -  
15 min 1578 274 -  
30 min 1774 139 -  
1 h 1765 38 -  
2 h 1556 115 -  
6 h 1625 155 -  
24 h 1429 68 -  
72 h 1469 62 -  
64 5 mM APAP 
0 1382 432 1 
15 min 190746 10679 121 
30 min 118959 6959 67 
1 h 81222 7031 46 
2 h 79352 3500 51 
6 h 69306 7285 43 
24 h 71951 3887 50 
72 h 57910 1574 39 
64 10 mM APAP 
0 2008 67 1 
15 min 234507 19520 149 
30 min 201145 3417 113 
1 h 187728 12749 106 
2 h 153054 12293 98 
6 h 159912 3331 98 
24 h 137293 12017 96 
72 h 100683 4388 69 
 
 
 
175 
 
 
 
 
Table C.7. Intensities, standard deviation and fold-changes for 3,3’-Biacetaminophen 
from Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 1052 37 -  
15 min 1046 88 -  
30 min 1201 223 -  
1 h 766 221 -  
2 h 1505 199 -  
6 h 1115 89 -  
24 h 1060 108 -  
72 h 846 4 -  
47 5 mM APAP 
0 1920 429 2 
15 min 420156 2322 402 
30 min 256456 46395 214 
1 h 196048 227 256 
2 h 217945 4272 145 
6 h 202957 34837 182 
24 h 77139 5617 73 
72 h 66999 12092 79 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 873 31 1 
15 min 12086 2271 12 
30 min 42519 4093 35 
1 h 38245 5574 50 
2 h 24824 3262 16 
6 h 38013 1660 34 
24 h 32190 517 30 
72 h 27900 4388 33 
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Table C.8. Intensities, standard deviation and fold-changes for Phenylalanine from 
Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 977040 62580 -  
15 min 566092 23963 -  
30 min 529862 67837 -  
1 h 819285 17942 -  
2 h 740438 36990 -  
6 h 1076366 66579 -  
24 h 768309 95664 -  
72 h 566296 13166 -  
77 10 mM APAP 
0 833196 167876 1 
15 min 430033 78756 1 
30 min 1280034 85211 2 
1 h 718906 73486 1 
2 h 717487 61318 1 
6 h 579223 74222 1 
24 h 518486 14772 1 
72 h 574965 16562 1 
77 
10 mM APAP 
+ NAC 
0 788530 180833 1 
15 min 431250 5110 1 
30 min 733276 77653 1 
1 h 968616 131906 1 
2 h 1016462 11484 1 
6 h 880157 77540 1 
24 h 549990 53879 1 
72 h 528508 6331 1 
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Table C.9. Intensities, standard deviation and fold-changes for Phenylalanine from 
Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 696726 6426 -  
15 min 565871 99094 -  
30 min 527079 81823 -  
1 h 713396 15683 -  
2 h 488158 494 -  
6 h 576057 32464 -  
24 h 446229 36697 -  
72 h 501032 20278 -  
64 5 mM APAP 
0 496905 50195 1 
15 min 828280 144791 1 
30 min 672615 72437 1 
1 h 628294 96478 1 
2 h 778622 7186 2 
6 h 959869 77206 2 
24 h 938160 49344 2 
72 h 532950 44572 1 
64 10 mM APAP 
0 576505 31675 1 
15 min 1012546 48573 2 
30 min 729072 46229 1 
1 h 544780 25743 1 
2 h 619168 88631 1 
6 h 813559 146781 1 
24 h 633260 62580 1 
72 h 711704 118510 1 
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Table C.10. Intensities, standard deviation and fold-changes for Phenylalanine from 
Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 435564 7907 -  
15 min 470414 471 -  
30 min 665260 162623 -  
1 h 690277 158950 -  
2 h 1029969 55480 -  
6 h 551439 2091 -  
24 h 443436 24092 -  
72 h 457624 95731 -  
47 5 mM APAP 
0 552947 29138 1 
15 min 548104 13639 1 
30 min 674082 95526 1 
1 h 573892 35537 1 
2 h 872372 170690 1 
6 h 913432 20589 2 
24 h 563054 43164 1 
72 h 964871 83469 2 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 815904 122333 2 
15 min 918113 109707 2 
30 min 721574 100309 1 
1 h 506147 50672 1 
2 h 1021825 54640 1 
6 h 524104 62157 1 
24 h 578714 15653 1 
72 h 862052 82884 2 
 
 
 
179 
 
 
 
 
Table C.11. Intensities, standard deviation and fold-changes for Arginine from Patient 
77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 1345457 204649 -  
15 min 410556 53621 -  
30 min 385843 79624 -  
1 h 1128906 165392 -  
2 h 836071 159868 -  
6 h 1575771 155031 -  
24 h 659176 160444 -  
72 h 477120 39 -  
77 10 mM APAP 
0 679689 188946 1 
15 min 391769 66499 1 
30 min 1374971 205989 4 
1 h 643168 217953 1 
2 h 1331008 159689 2 
6 h 498126 176045 0 
24 h 421690 16066 1 
72 h 382892 9507 1 
77 
10 mM APAP 
+ NAC 
0 939920 222194 1 
15 min 460387 56465 1 
30 min 737364 115520 2 
1 h 689806 60491 1 
2 h 1318750 213927 2 
6 h 1157185 72724 1 
24 h 657610 193914 1 
72 h 419117 3905 1 
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Table C.12. Intensities, standard deviation and fold-changes for Arginine from Patient 
64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 611381 33558 -  
15 min 440632 81226 -  
30 min 427186 67058 -  
1 h 1058685 74537 -  
2 h 414480 20956 -  
6 h 444487 4525 -  
24 h 411625 60369 -  
72 h 453469 5042 -  
64 5 mM APAP 
0 295212 47909 0 
15 min 489477 190521 1 
30 min 408092 128711 1 
1 h 436776 161277 0 
2 h 781667 33644 2 
6 h 1411024 116897 3 
24 h 947004 77754 2 
72 h 348591 1958 1 
64 10 mM APAP 
0 347771 45955 1 
15 min 697392 38308 2 
30 min 640884 26098 2 
1 h 396671 59735 0 
2 h 535752 117984 1 
6 h 850847 7810 2 
24 h 384354 18217 1 
72 h 321247 52916 1 
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Table C.13. Intensities, standard deviation and fold-changes for Arginine from Patient 
47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 310698 9919 -  
15 min 305709 12472 -  
30 min 923126 67562 -  
1 h 877311 63296 -  
2 h 872248 76009 -  
6 h 322164 1670 -  
24 h 349778 22754 -  
72 h 362761 20298 -  
47 5 mM APAP 
0 472213 77725 2 
15 min 335504 11411 1 
30 min 863497 50269 1 
1 h 285254 24020 0 
2 h 950137 129293 1 
6 h 1175813 84731 4 
24 h 368292 24562 1 
72 h 831213 60487 2 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 694795 100882 2 
15 min 1010159 125652 3 
30 min 906995 21706 1 
1 h 379956 2474 0 
2 h 1309121 80285 2 
6 h 416396 50596 1 
24 h 683310 148653 2 
72 h 965813 176239 3 
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Table C.14. Intensities, standard deviation and fold-changes for APAP-sulfate from 
Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 6326 260 -  
15 min 7496 523 -  
30 min 6157 246 -  
1 h 5617 59 -  
2 h 9676 564 -  
6 h 7979 297 -  
24 h 5224 400 -  
72 h 5021 588 -  
77 10 mM APAP 
0 8422 266 1 
15 min 6260 94 1 
30 min 7326 465 1 
1 h 5091 21 1 
2 h 4587 745 0 
6 h 12049 784 2 
24 h 37185 528 7 
72 h 32478 810 6 
77 
10 mM APAP 
+ NAC 
0 5538 217 1 
15 min 2404 24 0 
30 min 1986 102 0 
1 h 2653 73 0 
2 h 5969 163 1 
6 h 35670 1152 4 
24 h 80598 5650 15 
72 h 64900 4020 13 
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Table C.15. Intensities, standard deviation and fold-changes for APAP-sulfate from 
Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 6762 146 -  
15 min 7849 399 -  
30 min 5881 425 -  
1 h 7363 499 -  
2 h 6367 581 -  
6 h 6481 145 -  
24 h 7057 1095 -  
72 h 4230 88 -  
64 5 mM APAP 
0 8258 335 1 
15 min 7295 413 1 
30 min 6613 539 1 
1 h 5517 260 1 
2 h 7377 932 1 
6 h 25912 3688 4 
24 h 102704 5746 15 
72 h 97275 5245 23 
64 10 mM APAP 
0 8166 640 1 
15 min 8473 1081 1 
30 min 8343 171 1 
1 h 4918 436 1 
2 h 8656 269 1 
6 h 22501 1858 3 
24 h 52542 5506 7 
72 h 21600 2708 5 
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Table C.16. Intensities, standard deviation and fold-changes for APAP-sulfate from 
Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 682 17 -  
15 min 773 49 -  
30 min 688 128 -  
1 h 919 14 -  
2 h 2537 363 -  
6 h 810 27 -  
24 h 763 161 -  
72 h 765 117 -  
47 5 mM APAP 
0 766 2 1 
15 min 938 110 1 
30 min 2489 311 4 
1 h 1873 244 2 
2 h 4261 787 2 
6 h 31458 1835 39 
24 h 92311 7375 121 
72 h 127447 8647 167 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 1120 306 2 
15 min 934 589 1 
30 min 835 174 1 
1 h 1816 387 2 
2 h 7767 826 3 
6 h 47144 5420 58 
24 h 128306 1189 168 
72 h 148508 4534 194 
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Table C.17. Intensities, standard deviation and fold-changes for APAP-glucuronide 
from Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 1964 243 -  
15 min 5957 1494 -  
30 min 5302 89 -  
1 h 3977 1574 -  
2 h 1199 27 -  
6 h 1562 568 -  
24 h 2528 500 -  
72 h 7773 524 -  
77 10 mM APAP 
0 18969 2868 10 
15 min 18628 3468 3 
30 min 28883 6006 5 
1 h 15369 1680 4 
2 h 15434 1875 13 
6 h 14211 3856 9 
24 h 60275 3076 24 
72 h 48302 1075 6 
77 
10 mM APAP 
+ NAC 
0 11537 1663 6 
15 min 25233 1842 4 
30 min 53730 6286 10 
1 h 41225 7374 10 
2 h 125608 7941 105 
6 h 44289 1590 28 
24 h 116332 13817 46 
72 h 44023 513 6 
 
 
 
186 
 
 
 
 
Table C.18. Intensities, standard deviation and fold-changes for APAP-glucuronide 
from Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 7899 1438 -  
15 min 10073 1013 -  
30 min 6495 251 -  
1 h 2131 181 -  
2 h 5703 934 -  
6 h 4725 373 -  
24 h 4219 397 -  
72 h 4707 2069 -  
64 5 mM APAP 
0 4678 441 1 
15 min 6401 1899 1 
30 min 4175 1996 1 
1 h 4732 1301 2 
2 h 2339 61 0 
6 h 20334 4620 4 
24 h 103776 6387 25 
72 h 67610 7445 14 
64 10 mM APAP 
0 2195 215 0 
15 min 8328 844 1 
30 min 3206 201 0 
1 h 3196 1380 1 
2 h 1553 199 0 
6 h 9283 2683 2 
24 h 51897 7817 12 
72 h 59968 4122 13 
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Table C.19. Intensities, standard deviation and fold-changes for APAP-glucuronide 
from Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 909 108 -  
15 min 836 203 -  
30 min 1521 641 -  
1 h 1307 295 -  
2 h 2361 429 -  
6 h 871 29 -  
24 h 879 74 -  
72 h 1664 944 -  
47 5 mM APAP 
0 1163 375 1 
15 min 2047 199 2 
30 min 1270 152 1 
1 h 735 14 1 
2 h 1199 271 1 
6 h 51097 10794 59 
24 h 53933 12205 61 
72 h 253105 15368 152 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 2441 2292 3 
15 min 1314 40 2 
30 min 3824 3361 3 
1 h 1303 289 1 
2 h 6662 1550 3 
6 h 10292 1200 12 
24 h 52033 16945 59 
72 h 75966 12833 46 
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Table C.20. Intensities, standard deviation and fold-changes for Penicillin G from 
Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 226047 6780 -  
15 min 283327 10888 -  
30 min 251338 1228 -  
1 h 230408 7943 -  
2 h 349440 27626 -  
6 h 395965 17882 -  
24 h 189849 5081 -  
72 h 168579 6084 -  
77 10 mM APAP 
0 369482 44299 2 
15 min 270959 11528 1 
30 min 327306 20768 1 
1 h 247271 7916 1 
2 h 358094 34446 1 
6 h 251624 15654 1 
24 h 190686 2198 1 
72 h 151205 4103 1 
77 
10 mM APAP 
+ NAC 
0 235584 8585 1 
15 min 112568 7065 0 
30 min 443343 47030 2 
1 h 466668 10507 2 
2 h 383254 12077 1 
6 h 88729 361 0 
24 h 136216 392 1 
72 h 57494 270 0 
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Table C.21. Intensities, standard deviation and fold-changes for Penicillin G from 
Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 274427 13290 -  
15 min 316398 14713 -  
30 min 243393 27461 -  
1 h 289313 21204 -  
2 h 229946 12623 -  
6 h 249083 12056 -  
24 h 295003 35491 -  
72 h 173425 11077 -  
64 5 mM APAP 
0 304603 20025 1 
15 min 307710 19191 1 
30 min 281029 8990 1 
1 h 247968 18770 1 
2 h 269255 120 1 
6 h 264745 14517 1 
24 h 254722 13700 1 
72 h 235465 3268 1 
64 10 mM APAP 
0 324034 26016 1 
15 min 309327 7538 1 
30 min 316134 1567 1 
1 h 302298 11182 1 
2 h 310863 13403 1 
6 h 322924 2664 1 
24 h 287316 9845 1 
72 h 214447 14771 1 
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Table C.22. Intensities, standard deviation and fold-changes for Penicillin G from 
Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 55974 4656 -  
15 min 68675 10056 -  
30 min 69429 4430 -  
1 h 77630 2394 -  
2 h 117348 9669 -  
6 h 67499 2056 -  
24 h 65816 7296 -  
72 h 60355 5420 -  
47 5 mM APAP 
0 78124 11359 1 
15 min 101574 2537 1 
30 min 102735 21141 1 
1 h 102441 2542 1 
2 h 84030 4607 1 
6 h 96240 7856 1 
24 h 80938 427 1 
72 h 76488 1975 1 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 86201 8018 2 
15 min 31615 1035 0 
30 min 29953 2878 0 
1 h 1928 118 0 
2 h 65663 7809 1 
6 h 42069 2140 1 
24 h 9076 2453 0 
72 h 3894 2036 0 
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Table C.23. Intensities, standard deviation and fold-changes for Streptomycin -cysteine 
from Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 9515 1864 -  
15 min 6564 154 -  
30 min 2588 80 -  
1 h 12130 523 -  
2 h 2545 1472 -  
6 h 1682 119 -  
24 h 6583 1465 -  
72 h 467 269 -  
77 10 mM APAP 
0 9369 1967 1 
15 min 2070 331 0 
30 min 18197 6064 7 
1 h 16725 3734 1 
2 h 8965 6094 4 
6 h 20253 1208 12 
24 h 14813 147 2 
72 h 1963 75 4 
77 
10 mM APAP 
+ NAC 
0 6402 4361 1 
15 min 3034 1327 0 
30 min 79392 18617 31 
1 h 95281 31711 8 
2 h 207691 27640 82 
6 h 543754 36371 323 
24 h 783305 21390 119 
72 h 471220 14968 1008 
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Table C.24. Intensities, standard deviation and fold-changes for Streptomycin -cysteine 
from Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 1224 762 -  
15 min 1457 1701 -  
30 min 3224 5079 -  
1 h 3239 2564 -  
2 h 1474 1886 -  
6 h 419 126 -  
24 h 389 88 -  
72 h 4015 6098 -  
64 5 mM APAP 
0 8422 5 7 
15 min 943 205 1 
30 min 607 192 0 
1 h 8497 110 3 
2 h 931 438 1 
6 h 8320 2003 20 
24 h 6135 358 16 
72 h 3718 19 1 
64 10 mM APAP 
0 609 146 0 
15 min 744 42 1 
30 min 692 125 0 
1 h 2797 79 1 
2 h 899 75 1 
6 h 1202 100 3 
24 h 8154 74 21 
72 h 3831 41 1 
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Table C.25. Intensities, standard deviation and fold-changes for Streptomycin -cysteine 
from Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 386 25 -  
15 min 450 187 -  
30 min 3479 191 -  
1 h 3885 197 -  
2 h 3137 278 -  
6 h 519 129 -  
24 h 393 140 -  
72 h 2112 4 -  
47 5 mM APAP 
0 5612 80 15 
15 min 410 109 1 
30 min 1502 84 0 
1 h 344 121 0 
2 h 2649 70 1 
6 h 1616 330 3 
24 h 3966 72 10 
72 h 4730 312 2 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 2051 28 5 
15 min 123487 1751 275 
30 min 295702 32525 85 
1 h 511 69 0 
2 h 71312 3800 23 
6 h 1550 149 3 
24 h 378139 12006 962 
72 h 407757 8710 193 
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Table C.26. Intensities, standard deviation and fold-changes for Ox-NAC from Patient 
77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 3133 888 -  
15 min 2377 499 -  
30 min 1934 383 -  
1 h 4601 1004 -  
2 h 494 102 -  
6 h 2521 346 -  
24 h 3201 920 -  
72 h 1250 327 -  
77 10 mM APAP 
0 3776 479 1 
15 min 1700 727 1 
30 min 3228 581 2 
1 h 1887 66 0 
2 h 4922 201 10 
6 h 2761 888 1 
24 h 2360 45 1 
72 h 1124 72 1 
77 
10 mM APAP 
+ NAC 
0 2868 849 1 
15 min 126551 24682 53 
30 min 1013909 116030 524 
1 h 1058428 131450 230 
2 h 1109359 104106 2246 
6 h 1113304 125592 442 
24 h 679229 40134 212 
72 h 834836 43395 668 
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Table C.27. Intensities, standard deviation and fold-changes for Ox-NAC from Patient 
64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 850 44 -  
15 min 2322 724 -  
30 min 1863 101 -  
1 h 1234 28 -  
2 h 4389 349 -  
6 h 703 297 -  
24 h 1217 476 -  
72 h 3560 4113 -  
64 5 mM APAP 
0 2024 233 2 
15 min 1179 300 1 
30 min 1310 261 1 
1 h 1605 141 1 
2 h 564 96 0 
6 h 2366 773 3 
24 h 2815 1133 2 
72 h 2888 705 1 
64 10 mM APAP 
0 975 375 1 
15 min 1330 442 1 
30 min 622 15 0 
1 h 822 296 1 
2 h 536 240 0 
6 h 1230 171 2 
24 h 1534 126 1 
72 h 2191 144 1 
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Table C.28. Intensities, standard deviation and fold-changes for Ox-NAC from Patient 
47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 789 74 -  
15 min 849 142 -  
30 min 2063 1803 -  
1 h 2078 2232 -  
2 h 2397 2304 -  
6 h 398 344 -  
24 h 871 234 -  
72 h 3098 2193 -  
47 5 mM APAP 
0 4004 3842 5 
15 min 634 56 1 
30 min 699 50 0 
1 h 589 177 0 
2 h 2112 1805 1 
6 h 2172 1596 5 
24 h 9710 15290 11 
72 h 7059 8097 2 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 1959 81 2 
15 min 840655 94263 990 
30 min 861683 83236 418 
1 h 86020 571 41 
2 h 1048192 130420 437 
6 h 103043 2936 259 
24 h 694240 74720 797 
72 h 1244319 139659 402 
 
 
 
197 
 
 
 
 
Table C.29. Intensities, standard deviation and fold-changes for Penicillin G- cysteine 
from Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 774 792 -  
15 min 360 366 -  
30 min 452 147 -  
1 h 580 393 -  
2 h 338 156 -  
6 h 553 396 -  
24 h 418 455 -  
72 h 153 115 -  
77 10 mM APAP 
0 588 573 1 
15 min 150 110 0 
30 min 728 604 2 
1 h 917 957 2 
2 h 424 525 1 
6 h 736 762 1 
24 h 478 535 1 
72 h 426 499 3 
77 
10 mM APAP 
+ NAC 
0 294 70 0 
15 min 13303 6144 37 
30 min 343097 54671 759 
1 h 483981 34810 834 
2 h 606764 105376 1794 
6 h 705125 56187 1276 
24 h 667079 95112 1596 
72 h 266176 10189 1735 
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Table C.30. Intensities, standard deviation and fold-changes for Penicillin G- cysteine 
from Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 241 142 -  
15 min 278 87 -  
30 min 307 252 -  
1 h 334 135 -  
2 h 206 28 -  
6 h 202 65 -  
24 h 298 108 -  
72 h 260 136 -  
64 5 mM APAP 
0 560 686 2 
15 min 278 229 1 
30 min 343 173 1 
1 h 550 747 2 
2 h 272 54 1 
6 h 718 397 4 
24 h 706 306 2 
72 h 330 267 1 
64 10 mM APAP 
0 226 15 1 
15 min 360 28 1 
30 min 295 44 1 
1 h 492 32 1 
2 h 340 74 2 
6 h 320 29 2 
24 h 584 7 2 
72 h 479 117 2 
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Table C.31. Intensities, standard deviation and fold-changes for Penicillin G- cysteine 
from Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 131 12 -  
15 min 135 7 -  
30 min 244 47 -  
1 h 238 95 -  
2 h 326 359 -  
6 h 155 116 -  
24 h 156 1 -  
72 h 245 128 -  
47 5 mM APAP 
0 295 311 2 
15 min 88 27 1 
30 min 243 59 1 
1 h 139 26 1 
2 h 200 144 1 
6 h 277 155 2 
24 h 119 60 1 
72 h 402 307 2 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 321 143 2 
15 min 491536 73217 3633 
30 min 428933 21981 1761 
1 h 73199 5369 308 
2 h 542940 36588 1666 
6 h 62524 8257 403 
24 h 325300 2896 2088 
72 h 452593 23134 1851 
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Table C.32. Intensities, standard deviation and fold-changes for APAP-NAC from 
Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 3782 153 -  
15 min 5308 1926 -  
30 min 3975 394 -  
1 h 6451 962 -  
2 h 12567 2027 -  
6 h 8157 5733 -  
24 h 4531 3829 -  
72 h 2343 1030 -  
77 10 mM APAP 
0 11647 10182 3 
15 min 7432 3198 1 
30 min 5748 7186 1 
1 h 7153 6989 1 
2 h 4601 2767 0 
6 h 5404 2348 1 
24 h 4006 1047 1 
72 h 5197 2159 2 
77 
10 mM APAP 
+ NAC 
0 6568 970 2 
15 min 90873 6965 17 
30 min 206155 18498 52 
1 h 192332 5560 30 
2 h 208412 2976 17 
6 h 109149 18469 13 
24 h 101356 2576 22 
72 h 65279 8635 28 
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Table C.33. Intensities, standard deviation and fold-changes for APAP-NAC from 
Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 3669 4318 -  
15 min 1698 371 -  
30 min 1542 557 -  
1 h 1873 841 -  
2 h 37674 61605 -  
6 h 1237 297 -  
24 h 2800 2862 -  
72 h 1368 353 -  
64 5 mM APAP 
0 1100 188 0 
15 min 1378 188 1 
30 min 1984 338 1 
1 h 2484 2500 1 
2 h 1297 109 0 
6 h 2545 2322 2 
24 h 1836 1157 1 
72 h 1196 473 1 
64 10 mM APAP 
0 1411 244 0 
15 min 1500 369 1 
30 min 1575 87 1 
1 h 1453 4 1 
2 h 1348 109 0 
6 h 1669 190 1 
24 h 1191 12 0 
72 h 1793 143 1 
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Table C.34. Intensities, standard deviation and fold-changes for APAP-NAC from 
Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 1559 52 -  
15 min 1397 289 -  
30 min 1943 569 -  
1 h 2170 1239 -  
2 h 1846 369 -  
6 h 1581 666 -  
24 h 1806 487 -  
72 h 1486 177 -  
47 5 mM APAP 
0 1826 857 1 
15 min 2016 275 1 
30 min 1405 1256 1 
1 h 3668 1118 2 
2 h 2824 470 2 
6 h 2066 753 1 
24 h 1711 44 1 
72 h 1398 1052 1 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 1977 438 1 
15 min 190261 6921 136 
30 min 109519 14183 56 
1 h 60069 3607 28 
2 h 205375 15247 111 
6 h 163324 19564 103 
24 h 27859 2214 15 
72 h 26610 2158 18 
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Table C.35. Intensities, standard deviation and fold-changes for Penicillin G-NAC 
from Patient 77 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
77 Control 
0 18365 13559 -  
15 min 10060 9840 -  
30 min 10258 9366 -  
1 h 22205 15848 -  
2 h 1540 1302 -  
6 h 17525 11964 -  
24 h 10672 8006 -  
72 h 3130 2672 -  
77 10 mM APAP 
0 12722 15270 1 
15 min 5352 5881 1 
30 min 18721 14397 2 
1 h 20033 19746 1 
2 h 8366 11521 5 
6 h 19225 21498 1 
24 h 9803 11553 1 
72 h 5888 4813 2 
77 
10 mM APAP 
+ NAC 
0 10167 5294 1 
15 min 50632 11933 5 
30 min 644919 23487 63 
1 h 537961 29968 24 
2 h 459607 21109 298 
6 h 5038 1140 0 
24 h 229 81 0 
72 h 400 77 0 
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Table C.36. Intensities, standard deviation and fold-changes for Penicillin G-NAC 
from Patient 64 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
64 Control 
0 4873 4296 -  
15 min 4961 2369 -  
30 min 8563 6455 -  
1 h 2841 1070 -  
2 h 2780 2352 -  
6 h 5265 422 -  
24 h 4488 974 -  
72 h 7779 3201 -  
64 5 mM APAP 
0 14110 15532 3 
15 min 9426 5630 2 
30 min 6165 2009 1 
1 h 19441 24085 7 
2 h 3211 988 1 
6 h 15546 12282 3 
24 h 16599 6375 4 
72 h 12066 11813 2 
64 10 mM APAP 
0 3501 788 1 
15 min 12061 1900 2 
30 min 5768 735 1 
1 h 10071 9877 4 
2 h 4414 1739 2 
6 h 10043 5216 2 
24 h 15070 20349 3 
72 h 7701 8088 1 
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Table C.37. Intensities, standard deviation and fold-changes for Penicillin G-NAC 
from Patient 47 
Patient 
age 
(years) 
Treatment Time point Intensity 
Standard 
Dev. 
Fold 
change 
(compared 
to control) 
47 Control 
0 2001 280 -  
15 min 3190 81 -  
30 min 8045 7517 -  
1 h 9455 8310 -  
2 h 16384 15739 -  
6 h 2836 228 -  
24 h 2702 1033 -  
72 h 4171 2627 -  
47 5 mM APAP 
0 7591 7592 4 
15 min 3030 155 1 
30 min 10393 9893 1 
1 h 3326 94 0 
2 h 7929 7842 0 
6 h 7721 4838 3 
24 h 1790 1369 1 
72 h 9108 10287 2 
47 
5 mM APAP 
+ 10 mM 
NAC 
0 8463 847 4 
15 min 396645 17771 124 
30 min 36112 3263 4 
1 h 62046 3706 7 
2 h 744044 84705 45 
6 h 31940 6143 11 
24 h 796 93 0 
72 h 687 451 0 
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Figure C.6. Annotated retention time and drift selected fragmentation spectrum for 
Acetaminophen (APAP). 
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Figure C.7. Annotated retention time and drift selected fragmentation spectrum for 
3,3’Biacetaminophen (Bi-APAP). 
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Figure C.8. Annotated retention time and drift selected fragmentation spectrum for 
Phenylalanine (Phe). 
 
 
 
 
 
 
209 
 
 
 
 
 
 
 
 
 
 
Figure C.9. Annotated retention time and drift selected fragmentation spectrum for 
Arginine (Arg). 
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Figure C.10. Annotated retention time and drift selected fragmentation spectrum for 
Acetaminophen-sulfate (APAP-sulfate). 
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Figure C.11. Annotated retention time and drift selected fragmentation spectrum for 
Acetaminophen-glucuronide (APAP-gluc.) 
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Figure C.12. Annotated retention time and drift selected fragmentation spectrum for 
penicillin G. 
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Figure C.13. Annotated retention time and drift selected fragmentation spectrum for 
streptomycin-cysteine (Strep.-Cys) 
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Figure C.14. Annotated retention time and drift selected fragmentation spectrum for 
oxidized N-acetyl cysteine (Ox-NAC). 
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Figure C.15. Annotated retention time and drift selected fragmentation spectrum for 
penicillin G – cysteine (Pen. G-Cys). 
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Figure C.16. Annotated retention time and drift selected fragmentation spectrum for 
Acetaminophen – N-acetyl cysteine (APAP-NAC). 
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Figure C.17. Annotated retention time and drift selected fragmentation spectrum for 
penicillin G – N-acetyl cysteine (Pen. G-NAC). 
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APPENDIX D 
 
SUPPORTING INFORMATION FOR CHAPTER IV 
 
 
 
Figure D.1. MALDI spectrum of PE-225 in positive-ion mode. (A) m/z range of 500 to 
10,000 and expanded range of 4500 to 10,000. (B) Expanded range of 500 to 1,500 
shows linear (Lin) and cyclic (Cyc) species for n=3 to n=6. 
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Figure D.2. MALDI IM-MS spectrum of PE-225 in positive-ion mode. Characteristic 
MALDI singly charged species are observed for both linear and cyclic chains as both Na
+
 
and H
+
 species. Both linear and cyclic chains have linear gas-phase packing efficiency 
correlation proportional to their molecular weight. 
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Figure D.3. ESI IM-MS spectrum of PE-225 in positive-ion mode. Characteristic ESI 
multiply charged species (z = +2 and +3) are observed for linear chains as both Na
+
 and 
H
+
 species. However, cyclic species are singly charged. The effects in their mobility 
behavior and gas-phase packing efficiency of multiply charged linear chains is observed 
in charged specific trend lines in the 2D IM-MS separation space. 
. 
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Figure D.4. MS of PEG with ESI in positive-ion mode. Species are [M+Na
+
]
+
. 
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Figure D.5. MS of PEG methylether with ESI in positive-ion mode. Species are 
[M+Na
+
]
+
. 
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Figure D.6. MS of PEG dimethylether with ESI in positive-ion mode. Species are 
[M+Na
+
]
+
. 
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